<?xml version="1.0" encoding="ISO-8859-1"?><COCHRANE_REVIEW DESCRIPTION="For publication" DOI="10.1002/14651858.CD003686" GROUP_ID="MUSKEL" ID="474400080717524877" MERGED_FROM="" MODIFIED="2013-04-23 14:32:04 +0100" MODIFIED_BY="Elizabeth Tanjong Ghogomu" REVIEW_NO="C057-R" REVMAN_SUB_VERSION="5.1.7" REVMAN_VERSION="5" SPLIT_FROM="" STAGE="R" STATUS="A" TYPE="INTERVENTION" VERSION_NO="7.0">
<COVER_SHEET MODIFIED="2013-04-23 09:22:47 -0400" MODIFIED_BY="Elizabeth Tanjong Ghogomu">
<TITLE>Non-steroidal anti-inflammatory drugs (NSAIDs) for treating lateral elbow pain in adults</TITLE>
<CONTACT>
<PERSON ID="4495" ROLE="AUTHOR">
<PREFIX>Prof</PREFIX>
<FIRST_NAME>Rachelle</FIRST_NAME>
<MIDDLE_INITIALS/>
<LAST_NAME>Buchbinder</LAST_NAME>
<SUFFIX>MBBS (Hons) MSc PhD FRACP</SUFFIX>
<POSITION>Director</POSITION>
<EMAIL_1>rachelle.buchbinder@monash.edu</EMAIL_1>
<EMAIL_2/>
<URL/>
<MOBILE_PHONE/>
<ADDRESS>
<DEPARTMENT>Monash Department of Clinical Epidemiology at Cabrini Hospital</DEPARTMENT>
<ORGANISATION>Department of Epidemiology and Preventive Medicine, School of Public Health and Preventive Medicine, Monash University</ORGANISATION>
<ADDRESS_1>Suite 41, Cabrini Medical Centre</ADDRESS_1>
<ADDRESS_2>183 Wattletree Road</ADDRESS_2>
<CITY>Malvern</CITY>
<ZIP>3144</ZIP>
<REGION>Victoria</REGION>
<COUNTRY CODE="AU">Australia</COUNTRY>
<PHONE_1>613 9508 1652</PHONE_1>
<PHONE_2>613 9509 4445</PHONE_2>
<FAX_1>613 9508 1653</FAX_1>
<FAX_2/>
</ADDRESS>
<FOOTNOTE/>
</PERSON>
</CONTACT>
<CREATORS MODIFIED="2013-04-23 09:22:47 -0400" MODIFIED_BY="Elizabeth Tanjong Ghogomu">
<PERSON ID="B033EF4582E26AA2000D39ACB62B6543" ROLE="AUTHOR">
<PREFIX>Ms</PREFIX>
<FIRST_NAME>Porjai</FIRST_NAME>
<MIDDLE_INITIALS/>
<LAST_NAME>Pattanittum</LAST_NAME>
<SUFFIX/>
<POSITION>Assistant Professor</POSITION>
<EMAIL_1>pporja@kku.ac.th</EMAIL_1>
<EMAIL_2/>
<URL/>
<MOBILE_PHONE/>
<ADDRESS>
<DEPARTMENT>Department of Biostatistics and Demography</DEPARTMENT>
<ORGANISATION>Faculty of Public Health, Khon Kaen University</ORGANISATION>
<ADDRESS_1>Mitraparp Road</ADDRESS_1>
<ADDRESS_2>Mueng District</ADDRESS_2>
<CITY>Khon Kaen</CITY>
<ZIP>40002</ZIP>
<REGION>Khon Kaen</REGION>
<COUNTRY CODE="TH">Thailand</COUNTRY>
<PHONE_1>+66 433 47637</PHONE_1>
<PHONE_2/>
<FAX_1>+66 433 62075</FAX_1>
<FAX_2/>
</ADDRESS>
<FOOTNOTE/>
</PERSON>
<PERSON ID="9E61E31E82E26AA2002589C3A74A89B9" ROLE="AUTHOR">
<PREFIX/>
<FIRST_NAME>Tari</FIRST_NAME>
<MIDDLE_INITIALS/>
<LAST_NAME>Turner</LAST_NAME>
<SUFFIX/>
<POSITION/>
<EMAIL_1/>
<EMAIL_2/>
<URL/>
<MOBILE_PHONE/>
<ADDRESS>
<DEPARTMENT>School of Public Health &amp; Preventive Medicine</DEPARTMENT>
<ORGANISATION>Monash University</ORGANISATION>
<ADDRESS_1>The Alfred Centre</ADDRESS_1>
<ADDRESS_2>99 Commercial Road</ADDRESS_2>
<CITY>Melbourne</CITY>
<ZIP>3004</ZIP>
<REGION>Victoria</REGION>
<COUNTRY CODE="AU">Australia</COUNTRY>
<PHONE_1>+61 3 9076 8806</PHONE_1>
<PHONE_2/>
<FAX_1>+61 3 9903 0556</FAX_1>
<FAX_2/>
</ADDRESS>
<FOOTNOTE/>
</PERSON>
<PERSON ID="4663" ROLE="AUTHOR">
<PREFIX>Prof</PREFIX>
<FIRST_NAME>Sally</FIRST_NAME>
<MIDDLE_INITIALS/>
<LAST_NAME>Green</LAST_NAME>
<SUFFIX/>
<POSITION>Co-Director, Australasian Cochrane Centre</POSITION>
<EMAIL_1>sally.green@monash.edu</EMAIL_1>
<EMAIL_2/>
<URL/>
<MOBILE_PHONE/>
<ADDRESS>
<DEPARTMENT>School of Public Health &amp; Preventive Medicine</DEPARTMENT>
<ORGANISATION>Monash University</ORGANISATION>
<ADDRESS_1>The Alfred Centre</ADDRESS_1>
<ADDRESS_2>99 Commercial Road</ADDRESS_2>
<CITY>Melbourne</CITY>
<ZIP>3004</ZIP>
<REGION>Victoria</REGION>
<COUNTRY CODE="AU">Australia</COUNTRY>
<PHONE_1>+61 3 9903 0945</PHONE_1>
<PHONE_2/>
<FAX_1>+61 3 9903 0556</FAX_1>
<FAX_2/>
</ADDRESS>
<FOOTNOTE/>
</PERSON>
<PERSON ID="4495" ROLE="AUTHOR">
<PREFIX>Prof</PREFIX>
<FIRST_NAME>Rachelle</FIRST_NAME>
<MIDDLE_INITIALS/>
<LAST_NAME>Buchbinder</LAST_NAME>
<SUFFIX>MBBS (Hons) MSc PhD FRACP</SUFFIX>
<POSITION>Director</POSITION>
<EMAIL_1>rachelle.buchbinder@monash.edu</EMAIL_1>
<EMAIL_2/>
<URL/>
<MOBILE_PHONE/>
<ADDRESS>
<DEPARTMENT>Monash Department of Clinical Epidemiology at Cabrini Hospital</DEPARTMENT>
<ORGANISATION>Department of Epidemiology and Preventive Medicine, School of Public Health and Preventive Medicine, Monash University</ORGANISATION>
<ADDRESS_1>Suite 41, Cabrini Medical Centre</ADDRESS_1>
<ADDRESS_2>183 Wattletree Road</ADDRESS_2>
<CITY>Malvern</CITY>
<ZIP>3144</ZIP>
<REGION>Victoria</REGION>
<COUNTRY CODE="AU">Australia</COUNTRY>
<PHONE_1>613 9508 1652</PHONE_1>
<PHONE_2>613 9509 4445</PHONE_2>
<FAX_1>613 9508 1653</FAX_1>
<FAX_2/>
</ADDRESS>
<FOOTNOTE/>
</PERSON>
</CREATORS>
<DATES MODIFIED="2013-02-12 23:37:59 -0500" MODIFIED_BY="Renea Johnston">
<UP_TO_DATE>
<DATE DAY="11" MONTH="10" YEAR="2012"/>
</UP_TO_DATE>
<LAST_SEARCH>
<DATE DAY="11" MONTH="10" YEAR="2012"/>
</LAST_SEARCH>
<NEXT_STAGE>
<DATE DAY="11" MONTH="10" YEAR="2014"/>
</NEXT_STAGE>
<PROTOCOL_PUBLISHED ISSUE="3" YEAR="1999"/>
<REVIEW_PUBLISHED ISSUE="2" YEAR="2002"/>
<LAST_CITATION_ISSUE ISSUE="2" YEAR="2002"/>
</DATES>
<WHATS_NEW MODIFIED="2013-04-22 11:35:46 -0400" MODIFIED_BY="[Empty name]">
<WHATS_NEW_ENTRY EVENT="NEW_CITATION_OLD_CONCLUSIONS" MODIFIED="2013-02-12 23:39:11 -0500" MODIFIED_BY="[Empty name]">
<DATE DAY="13" MONTH="2" YEAR="2013"/>
<DESCRIPTION>
<P>New authors; substantial changes to methodology including outcomes as recommended by IMMPACT, risk of bias tables, and summary of findings tables.</P>
</DESCRIPTION>
</WHATS_NEW_ENTRY>
<WHATS_NEW_ENTRY EVENT="UPDATE" MODIFIED="2013-04-22 11:35:40 -0400" MODIFIED_BY="[Empty name]">
<DATE DAY="11" MONTH="10" YEAR="2012"/>
<DESCRIPTION>
<P>New search conducted 11 October 2012, and four new trials were added to the review. Fifteen trials are included in this review update; 11/14 trials from the first review, plus four trials identified from the updated search. <LINK REF="STD-Tsuyama-1979" TYPE="STUDY">Tsuyama 1979</LINK> was not identified in the previous search; <LINK REF="STD-Spacca-2005" TYPE="STUDY">Spacca 2005</LINK>, <LINK REF="STD-B_x00e4_cker-2011" TYPE="STUDY">Bäcker 2011</LINK>, and <LINK REF="STD-Polat-2011" TYPE="STUDY">Polat 2011</LINK> were published after publication of the previous review.</P>
<P>The three trials that were included in the original review but excluded in the update were <LINK REF="STD-Primbs-1983" TYPE="STUDY">Primbs 1983</LINK> (excluded because it was clearly not an RCT in the translated report); <LINK REF="STD-Percy-1981" TYPE="STUDY">Percy 1981</LINK> (excluded because it was not clear what proportion of participants labelled as having tennis elbow had lateral versus medial epicondylitis); and <LINK REF="STD-F_x00f6_rster-1997" TYPE="STUDY">Förster 1997</LINK> (excluded because the published paper was a subgroup analysis of an unpublished RCT).</P>
</DESCRIPTION>
</WHATS_NEW_ENTRY>
<WHATS_NEW_ENTRY EVENT="AMENDMENT" MODIFIED="2013-04-22 11:35:46 -0400" MODIFIED_BY="[Empty name]">
<DATE DAY="28" MONTH="10" YEAR="2009"/>
<DESCRIPTION>
<P>L Barnsley and S Hall contributed content expertise for the original review.</P>
</DESCRIPTION>
</WHATS_NEW_ENTRY>
</WHATS_NEW>
<HISTORY MODIFIED="2009-10-27 23:06:28 -0400" MODIFIED_BY="[Empty name]">
<WHATS_NEW_ENTRY EVENT="NEW_CITATION_OLD_CONCLUSIONS" MODIFIED="2009-06-11 00:52:24 -0400" MODIFIED_BY="[Empty name]">
<DATE DAY="11" MONTH="6" YEAR="2009"/>
<DESCRIPTION>
<P>Substantive amendment</P>
</DESCRIPTION>
</WHATS_NEW_ENTRY>
<WHATS_NEW_ENTRY EVENT="AMENDMENT" MODIFIED="2009-10-27 23:06:28 -0400" MODIFIED_BY="[Empty name]">
<DATE DAY="11" MONTH="6" YEAR="2009"/>
<DESCRIPTION>
<P>Converted to new review format.</P>
</DESCRIPTION>
</WHATS_NEW_ENTRY>
</HISTORY>
<SOURCES_OF_SUPPORT>
<INTERNAL_SOURCES>
<SOURCE>
<NAME>Thai Cochrane Network</NAME>
<COUNTRY CODE="TH">Thailand</COUNTRY>
<DESCRIPTION/>
</SOURCE>
<SOURCE>
<NAME>Australasian Cochrane Centre</NAME>
<COUNTRY CODE="AU">Australia</COUNTRY>
<DESCRIPTION/>
</SOURCE>
</INTERNAL_SOURCES>
<EXTERNAL_SOURCES>
<SOURCE>
<NAME>The Wellcome Trust, UK and the Australian National Health and Medical Research Council, through funding of the SEA-ORCHID Project</NAME>
<COUNTRY CODE="AU">Australia</COUNTRY>
<DESCRIPTION/>
</SOURCE>
</EXTERNAL_SOURCES>
</SOURCES_OF_SUPPORT>
<MESH_TERMS VERIFIED="NO"/>
<KEYWORDS/>
</COVER_SHEET>
<MAIN_TEXT MODIFIED="2013-04-23 09:29:09 -0400" MODIFIED_BY="[Empty name]">
<SUMMARY MODIFIED="2013-04-22 11:50:12 -0400" MODIFIED_BY="[Empty name]">
<TITLE MODIFIED="2009-10-29 05:45:37 -0400" MODIFIED_BY="[Empty name]">Non-steroidal anti-inflammatory drugs (NSAIDs) for treating tennis elbow pain in adults</TITLE>
<SUMMARY_BODY MODIFIED="2013-04-22 11:50:12 -0400" MODIFIED_BY="[Empty name]">
<P>This summary of a Cochrane review presents what we know from research about the effects of non-steroidal anti-inflammatory drugs (NSAIDs) on lateral elbow pain, also known as <I>tennis elbow</I>. The review, which included 13 trials involving 664 participants, shows the following:</P>
<P>
<B>In people with lateral elbow pain:</B>
</P>
<P>- Topical NSAIDs (applied to the skin in a gel) may improve treatment success.</P>
<P>- We are uncertain whether topical NSAIDs improve pain because of the low quality of the evidence.</P>
<P>- NSAIDs applied to the skin may result in a skin rash.</P>
<P>- We are uncertain whether NSAIDs taken orally in tablet form improve pain or function because of the low quality of the evidence.</P>
<P>- NSAIDs in tablet form probably result in increased stomach pain and diarrhoea, but we are not certain of the precise estimates because of the low quality of the evidence.</P>
<P>Function and quality of life were not reported.</P>
<P>We do not have precise information about side effects and complications, particularly for rare but serious side effects. NSAIDs may cause stomach, kidney or heart problems, and NSAIDs applied to the skin may cause rash.</P>
<P>
<B>What is lateral elbow pain and what are NSAIDs?</B>
</P>
<P>Lateral elbow pain, or tennis elbow, can occur for no reason or can be caused by too much stress on the tendon at the elbow. This condition can cause the outside of the elbow (lateral epicondyle) and the upper forearm to become painful and tender to touch. Pain can last for 6 months to 2 years, and may get better on its own. Many treatments have been used to treat elbow pain, but it is not clear whether these treatments work, or if the pain simply goes away on its own.</P>
<P>Non-steroidal anti-inflammatory drugs (NSAIDs) (e.g. ibuprofen, diclofenac, celecoxib) can be used to manage the pain. NSAIDs can be applied directly to the skin in the form of a gel, or can be taken in tablet form.</P>
<P>
<B>Best estimate of what happens to people with lateral elbow pain who use NSAIDs</B>
</P>
<P>
<B>Pain (higher scores mean worse or more severe pain):</B>
<BR/>- People who used NSAID gel compared with a placebo gel rated their pain 1.6 points lower on a scale of 0 to 10 after 4 weeks (16% absolute improvement).</P>
<P>- People who applied NSAID gel rated their pain to be 2.14 on a scale of 0 to 10 after 4 weeks.</P>
<P>- People who applied placebo gel rated their pain to be 3.78 on a scale of 0 to 10.</P>
<P>
<B>Successful treatment:</B>
</P>
<P>- 24 more people out of 100 reported improvement in their condition with topical NSAIDs (24% absolute improvement).</P>
<P>- 73 out of 100 people who applied NSAID gel improved.</P>
<P>- 49 out of 100 people who applied placebo gel improved.</P>
<P>
<B>Side effects:</B>
<BR/>- 1 more person using NSAID gel out of 100 had minor side effects such as skin rash at the site of application (0% absolute difference, ranging from 5% fewer to 6% more).</P>
<P>- 2 out of 100 using NSAID gel had side effects,</P>
<P>- 1 out of 100 people using placebo gel had side effects.</P>
</SUMMARY_BODY>
</SUMMARY>
<ABSTRACT MODIFIED="2013-04-22 11:43:27 -0400" MODIFIED_BY="[Empty name]">
<ABS_BACKGROUND MODIFIED="2013-04-22 11:36:12 -0400" MODIFIED_BY="[Empty name]">
<P>Lateral elbow pain, or tennis elbow, is a common condition that causes pain in the elbow and forearm. Although self-limiting, it can be associated with significant disability and often results in work absence. It is often treated with topical and oral non-steroidal anti-inflammatory drugs (NSAIDs). This is an update of a review first published in 2002 (search date October 11, 2012).</P>
</ABS_BACKGROUND>
<ABS_OBJECTIVES MODIFIED="2012-12-17 20:15:40 -0500" MODIFIED_BY="[Empty name]">
<P>To assess the benefits and harms of topical and oral NSAIDs for treating people with lateral elbow pain.</P>
</ABS_OBJECTIVES>
<ABS_SEARCH_STRATEGY MODIFIED="2013-04-22 11:36:24 -0400" MODIFIED_BY="[Empty name]">
<P>We searched the Cochrane Central Register of Controlled Trials, MEDLINE, CINAHL, EMBASE and SciSearch up to October 11, 2012. No language restriction was applied.</P>
</ABS_SEARCH_STRATEGY>
<ABS_SELECTION_CRITERIA MODIFIED="2013-04-22 11:36:32 -0400" MODIFIED_BY="[Empty name]">
<P>Studies were included if they were randomised or quasi-randomised controlled trials (RCTs or CCTs) that compared topical or oral NSAIDs with placebo or another intervention, or compared two NSAIDs in adults with lateral elbow pain. Outcomes of interest were pain, function, quality of life, pain-free grip strength, overall treatment success, work loss and adverse effects.</P>
</ABS_SELECTION_CRITERIA>
<ABS_DATA_COLLECTION MODIFIED="2012-05-26 01:45:30 -0400" MODIFIED_BY="Porjai Pattanittum">
<P>Two review authors independently selected the studies for inclusion, extracted the data, and performed a risk of bias assessment.</P>
</ABS_DATA_COLLECTION>
<ABS_RESULTS MODIFIED="2013-04-22 11:42:23 -0400" MODIFIED_BY="[Empty name]">
<P>Fifteen trials, involving 759 participants and reporting 17 comparisons, were included in the review. Four new trials identified from the updated search were included, along with 11 of 14 trials included in the original review (three trials included in the previous review were found not to meet inclusion criteria). Of eight trials that studied topical NSAIDs (301 participants), five compared topical NSAIDs with placebo, one compared manipulative therapy and topical NSAIDs with manipulative therapy alone, one compared leech therapy with topical NSAIDs and one compared two different topical NSAIDs. Of seven trials that investigated oral NSAIDs (437 participants), two compared oral NSAIDs with placebo, one compared oral NSAIDs and bandaging with bandaging alone, three compared oral NSAIDs with glucocorticoid injection, one compared oral NSAIDs with a vasodilator and two compared two different oral NSAIDs. No trials directly compared topical NSAIDs with oral NSAIDs. Few trials used intention-to-treat analysis, and the sample size of most was small. The median follow-up was 2 weeks (range 1 week to 1 year).<B> </B>
</P>
<P>Low-quality evidence was obtained from three trials (153 participants) suggesting that topical NSAIDs were significantly more effective than placebo with respect to pain in the short term (mean difference -1.64, 95% confidence interval (CI) -2.42 to -0.86) and number needed to treat to benefit (7 (95% CI 3 to 21) on a 0 to 10 scale). Low-quality evidence was obtained from one trial (85 participants) indicating that significantly more participants report fair, good or excellent effectiveness with topical NSAIDs versus placebo at 28 days (14 days of therapy) (risk ratio (RR) 1.49, 95% CI 1.04 to 2.14). No participants withdrew as the result of adverse events, but some studies reported mild adverse effects such as rash in 2.5% of those exposed to topical NSAIDs compared with 1.3% of those exposed to placebo.</P>
<P>Low-quality and conflicting evidence regarding the benefits of oral NSAIDs obtained from two trials could not be pooled. One trial found significantly greater improvement in pain compared with placebo, and the other trial found no between-group differences; neither trial found differences in function. One trial reported a withdrawal due to adverse effects for a participant in the NSAIDs group. Use of oral NSAIDs was associated with increased risk of gastrointestinal side effects compared with placebo in one trial in the review. Another trial reported discontinuation of treatment due to gastrointestinal side effects in four participants taking NSAIDs, and another participant developed an allergic reaction in response to oral NSAIDs.</P>
<P>Very scant and conflicting evidence regarding the comparative effects of oral NSAIDs and glucocorticoid injection was obtained. One trial reported a significant improvement in pain with glucocorticoid injection, and another found no between-group differences; treatment success was similar between groups (RR of fair, good or excellent effectiveness 0.74; 95% CI 0.43 to 1.26). Transient pain may occur following injection.</P>
</ABS_RESULTS>
<ABS_CONCLUSIONS MODIFIED="2013-04-22 11:43:27 -0400" MODIFIED_BY="[Empty name]">
<P>There remains limited evidence from which to draw firm conclusions about the benefits or harms of topical or oral NSAIDs in treating lateral elbow pain. Although data from five placebo-controlled trials suggest that topical NSAIDs may be beneficial in improving pain (for up to 4 weeks), non-normal distribution of data and other methodological issues precluded firm conclusions. Some people may expect a mild transient skin rash. Evidence about the benefits of oral NSAIDs has been conflicting, although oral NSAID use may result in gastrointestinal adverse effects in some people. No direct comparisons between oral and topical NSAIDs were available. Some trials demonstrated greater benefit from glucocorticoid injection than from NSAIDs in the short term, but this was not apparent in all studies and was not apparent by 6 months in the only study that included longer-term outcomes.</P>
</ABS_CONCLUSIONS>
</ABSTRACT>
<BODY MODIFIED="2013-04-22 21:36:48 -0400" MODIFIED_BY="[Empty name]">
<BACKGROUND MODIFIED="2013-04-22 12:00:15 -0400" MODIFIED_BY="[Empty name]">
<P>This Cochrane review is one of a series of Cochrane reviews of interventions for lateral elbow pain in adults and is an update of a Cochrane review first published in 2002 (<LINK REF="REF-Green-2002" TYPE="REFERENCE">Green 2002</LINK>).</P>
<CONDITION MODIFIED="2013-04-22 11:57:23 -0400" MODIFIED_BY="[Empty name]">
<P>Lateral elbow pain is described by many analogous terms in the literature, including <I>tennis elbow, lateral epicondylitis, lateral epicondylalgia, rowing elbow, tendonitis of the common extensor origin,</I> and <I>peritendonitis of the elbow.</I> For the purposes of this review, the term <I>lateral elbow pain</I> will be used as it best describes the site of the pain, and will allow for greater clarity of inclusion.</P>
<P>Lateral elbow pain is a common disorder with a prevalence of 1% to 3% in adults of working age (<LINK REF="REF-Allander-1974" TYPE="REFERENCE">Allander 1974</LINK>; <LINK REF="REF-Roquelaure-2006" TYPE="REFERENCE">Roquelaure 2006</LINK>; <LINK REF="REF-Shiri-2006" TYPE="REFERENCE">Shiri 2006</LINK>; <LINK REF="REF-Walker_x002d_Bone-2004" TYPE="REFERENCE">Walker-Bone 2004</LINK>). It affects up to 15% of workers in at-risk industries and is a common sports injury ( <LINK REF="REF-Hume-2006" TYPE="REFERENCE">Hume 2006</LINK>; <LINK REF="REF-Ranney-1995" TYPE="REFERENCE">Ranney 1995</LINK>; <LINK REF="REF-Walker_x002d_Bone-2004" TYPE="REFERENCE">Walker-Bone 2004</LINK>). It has a reported incidence of between 4.8% and 5.3% in Dutch general practice, with an incidence of 11 per 1000 person-years in the 40 to 60-year age group&#65293;the age group most affected (<LINK REF="REF-Bot-2005" TYPE="REFERENCE">Bot 2005</LINK>). <LINK REF="REF-Shiri-2006" TYPE="REFERENCE">Shiri 2006</LINK> reported no gender difference in the prevalence of lateral elbow pain, although a slight excess of men (<LINK REF="REF-Walker_x002d_Bone-2004" TYPE="REFERENCE">Walker-Bone 2004</LINK>) or women (<LINK REF="REF-Roquelaure-2006" TYPE="REFERENCE">Roquelaure 2006</LINK>) has been reported.</P>
<P>The acute pain of lateral elbow pain usually lasts 6 to 12 weeks and often results in work absence (<LINK REF="REF-Mallen-2009" TYPE="REFERENCE">Mallen 2009</LINK>). For most it is a self-limiting condition, but for some episodes may persist for up to 2 years. One study found that 80% of participants with elbow pain already greater than 4 weeks' duration recovered after one year without any specific treatment (<LINK REF="REF-Bisset-2005" TYPE="REFERENCE">Bisset 2005</LINK>). Prognostic factors at least moderately associated with a poorer outcome at one year include previous occurrence, high physical strain at work, manual jobs, high baseline levels of pain and/or distress, and inadequate social support. Depression and ineffective coping skills have also been found to strongly predict disability from lateral elbow pain (<LINK REF="REF-Alizadehkhaiyat-2007" TYPE="REFERENCE">Alizadehkhaiyat 2007</LINK>). A recent ultrasound study determined that a lateral collateral ligament tear or large (&#8805; 6 mm) intrasubstance tears were associated with a poorer outcome, but no relationship between tendon thickness or neovascularity and outcome was seen (<LINK REF="REF-Clarke-2010" TYPE="REFERENCE">Clarke 2010</LINK>). Fewer than 10% of patients with lateral elbow pain need to undergo surgery (<LINK REF="REF-Nirschl-1979" TYPE="REFERENCE">Nirschl 1979</LINK>).</P>
</CONDITION>
<INTERVENTION MODIFIED="2013-04-22 11:57:58 -0400" MODIFIED_BY="[Empty name]">
<P>Non-steroidal anti-inflammatory drugs (NSAIDs) have long been the first line of treatment, along with simple analgesics, for all sites of tendonitis, including that of the lateral elbow. Several types of oral and topical NSAIDs are available over-the-counter or on prescription. These drugs are among the most frequently prescribed in the developed world. They are also well known to be associated with significant morbidity, particularly in terms of gastrointestinal and cardiovascular adverse effects (<LINK REF="REF-Biskupiak-2006" TYPE="REFERENCE">Biskupiak 2006</LINK>; <LINK REF="REF-Garcia-2001" TYPE="REFERENCE">Garcia 2001</LINK>; <LINK REF="REF-Kearney-2006" TYPE="REFERENCE">Kearney 2006</LINK>).</P>
</INTERVENTION>
<THEORY MODIFIED="2013-04-22 11:59:28 -0400" MODIFIED_BY="[Empty name]">
<P>NSAIDs work by preventing an enzyme called <I>cyclooxygenase</I> (COX) from making prostaglandins. Prostaglandins are hormone-like chemicals in the body that contribute to inflammation, pain and fever. By reducing production of prostaglandins, NSAIDs help relieve symptoms related to fever, inflammation and mild to moderate pain.</P>
<P>Two COX enzymes&#65293;COX-1 and COX-2&#65293;produce prostaglandins. However, only COX-1 produces prostaglandins that support platelets and protect the stomach lining. It also helps to maintain kidney function. COX-2 is produced when joints are injured or inflamed.</P>
<P>Most NSAIDs are nonselective inhibitors. This means that they inhibit both COX-1 and COX-2. Because nonselective NSAIDs also act on COX-1, they may decrease protective stomach prostaglandin levels, leading to stomach ulcers. A newer class of NSAIDs&#65293;the coxibs&#65293;selectively inhibit COX-2 and therefore have less adverse effect on the stomach.</P>
</THEORY>
<IMPORTANCE MODIFIED="2013-04-22 12:00:15 -0400" MODIFIED_BY="[Empty name]">
<P>NSAIDs are often used to treat lateral elbow pain. In our previous review, we concluded that there was some support for the use of topical NSAIDs to relieve lateral elbow pain in the short term but insufficient evidence to recommend or discourage the use of oral NSAIDs (<LINK REF="REF-Green-2002" TYPE="REFERENCE">Green 2002</LINK>). No data have directly compared topical with oral NSAIDs, and some data suggest that glucocorticoid injection may be more effective than oral NSAIDs in the short term. It is important to perform an update of this review to determine whether new data are available that may alter our conclusions.</P>
</IMPORTANCE>
</BACKGROUND>
<OBJECTIVES MODIFIED="2012-12-17 20:22:15 -0500" MODIFIED_BY="[Empty name]">
<P>To determine the benefits and harms of NSAIDs for patients with lateral elbow pain.</P>
</OBJECTIVES>
<METHODS MODIFIED="2013-04-22 14:12:13 -0400" MODIFIED_BY="[Empty name]">
<SELECTION_CRITERIA MODIFIED="2013-04-22 12:05:47 -0400" MODIFIED_BY="[Empty name]">
<CRIT_STUDIES MODIFIED="2013-04-22 12:00:46 -0400" MODIFIED_BY="[Empty name]">
<P>All published randomised or quasi-randomised controlled trials (RCTs or CCTs) that compare NSAID therapy with another therapy (placebo or active, including non-pharmacological therapies) for lateral elbow pain were considered for inclusion.</P>
<P>Only trials published as a full article or available as a full trial report were considered for inclusion.</P>
</CRIT_STUDIES>
<CRIT_PARTICIPANTS MODIFIED="2013-04-22 12:01:18 -0400" MODIFIED_BY="[Empty name]">
<P>Inclusion in this review was restricted to trials with participants meeting the following criteria:</P>
<UL>
<LI>Adults &gt;16 years of age.</LI>
<LI>No history of significant trauma or systemic inflammatory conditions such as rheumatoid arthritis.</LI>
<LI>Studies of various soft tissue diseases and pain due to tendonitis at all sites were included provided that the lateral elbow pain results were presented separately, or &gt; 90% of participants in the trial had lateral elbow pain.</LI>
</UL>
</CRIT_PARTICIPANTS>
<CRIT_INTERVENTIONS MODIFIED="2013-04-22 12:01:33 -0400" MODIFIED_BY="[Empty name]">
<P>All randomised controlled comparisons of NSAIDs versus placebo, or another intervention, or of varying types and dosages of topical or oral NSAIDs compared with each other were included, and comparisons were established according to intervention.</P>
</CRIT_INTERVENTIONS>
<CRIT_OUTCOMES MODIFIED="2013-04-22 12:05:47 -0400" MODIFIED_BY="[Empty name]">
<P>Considerable variation has been noted in the outcome measures reported in clinical trials of interventions for pain. However, there is general agreement that outcome measures of greatest importance to patients should be considered.</P>
<P>The Initiative on Methods, Measurement, and Pain Assessment in Clinical Trials (IMMPACT) has published consensus recommendations for determining clinically important changes in outcome measures in clinical trials of interventions for chronic pain (<LINK REF="REF-Dworkin-2008" TYPE="REFERENCE">Dworkin 2008</LINK>). Reductions in pain intensity of &#8805; 30% and &#8805; 50% reflect moderate and substantial clinically important differences, respectively, and it is recommended that the proportion of patients who respond with these degrees of pain relief should be reported.<BR/>
</P>
<P>Continuous outcome measures in pain trials (such as mean change on a 100-mm visual analogue scale (VAS)) may not follow a Gaussian distribution. Often, a bimodal distribution is seen instead, where patients tend to report either very good or very poor pain relief (<LINK REF="REF-Moore-2010a" TYPE="REFERENCE">Moore 2010a</LINK>). This creates difficulty in interpreting the meaning of average changes in continuous pain measures. For this reason, a dichotomous outcome measure (the proportion of participants reporting &#8805; 30% pain relief) is likely to be more clinically relevant and was the primary efficacy measure in this review.</P>
<P>The original review determined that no trials had included a dichotomous outcome for pain, in keeping with the recognition that it has been the practice in most trials of interventions for chronic pain to report continuous measures only. We therefore also included the mean change in pain score as a secondary efficacy measure.</P>
<P>The pain state at the end of a clinical trial of an analgesic intervention, in contrast to measures of pain improvement, has also been recommended as a clinically relevant dichotomous outcome measure and was included as a secondary efficacy measure in this review (<LINK REF="REF-Moore-2010a" TYPE="REFERENCE">Moore 2010a</LINK>). A global rating of treatment satisfaction, such as the Patient Global Impression of Change scale (PGIC), which provides an outcome measure that integrates pain relief, changes in function and side effects into a single, interpretable measure, is also recommended by IMMPACT, and was included as a secondary outcome measure (<LINK REF="REF-Dworkin-2008" TYPE="REFERENCE">Dworkin 2008</LINK>).</P>
<CRIT_OUTCOMES_PRIMARY MODIFIED="2013-04-22 12:04:11 -0400" MODIFIED_BY="Miranda Cumpston">
<UL>
<LI>Primary endpoint to assess benefit: patient-reported pain relief of 30% or greater.</LI>
<LI>Primary endpoint to assess harm: number of withdrawals due to adverse events.</LI>
</UL>
</CRIT_OUTCOMES_PRIMARY>
<CRIT_OUTCOMES_SECONDARY MODIFIED="2013-04-22 12:05:47 -0400" MODIFIED_BY="Miranda Cumpston">
<UL>
<LI>Pain:</LI>
</UL>
<UL>
<UL>
<LI>Patient-reported pain relief of 50% or greater.</LI>
<LI>Patient-reported global impression of clinical change (PGIC) in pain much or very much improved.</LI>
<LI>Proportion of patients achieving pain score below 30/100 mm on a visual analogue scale (VAS).</LI>
<LI>Mean change in pain score on a VAS or a numerical rating scale.</LI>
</UL>
</UL>
<UL>
<LI>Function/disability as measured by disease-specific disability measures such as the Patient-Rated Tennis Elbow Evaluation questionnaire (PRTEE) (<LINK REF="REF-Rompe-2007" TYPE="REFERENCE">Rompe 2007</LINK>).</LI>
<LI>Quality of life as measured by generic measures (such as components of the Short Form-36 (SF-36)) or disease-specific tools.</LI>
<LI>Grip strength (preferably pain-free maximum grip strength).</LI>
<LI>Patient's perception of overall effect as measured by a global rating of treatment satisfaction such as the Patient Global Impression of Change scale (PGIC).</LI>
<LI>Numbers and types of adverse events (AEs) and serious adverse events (SAEs, defined as AEs that are fatal, are life-threatening, or require hospitalisation).</LI>
<LI>Return to work.</LI>
</UL>
<P>The duration of trials of interventions for pain varies considerably. The efficacy of interventions, and the relative balance of benefits and harms, may vary according to the duration of the trial; therefore the combination of results from trials of different duration may represent a source of bias in systematic reviews (<LINK REF="REF-Moore-2010a" TYPE="REFERENCE">Moore 2010a</LINK>).</P>
<P>For the purpose of this review, and if data were available, we planned to group endpoints into &lt; 1 week, 1 to 6 weeks and &gt; 6 weeks.</P>
</CRIT_OUTCOMES_SECONDARY>
</CRIT_OUTCOMES>
</SELECTION_CRITERIA>
<SEARCH_METHODS MODIFIED="2013-04-22 12:06:07 -0400" MODIFIED_BY="[Empty name]">
<ELECTRONIC_SEARCHES MODIFIED="2013-04-22 12:06:07 -0400" MODIFIED_BY="[Empty name]">
<P>We searched the following databases for RCTs or CCTs using the search strategies detailed in the appendices on October 11, 2012:</P>
<UL>
<LI>Ovid MEDLINE 1946 to October 11, 2012 (<LINK REF="APP-01" TYPE="APPENDIX">Appendix 1</LINK>).</LI>
<LI>Ovid EMBASE 1947 to October 1, 2012 (<LINK REF="APP-02" TYPE="APPENDIX">Appendix 2</LINK>).</LI>
<LI>The Cochrane Central Register of Controlled Trials (CENTRAL) via <I>The Cochrane Library,</I> Issue 9 of 12, Sept 2012 (<LINK REF="APP-03" TYPE="APPENDIX">Appendix 3</LINK>).</LI>
<LI>EbscoHost CINAHL 1982 to October 2012 (<LINK REF="APP-04" TYPE="APPENDIX">Appendix 4</LINK>).</LI>
<LI>ISI Web of Science Science Citation Index Expanded (SCI-EXPANDED) 1899 to present (<LINK REF="APP-05" TYPE="APPENDIX">Appendix 5</LINK>).</LI>
</UL>
<P>No language restrictions were applied.</P>
</ELECTRONIC_SEARCHES>
</SEARCH_METHODS>
<DATA_COLLECTION MODIFIED="2013-04-22 14:12:13 -0400" MODIFIED_BY="[Empty name]">
<STUDY_SELECTION MODIFIED="2013-04-22 12:06:54 -0400" MODIFIED_BY="[Empty name]">
<P>Following identification of potential trials for inclusion by the previously outlined search strategy (TT), the methods sections of all identified trials were reviewed independently according to the predetermined criteria by two investigators (PP, TT). The investigator compiling the references (TT) decided on potentially relevant trials (based on whether the article was an RCT of an NSAID for lateral elbow pain), excluding those for which it was clear that the intervention and the population did not meet the inclusion criteria. Any disagreement in study selection was resolved by consensus or by discussion with a third and a fourth review author (RB and SG) as needed. Studies were translated into English where necessary.</P>
</STUDY_SELECTION>
<DATA_EXTRACTION MODIFIED="2011-10-17 23:23:05 -0400" MODIFIED_BY="[Empty name]">
<P>Two review authors (PP and TT) independently extracted data using a standardised data extraction form for the newly included trials. Both authors also checked extracted data for the original studies in the review. RB checked all data extraction and helped to resolve any disagreements. </P>
<P>Raw data for outcomes of interest (means and standard deviations for continuous outcomes and number of events for dichotomous outcomes) were extracted where available from the published reports.</P>
</DATA_EXTRACTION>
<QUALITY_ASSESSMENT MODIFIED="2013-04-22 12:19:44 -0400" MODIFIED_BY="Porjai Pattanittum">
<P>All studies, including those previously included,<B> </B>were reviewed independently by two review authors (PP, TT) for assessment of risk of bias according to the guidelines put forth in the <I>Cochrane Handbook for Systematic Reviews of Interventions</I> (<LINK REF="REF-Higgins-2011" TYPE="REFERENCE">Higgins 2011</LINK>). Assessment criteria included appropriateness of sequence generation, allocation concealment, blinding of participants, personnel and outcome assessments, management of incomplete outcome data, selective outcome reporting, and other sources of bias.<BR/>

<BR/>
To determine the risk of bias of a study, for each criterion the presence of sufficient information and the likelihood of potential bias were evaluated. Each criterion was rated as low, high, or unclear (either lack of information or uncertainty over the potential for) risk of bias. In a consensus meeting, disagreements among the review authors were discussed and resolved. A third and a fourth review author (RB and SG) were available for assistance if no consensus had been reached.</P>
</QUALITY_ASSESSMENT>
<EFFECT_MEASURES MODIFIED="2013-04-22 12:21:06 -0400" MODIFIED_BY="Porjai Pattanittum">
<P>The data were summarized in a meta-analysis only if clinical and statistical homogeneity was sufficient.</P>
<P>For continuous data, results were analysed as mean differences between the intervention and the comparator group (MD), with corresponding 95% confidence intervals (CIs). When outcomes were reported on non-standard scales, using differing units and methods of assessment (e.g. disability scales), a standardised mean difference was selected. The mean difference between the treated group and the control group is weighted by the inverse of the variance in the pooled treatment estimate.</P>
<P>When trial results were not normally distributed and so reported as median and range, the trial was not included in the meta-analysis, but results were presented in Additional Tables.<BR/>
</P>
<P>For dichotomous data, we calculated risk ratios (RRs) with corresponding 95% CIs.</P>
<P>Meta-analysis was facilitated by RevMan5 (<LINK REF="REF-RevMan2011" TYPE="REFERENCE">RevMan2011</LINK>). The statistics and the 95% CIs were presented for all outcomes.</P>
<P>For studies that included more than two intervention groups, making multiple pairwise comparisons between all possible pairs of intervention groups possible, we planned to include the same group of participants only once in the meta-analysis.</P>
</EFFECT_MEASURES>
<MISSING_DATA MODIFIED="2013-04-22 12:21:36 -0400" MODIFIED_BY="[Empty name]">
<P>For included trials where required data were not reported or could not be calculated, further details were requested of first authors. If no further details were provided, the trial was included in the review and was fully described, but was not included in the meta-analysis. An entry to that effect was made in the notes section of the <LINK TAG="CHARACTERISTICS_OF_INCLUDED_STUDIES" TYPE="SECTION">Characteristics of included studies</LINK> table.</P>
</MISSING_DATA>
<HETEROGENEITY_ASSESSMENT MODIFIED="2013-04-22 12:22:03 -0400" MODIFIED_BY="[Empty name]">
<P>Before a meta-analysis was performed, we assessed studies for clinical homogeneity with respect to type of therapy, control group, and outcomes. For any studies judged as clinically homogeneous, statistical heterogeneity was assessed using the I<SUP>2 </SUP>statistic (<LINK REF="REF-Deeks-2009" TYPE="REFERENCE">Deeks 2009</LINK>) and the following as a rough guide for interpretation: 0% to 40% might not be important, 30% to 60% might represent moderate heterogeneity, 50% to 90% might represent substantial heterogeneity, and 75% to 100% might signify considerable heterogeneity.</P>
<P>In cases of considerable heterogeneity (defined as I<SUP>2 </SUP>&#8805; 75%), we planned to explore the data further, including subgroup analyses, in an attempt to explain the heterogeneity.</P>
</HETEROGENEITY_ASSESSMENT>
<BIAS_ASSESSMENT MODIFIED="2013-04-22 12:22:18 -0400" MODIFIED_BY="[Empty name]">
<P>We planned to assess the potential for reporting bias using funnel plots if &#8805;10 studies were available. However, the lack of trials and the heterogeneity of outcomes in the included studies precluded this analysis.</P>
</BIAS_ASSESSMENT>
<DATA_SYNTHESIS MODIFIED="2013-04-22 12:22:35 -0400" MODIFIED_BY="[Empty name]">
<P>Where studies were sufficiently homogeneous that it remained clinically meaningful for data to be pooled, meta-analysis was performed using a random-effects model, regardless of the I<SUP>2 </SUP>results. Analysis was performed using Review Manager 5, and forest plots were produced for all analyses.</P>
</DATA_SYNTHESIS>
<SENSITIVITY_ANALYSIS MODIFIED="2013-04-22 14:12:13 -0400" MODIFIED_BY="[Empty name]">
<P>Two sensitivity analyses were planned and performed in the original review:</P>
<UL>
<LI>Trials published in languages other than English were excluded to assess the effect of possible publication bias. This sensitivity analysis was not performed in this update because of reduced concerns about publication and outcome assessment bias in non-English studies.</LI>
<LI>Trials in which the outcome assessor was not blinded were excluded to assess the possible effect of detection bias. This was not done in this update because it is recognised that all trials included in this review were at generally high risk of bias.</LI>
</UL>
<P>A third sensitivity analysis, not prespecified, was conducted to assess the effect of including skewed data in a single meta-analysis (<LINK REF="CMP-001.01" TYPE="ANALYSIS">Analysis 1.1</LINK>).</P>
<SUBSECTION>
<HEADING LEVEL="3">Presentation of key results</HEADING>
<P>Key results for the main comparisons (topical NSAIDs vs placebo, oral NSAIDs vs placebo and oral NSAIDs vs glucocorticoid injection) are presented in the summary of findings tables. These tables provide key information concerning the quality of evidence, the magnitude of effect of the interventions examined, and the sum of available data on outcomes (patient-reported pain relief &#8805; 30%, number of withdrawals due to adverse events, mean change in pain score on a VAS or a numerical rating scale, function, quality of life, participant's perception of overall effect and the total number of adverse events), as recommended by The Cochrane Collaboration (<LINK REF="REF-Sch_x00fc_nemann-2011a" TYPE="REFERENCE">Schünemann 2011a</LINK>); and an overall grading of the evidence related to each of the main outcomes using the GRADE approach (<LINK REF="REF-Sch_x00fc_nemann-2011b" TYPE="REFERENCE">Schünemann 2011b</LINK>).</P>
<P>In addition to the absolute and relative magnitude of effect for dichotomous outcomes provided in the summary of findings table, the number needed to treat to benefit (NNTB) or the number needed to treat to harm (NNTH) was calculated where appropriate from the control group event rate and the risk ratio (RR) using the Visual Rx number needed to treat (NNT) calculator (<LINK REF="REF-Cates-2008" TYPE="REFERENCE">Cates 2008</LINK>). For continuous outcomes, the NNT was calculated using the Wells calculator software available at the Cochrane Musculoskeletal Group (CMSG) editorial office (<A HREF="http://musculoskeletal.cochrane.org/">http://musculoskeletal.cochrane.org/</A>). We assumed a minimal clinically important difference (MCID) of 1.5 points on a 10-point scale for pain, and 10 points on a 100-point scale for function or disability for input into the calculator.</P>
</SUBSECTION>
</SENSITIVITY_ANALYSIS>
</DATA_COLLECTION>
</METHODS>
<RESULTS MODIFIED="2013-04-22 21:36:48 -0400" MODIFIED_BY="[Empty name]">
<STUDY_DESCRIPTION MODIFIED="2013-04-22 21:36:48 -0400" MODIFIED_BY="[Empty name]">
<SEARCH_RESULTS MODIFIED="2013-04-22 12:29:19 -0400" MODIFIED_BY="[Empty name]">
<P>The initial database search identified 49 potentially relevant records, of which 14 studies were included in the original review (<LINK REF="FIG-01" TYPE="FIGURE">Figure 1</LINK>). The updated search identified 3002 records, of which 20 possibly eligible studies were assessed in full text. Fifteen trials (11/14 studies from the original review and 4 new studies identified from the updated search), reporting 17 comparisons, met the inclusion criteria.</P>
</SEARCH_RESULTS>
<INCLUDED_STUDIES_DESCR MODIFIED="2013-04-22 21:36:48 -0400" MODIFIED_BY="[Empty name]">
<P>A full description of each included study is given in the <LINK TAG="CHARACTERISTICS_OF_INCLUDED_STUDIES" TYPE="SECTION">Characteristics of included studies</LINK> table.</P>
<P>We identified four new trials that were not included in the previous review (<LINK REF="STD-B_x00e4_cker-2011" TYPE="STUDY">Bäcker 2011</LINK>; <LINK REF="STD-Polat-2011" TYPE="STUDY">Polat 2011</LINK>; <LINK REF="STD-Spacca-2005" TYPE="STUDY">Spacca 2005</LINK>; <LINK REF="STD-Tsuyama-1979" TYPE="STUDY">Tsuyama 1979</LINK>). <LINK REF="STD-Tsuyama-1979" TYPE="STUDY">Tsuyama 1979</LINK> was not identified in the previous search; and <LINK REF="STD-B_x00e4_cker-2011" TYPE="STUDY">Bäcker 2011</LINK>, <LINK REF="STD-Polat-2011" TYPE="STUDY">Polat 2011</LINK> and <LINK REF="STD-Spacca-2005" TYPE="STUDY">Spacca 2005</LINK> were published after publication of the previous review.</P>
<P>Eight trials investigated topical NSAIDs. Five trials compared topical NSAIDs with placebo (<LINK REF="STD-Burnham-1998" TYPE="STUDY">Burnham 1998</LINK>; <LINK REF="STD-Jenoure-1997" TYPE="STUDY">Jenoure 1997</LINK>; <LINK REF="STD-Schapira-1991" TYPE="STUDY">Schapira 1991</LINK>; <LINK REF="STD-Spacca-2005" TYPE="STUDY">Spacca 2005</LINK>; <LINK REF="STD-Tsuyama-1979" TYPE="STUDY">Tsuyama 1979</LINK>). Four of these assessed the effect of topical diclofenac (<LINK REF="STD-Burnham-1998" TYPE="STUDY">Burnham 1998</LINK>; <LINK REF="STD-Jenoure-1997" TYPE="STUDY">Jenoure 1997</LINK>; <LINK REF="STD-Schapira-1991" TYPE="STUDY">Schapira 1991</LINK>; <LINK REF="STD-Spacca-2005" TYPE="STUDY">Spacca 2005</LINK>), and one assessed the effect of topical indomethacin (<LINK REF="STD-Tsuyama-1979" TYPE="STUDY">Tsuyama 1979</LINK>).</P>
<P>One trial compared topical NSAIDs with no treatment (both groups also received manipulative therapy) (<LINK REF="STD-Burton-1988" TYPE="STUDY">Burton 1988</LINK>), another trial compared topical diclofenac with locally applied leeches (<LINK REF="STD-B_x00e4_cker-2011" TYPE="STUDY">Bäcker 2011</LINK>) and another trial compared two different topical NSAIDs (iontophoresis of topical sodium diclofenac or sodium salicylate) (<LINK REF="STD-Demirtas-1998" TYPE="STUDY">Demirtas 1998</LINK>).</P>
<P>Six trials investigated oral NSAIDs: two trials compared oral NSAIDs with placebo (<LINK REF="STD-Hay-1999" TYPE="STUDY">Hay 1999</LINK>; <LINK REF="STD-Labelle-1997" TYPE="STUDY">Labelle 1997</LINK>); one trial compared oral NSAIDs and bandaging with bandaging alone (<LINK REF="STD-Erturk-1997" TYPE="STUDY">Erturk 1997</LINK>); three trials compared oral NSAIDs with glucocorticoid injection (<LINK REF="STD-Erturk-1997" TYPE="STUDY">Erturk 1997</LINK>; <LINK REF="STD-Hay-1999" TYPE="STUDY">Hay 1999</LINK>; <LINK REF="STD-Saartok-1986" TYPE="STUDY">Saartok 1986</LINK>); one trial compared oral NSAIDs with betahistine dihydrochloride (<LINK REF="STD-Polat-2011" TYPE="STUDY">Polat 2011</LINK>) and two trials compared two different oral NSAIDs (<LINK REF="STD-Adelaar-1987" TYPE="STUDY">Adelaar 1987</LINK>; <LINK REF="STD-Stull-1986" TYPE="STUDY">Stull 1986</LINK>).</P>
<P>No trials were identified that directly compared topical NSAIDs with oral NSAIDs.</P>
<P>Of the included trials, 13 were published in English, one in Italian (<LINK REF="STD-Jenoure-1997" TYPE="STUDY">Jenoure 1997</LINK>) and one in Japanese (<LINK REF="STD-Tsuyama-1979" TYPE="STUDY">Tsuyama 1979</LINK>).</P>
<P>Only three trials followed participants for longer than 1 month: <LINK REF="STD-B_x00e4_cker-2011" TYPE="STUDY">Bäcker 2011</LINK> for 45 days, <LINK REF="STD-Polat-2011" TYPE="STUDY">Polat 2011</LINK> for six months and <LINK REF="STD-Hay-1999" TYPE="STUDY">Hay 1999</LINK> for 12 months.<BR/>
</P>
</INCLUDED_STUDIES_DESCR>
<EXCLUDED_STUDIES_DESCR MODIFIED="2013-04-22 12:31:38 -0400" MODIFIED_BY="[Empty name]">
<P>We excluded three trials that were included in the original review (<LINK REF="STD-Primbs-1983" TYPE="STUDY">Primbs 1983</LINK>; <LINK REF="STD-Percy-1981" TYPE="STUDY">Percy 1981</LINK>; <LINK REF="STD-F_x00f6_rster-1997" TYPE="STUDY">Förster 1997</LINK>). <LINK REF="STD-Primbs-1983" TYPE="STUDY">Primbs 1983</LINK> was excluded because the translated report clearly indicated that it was not an RCT; <LINK REF="STD-Percy-1981" TYPE="STUDY">Percy 1981</LINK> was excluded because it was not clear what proportion of participants labelled as having tennis elbow had lateral versus medial epicondylitis; and <LINK REF="STD-F_x00f6_rster-1997" TYPE="STUDY">Förster 1997</LINK> was excluded because the published paper was a subgroup analysis of an unpublished RCT. Only data for 48/116 participants who had acute epicondylitis (&lt; 48 hours) due to squash, tennis, golf or other sporting activities were presented, and data were not presented separately for lateral elbow pain.</P>
<P>Reasons for exclusion of the other 51 excluded trials are outlined in the <LINK TAG="CHARACTERISTICS_OF_EXCLUDED_STUDIES" TYPE="SECTION">Characteristics of excluded studies</LINK> table.</P>
</EXCLUDED_STUDIES_DESCR>
</STUDY_DESCRIPTION>
<STUDY_QUALITY MODIFIED="2013-04-22 12:37:28 -0400" MODIFIED_BY="Porjai Pattanittum">
<P>The risk of bias of included studies is presented in the <LINK TAG="CHARACTERISTICS_OF_INCLUDED_STUDIES" TYPE="SECTION">Characteristics of included studies</LINK> table and is shown graphically across all trials and for individual trials in <LINK REF="FIG-02" TYPE="FIGURE">Figure 2</LINK> and <LINK REF="FIG-03" TYPE="FIGURE">Figure 3</LINK>, respectively.</P>
<P>Most included trials were small, and risk of bias was generally high. Only three trials adequately described the method of sequence generation used (<LINK REF="STD-B_x00e4_cker-2011" TYPE="STUDY">Bäcker 2011</LINK>; <LINK REF="STD-Hay-1999" TYPE="STUDY">Hay 1999</LINK>; <LINK REF="STD-Labelle-1997" TYPE="STUDY">Labelle 1997</LINK>), and only four trials adequately described allocation concealment (<LINK REF="STD-B_x00e4_cker-2011" TYPE="STUDY">Bäcker 2011</LINK>; <LINK REF="STD-Burnham-1998" TYPE="STUDY">Burnham 1998</LINK>; <LINK REF="STD-Hay-1999" TYPE="STUDY">Hay 1999</LINK>; <LINK REF="STD-Labelle-1997" TYPE="STUDY">Labelle 1997</LINK>). Blinding was not undertaken or was not clearly described in nine trials (<LINK REF="STD-Adelaar-1987" TYPE="STUDY">Adelaar 1987</LINK>; <LINK REF="STD-B_x00e4_cker-2011" TYPE="STUDY">Bäcker 2011</LINK>; <LINK REF="STD-Burton-1988" TYPE="STUDY">Burton 1988</LINK>; <LINK REF="STD-Demirtas-1998" TYPE="STUDY">Demirtas 1998</LINK>; <LINK REF="STD-Erturk-1997" TYPE="STUDY">Erturk 1997</LINK>; <LINK REF="STD-Saartok-1986" TYPE="STUDY">Saartok 1986</LINK>; <LINK REF="STD-Schapira-1991" TYPE="STUDY">Schapira 1991</LINK>; <LINK REF="STD-Stull-1986" TYPE="STUDY">Stull 1986</LINK>; <LINK REF="STD-Tsuyama-1979" TYPE="STUDY">Tsuyama 1979</LINK>); one trial blinded the single outcome assessor but most of the outcomes were patient-reported and participants were only partially blinded (NSAID or placebo or injection) (<LINK REF="STD-Hay-1999" TYPE="STUDY">Hay 1999</LINK>). Seven trials did not adequately address or did not adequately describe how incomplete data were managed (<LINK REF="STD-Adelaar-1987" TYPE="STUDY">Adelaar 1987</LINK>; <LINK REF="STD-Erturk-1997" TYPE="STUDY">Erturk 1997</LINK>; <LINK REF="STD-Hay-1999" TYPE="STUDY">Hay 1999</LINK>; <LINK REF="STD-Labelle-1997" TYPE="STUDY">Labelle 1997</LINK>; <LINK REF="STD-Saartok-1986" TYPE="STUDY">Saartok 1986</LINK>; <LINK REF="STD-Schapira-1991" TYPE="STUDY">Schapira 1991</LINK>; <LINK REF="STD-Stull-1986" TYPE="STUDY">Stull 1986</LINK>). No study demonstrated that it was free of selective outcome reporting, and all studies had other potential sources of bias.</P>
</STUDY_QUALITY>
<INTERVENTION_EFFECTS MODIFIED="2013-04-22 21:34:04 -0400" MODIFIED_BY="[Empty name]">
<SUBSECTION>
<HEADING LEVEL="3">Topical NSAIDs versus placebo</HEADING>
<P>Among five trials (204 participants) that assessed the effects of topical NSAIDs compared with placebo (<LINK REF="STD-Burnham-1998" TYPE="STUDY">Burnham 1998</LINK>; <LINK REF="STD-Jenoure-1997" TYPE="STUDY">Jenoure 1997</LINK>; <LINK REF="STD-Schapira-1991" TYPE="STUDY">Schapira 1991</LINK>, <LINK REF="STD-Spacca-2005" TYPE="STUDY">Spacca 2005</LINK>; <LINK REF="STD-Tsuyama-1979" TYPE="STUDY">Tsuyama 1979</LINK>), only three studies, with a total population of 153 participants, could be included in the meta-analysis (<LINK REF="STD-Jenoure-1997" TYPE="STUDY">Jenoure 1997</LINK>, <LINK REF="STD-Burnham-1998" TYPE="STUDY">Burnham 1998</LINK>, <LINK REF="STD-Spacca-2005" TYPE="STUDY">Spacca 2005</LINK>).</P>
<P>All three trials assessed the effects of topical diclofenac. No trial included a dichotomous measure of pain, and all included one or more continuous measures of pain. We pooled the final endpoint data, although timing varied (10 days (<LINK REF="STD-Spacca-2005" TYPE="STUDY">Spacca 2005</LINK>); 3 weeks (<LINK REF="STD-Burnham-1998" TYPE="STUDY">Burnham 1998</LINK>) and 4 weeks (<LINK REF="STD-Jenoure-1997" TYPE="STUDY">Jenoure 1997</LINK>)). No significant heterogeneity was noted, and the pooled MD favoured topical NSAIDs (RR -1.64, 95% CI -2.42 to -0.86; <LINK REF="CMP-001.01" TYPE="ANALYSIS">Analysis 1.1</LINK>). In other words, those in the topical NSAIDs group reported<B> </B>just over 1½ points (out of 10) less pain at the end of the trial compared with those who had received placebo, with an NNTB of 7 (95% CI 3 to 21) (see <LINK REF="SOF-01" TYPE="SOF">Summary of findings table 1</LINK>). However when skewed data from two of the studies were excluded, the between-group difference was no longer statistically significant (-0.79, 95% CI -2.17 to 0.59; data not shown).</P>
<P>One trial (85 participants) found that significantly more participants reported fair, good or excellent effectiveness with topical NSAIDs versus placebo at 28 days (14 days of therapy) (RR 1.49, 95% CI 1.04 to 2.14; <LINK REF="CMP-001.02" TYPE="ANALYSIS">Analysis 1.2</LINK>) (<LINK REF="STD-Jenoure-1997" TYPE="STUDY">Jenoure 1997</LINK>).</P>
<P>One of the trials that could not be included in the meta-analysis because of inability to extract data also reported statistically significant benefits of diclofenac gel over placebo in terms of pain (<LINK REF="STD-Schapira-1991" TYPE="STUDY">Schapira 1991</LINK>); the other reported statistically significant benefits of indomethacin gel for final degree of general improvement (<LINK REF="STD-Tsuyama-1979" TYPE="STUDY">Tsuyama 1979</LINK>).</P>
<P>Very few adverse effects were reported in the topical NSAIDs or placebo group in any of the trials, and no between-group differences were apparent (<LINK REF="CMP-001.03" TYPE="ANALYSIS">Analysis 1.3</LINK>). No participants withdrew because of adverse effects. <LINK REF="STD-Burnham-1998" TYPE="STUDY">Burnham 1998</LINK> reported that one participant developed a rash at the site of application of diclofenac gel. <LINK REF="STD-Jenoure-1997" TYPE="STUDY">Jenoure 1997</LINK> reported that tolerability of treatment was excellent in both treatment groups. One participant in each group developed a mild and transient skin rash, but in neither case was it necessary to discontinue treatment. <LINK REF="STD-Schapira-1991" TYPE="STUDY">Schapira 1991</LINK> reported no adverse effects, except for one participant in the diclofenac gel group who developed a transient mild and localised skin rash that did not necessitate discontinuation of the drug. <LINK REF="STD-Spacca-2005" TYPE="STUDY">Spacca 2005</LINK> reported no adverse events and no signs of cutaneous irritation and/or sensitisation in either group. <LINK REF="STD-Tsuyama-1979" TYPE="STUDY">Tsuyama 1979</LINK> did not report adverse effects separately for the lateral elbow pain group.</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="3">Topical NSAIDs and manipulative therapy versus manipulative therapy alone</HEADING>
<P>
<LINK REF="STD-Burton-1988" TYPE="STUDY">Burton 1988</LINK> compared topical NSAIDs with no topical therapy in 17 participants, all of whom also received manipulative therapy. Improvements over time were seen in both groups, but no between-group differences were noted for degree of improvement in grip strength or pain on performing chosen function measured at three days, one week or three weeks (data not shown). The article did not report the presence or absence of adverse events.</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="3">Topical NSAID versus leech therapy</HEADING>
<P>
<LINK REF="STD-B_x00e4_cker-2011" TYPE="STUDY">Bäcker 2011</LINK> compared a single treatment with two to four leeches (until they detached themselves; mean about 45 minutes) with topical diclofenac applied at least twice daily for 30 days. The authors reported a significant difference between groups favouring leeches in total pain score (derived as the sum of three single 100-mm VAS pain scores for pain at rest, in motion and during grip; scale 0 to 300 where higher score indicates increased pain) at 7 days (mean difference -49.0, 95% CI -82.9 to -15.1) but no between-group difference at 45 days (reported only graphically in the paper). Our analysis comparing pain scores at 7 and 45 days (with no adjustment for a higher pain score in the leech group at baseline) confirmed these findings (<LINK REF="CMP-002.01" TYPE="ANALYSIS">Analysis 2.1</LINK>). A statistically significant difference between groups favoured leech therapy at 45 days but not at 7 days for function (<LINK REF="CMP-002.02" TYPE="ANALYSIS">Analysis 2.2</LINK>), but no between-group differences were reported at either time point for quality of life (<LINK REF="CMP-002.03" TYPE="ANALYSIS">Analysis 2.3</LINK>) or grip strength (<LINK REF="CMP-002.04" TYPE="ANALYSIS">Analysis 2.4</LINK>). Of note, expectation of benefit was significantly greater in the leech group, but adjustment for this did not alter the results of analysis. Significantly fewer skin reactions were seen in the topical NSAID group (5% vs 50%, RR 0.10, 95% CI 0.01 to 0.71) (<LINK REF="CMP-002.05" TYPE="ANALYSIS">Analysis 2.5</LINK>).</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="3">One topical NSAID compared with another</HEADING>
<P>
<LINK REF="STD-Demirtas-1998" TYPE="STUDY">Demirtas 1998</LINK> compared iontophoresis of topical sodium diclofenac or sodium salicylate in 40 participants and reported that diclofenac was more effective in reducing pain on pressure (RR 0.22, 95% CI 0.05 to 0.90); however, no between-group differences were noted for pain with wrist extension (RR 0.07, 95% CI 0.00 to 1.09), pain on using the wrist (RR 0.43, 95% CI 0.13 to 1.43) or pain at rest (RR 0.20, 95% CI 0.01 to 3.92) (data not shown).</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="3">Oral NSAIDs versus placebo</HEADING>
<P>The data for two<B> </B>trials that compared oral NSAIDs with placebo could not be pooled because one of the trials presented median and interquartile ranges (<LINK REF="STD-Hay-1999" TYPE="STUDY">Hay 1999</LINK>) and neither reported pain as a dichotomous measure.</P>
<P>
<LINK REF="STD-Labelle-1997" TYPE="STUDY">Labelle 1997</LINK> (128 participants) found that oral NSAIDs (75 mg diclofenac sodium twice daily for 28 days) were significantly better than placebo in improving pain (MD -13.9, 95% CI -23.2 to -4.6, 100 mm VAS) (<LINK REF="CMP-003.01" TYPE="ANALYSIS">Analysis 3.1</LINK>), but no significant between-group differences were noted in improvement in function (MD -3.30, 95% CI -13.13 to 6.53 (<LINK REF="CMP-003.02" TYPE="ANALYSIS">Analysis 3.2</LINK>), 100 mm VAS) or improvement in maximum pain-free grip strength (MD 2.60, 95% CI -0.85 to 6.05) (<LINK REF="CMP-003.03" TYPE="ANALYSIS">Analysis 3.3</LINK>) (see <LINK REF="SOF-02" TYPE="SOF">Summary of findings table 2</LINK>).</P>
<P>The second trial, <LINK REF="STD-Hay-1999" TYPE="STUDY">Hay 1999</LINK>, reported no significant difference between NSAIDs and placebo with respect to their primary outcome of treatment success at 4 weeks (defined as complete recovery or some improvement) (<LINK REF="CMP-003.04" TYPE="ANALYSIS">Analysis 3.4</LINK>). Results for pain and function were reported as medians (interquartile ranges) at 4 weeks, 6 months and 12 months (see Additional <LINK REF="TBL-01" TYPE="TABLE">Table 1</LINK>). Results appeared similar between groups at each time point, and a post hoc analysis performed by the trial authors, which dichotomised pain as 'better' (pain &#8804; 3) or 'not better' (pain &#8805; 4), also failed to demonstrate any significant between-group differences at 4 weeks, 6 months or 12 months (numbers (%) better at 4 weeks, 6 months and 12 months in the NSAIDs and placebo groups, respectively, were 25 (48) and 28 (50), 42 (81) and 47 (83) and 45 (85) and 44 (82)).</P>
<P>In this trial, the number of participants with pain on extension of the wrist or middle finger or grip strength &gt; 300 mm Hg or the number of people disabled for eight items related to daily living did not differ between groups at any time point except for disability for opening doors, which favoured the NSAIDs group at 12 months (NSAIDs 1 (2%), placebo 9 (17%), P &lt; 0.05) and was most likely a chance finding (<LINK REF="STD-Hay-1999" TYPE="STUDY">Hay 1999</LINK>). The number of participants taking time off paid employment was also not reported to differ between groups at 4 weeks or 12 months (NSAIDs 4 (10%) and 4 (10%), placebo 8 (17%) and 10 (21%), P &gt; 0.05)).</P>
<P>
<LINK REF="STD-Labelle-1997" TYPE="STUDY">Labelle 1997</LINK> reported a wide variety of adverse outcomes, but we could not extract numbers of participants with adverse events as these were not reported by participants. Investigators reported that oral NSAIDs significantly increased the risk of developing abdominal pain (RR 3.17, 95% CI 1.35 to 7.41) and diarrhoea (RR 1.92, 95% CI 1.08 to 3.41). One participant in the NSAIDs group withdrew from the study because of diarrhoea. <LINK REF="STD-Hay-1999" TYPE="STUDY">Hay 1999</LINK> reported that oral NSAIDs were discontinued in four participants because of gastrointestinal side effects, and another participant who received NSAIDs had an allergic reaction characterised by oedema. No side effects were reported for those in the placebo group other than skin atrophy at the lateral epicondyle, which was reported to have occurred in three participants in the NSAIDs and placebo groups (number in each not specified), not all of whom had received a glucocorticoid injection (see later).</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="3">Oral NSAIDs and bandaging versus bandaging alone</HEADING>
<P>
<LINK REF="STD-Erturk-1997" TYPE="STUDY">Erturk 1997</LINK> incompletely reported their results. Mean improvements in pain, pain during resisted wrist extension and grip strength for each treatment group are reported in <LINK REF="TBL-02" TYPE="TABLE">Table 2</LINK>. From the data presented, mean improvements favoured NSAID + bandaging for pain at rest and grip strength but not for pain with resisted wrist extension, but it was not possible to determine whether any of the differences were significant as the authors did not report standard deviations or any other measures of variance. Adverse event findings were not reported.</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="3">Oral NSAIDs versus glucocorticoid injection</HEADING>
<P>Only two of the three trials that compared oral NSAIDs with glucocorticoid injection provided data for meta-analysis (<LINK REF="STD-Saartok-1986" TYPE="STUDY">Saartok 1986</LINK>, <LINK REF="STD-Hay-1999" TYPE="STUDY">Hay 1999</LINK>). At 2 to 4 weeks, treatment success was not significantly different between groups (RR 0.74, 95% CI 0.43 to 1.26) (<LINK REF="CMP-004.01" TYPE="ANALYSIS">Analysis 4.1</LINK>).</P>
<P>However, <LINK REF="STD-Saartok-1986" TYPE="STUDY">Saartok 1986</LINK>, the only trial that blinded participants to treatment allocation, did not find any between-group differences across a range of outcomes at 2 weeks, including pain and grip strength (<LINK REF="CMP-004.02" TYPE="ANALYSIS">Analysis 4.2</LINK>). Small sample size means that this study was most likely to have been underpowered.</P>
<P>On the other hand, <LINK REF="STD-Hay-1999" TYPE="STUDY">Hay 1999</LINK> reported significant between-group differences favouring glucocorticoid for their primary outcome of treatment success at 4 weeks, and mean pain and function scores at 4 weeks (reported as medians and interquartile ranges; see Additional <LINK REF="TBL-01" TYPE="TABLE">Table 1</LINK>) also appeared to favour glucocorticoid injection. Pain on extension of wrist or middle finger, grip strength &gt; 300 mm Hg and number of people disabled for eight items related to daily living also favoured the glucocorticoid group at 4 weeks (data not shown). In a post hoc analysis that dichotomised pain as 'better' (pain &#8804; 3) or 'not better' (pain &#8805; 4), significantly more participants receiving glucocorticoid injection were better at 4 weeks compared with those given oral NSAIDs (41 (82%) vs 25 (48%), respectively, P &lt; 0.05). However differences between groups could have been exaggerated because participants were unblinded with respect to whether or not they were receiving a glucocorticoid injection, but those who received tablets were blinded as to whether they were receiving NSAIDs or placebo tablets.</P>
<P>In the only trial that included longer-term outcomes, <LINK REF="STD-Hay-1999" TYPE="STUDY">Hay 1999</LINK> found that some participants who received glucocorticoid injection seemed to have worsened at 6 months, with outcomes generally appearing to favour oral NSAIDs; by 12 months outcomes appeared generally similar between groups. The number of participants taking time off paid employment did not differ between groups at 4 weeks or 12 months (NSAIDs 4 (10%) and 4 (10%); glucocorticoid injection 5 (14%) and 5 (14%), P &gt; 0.05).</P>
<P>
<LINK REF="STD-Erturk-1997" TYPE="STUDY">Erturk 1997</LINK>, which was also unblinded, found no significant differences between NSAIDs and glucocorticoid injection in mean improvement in pain at rest at 3 weeks, but results for pain with resisted wrist extension and grip strength appeared to favour the injection group (<LINK REF="TBL-02" TYPE="TABLE">Table 2</LINK>). However, without standard deviations (SDs) it is not possible to determine whether these results were statistically significant.</P>
<P>Adverse event findings were not reported in two trials (<LINK REF="STD-Erturk-1997" TYPE="STUDY">Erturk 1997</LINK>; <LINK REF="STD-Saartok-1986" TYPE="STUDY">Saartok 1986</LINK>). In addition to the side effects that occurred in those exposed to oral NSAIDs, as described previously, <LINK REF="STD-Hay-1999" TYPE="STUDY">Hay 1999</LINK> reported that local skin atrophy at the lateral epicondyle was observed in three trial participants (two at 6 months and one at 12 months), although only one had received a local injection of glucocorticoid (exact group not specified). As well, they reported that a minor increase in severity of pain lasted one day after injection, although the number of participants affected was not provided.</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="3">Oral NSAID versus a vasodilator</HEADING>
<P>One trial compared naproxen with a central vasodilator, betahistine dihydrochloride (<LINK REF="STD-Polat-2011" TYPE="STUDY">Polat 2011</LINK>). Significantly less pain was reported at all follow-up time points (7 days, 3 months and 6 months) in the vasodilator group compared with the topical NSAIDs group (<LINK REF="CMP-005.01" TYPE="ANALYSIS">Analysis 5.1</LINK>) (data only at 7 days and 6 months shown). At 7 days, people in the vasodilator group had a pain score of 2.39 (SD 1.68) versus 6 (SD 1.38) in the topical NSAID group (MD 3.61, 95% CI 2.80 to 4.42) with a similar between-group difference reported at 3 and 6 months.</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="3">One oral NSAID compared with another</HEADING>
<P>Diflunisal was compared with naproxen in two trials (<LINK REF="STD-Adelaar-1987" TYPE="STUDY">Adelaar 1987</LINK>; <LINK REF="STD-Stull-1986" TYPE="STUDY">Stull 1986</LINK>); the treatment regimens were similar and outcome data were pooled. No between-group differences were noted with respect to treatment success defined as either no remaining or improved symptoms (RR 1.19, 95% CI 0.88 to 1.62) (<LINK REF="CMP-006.01" TYPE="ANALYSIS">Analysis 6.1</LINK>) or as excellent, very good or good overall pain relief (RR 1.40, 95% CI 0.96 to 2.05) (<LINK REF="CMP-006.02" TYPE="ANALYSIS">Analysis 6.2</LINK>).</P>
<P>
<LINK REF="TBL-03" TYPE="TABLE">Table 3</LINK> provides additional incomplete results from <LINK REF="STD-Adelaar-1987" TYPE="STUDY">Adelaar 1987</LINK> for pain and functional capacity before and after treatment.</P>
<P>No differences were reported between groups with respect to numbers of participants experiencing any adverse effects (RR 3.65, 95% CI 0.65 to 20.66) (<LINK REF="CMP-006.03" TYPE="ANALYSIS">Analysis 6.3</LINK>), although more adverse events occurred in the diflunisal group overall. Four participants who received diflunisal in <LINK REF="STD-Stull-1986" TYPE="STUDY">Stull 1986</LINK> reported adverse effects: two had nausea and one each reported vomiting and burning during urination, whereas one participant who received naproxen complained of feeling drowsy. <LINK REF="STD-Adelaar-1987" TYPE="STUDY">Adelaar 1987</LINK> reported that one participant in the diflunisal group developed transient nausea and stomach cramps.</P>
</SUBSECTION>
</INTERVENTION_EFFECTS>
</RESULTS>
<DISCUSSION MODIFIED="2013-04-22 13:09:53 -0400" MODIFIED_BY="[Empty name]">
<SUMMARY_OF_RESULTS MODIFIED="2013-04-22 13:04:36 -0400" MODIFIED_BY="[Empty name]">
<P>Based upon data from fifteen trials, involving 759 trial participants, limited evidence was obtained from which firm conclusions could be drawn about the benefits or harms of topical or oral NSAIDs, and the following summary of results needs to be interpreted cautiously. Only two studies included in this review followed participants for longer than one month; consequently conclusions refer to short-term outcomes only. In addition none of the included studies reported the primary efficacy outcome of this review&#65293;patient-reported pain relief &#8805; 30%&#65293;and the secondary efficacy outcomes were variably reported.</P>
<P>Eight of the included trials studied the effects of topical NSAIDs (301 participants). We found very low-quality evidence (from three trials with 153 participants) that topical NSAIDs may provide a small but significant benefit with respect to pain in the short term. In a pooled analysis of data from three of five placebo-controlled trials, topical NSAIDs provided an additional 1½ points out of 10 improvement in pain at the end of the trial period (10 days to 4 weeks) compared with placebo, with an NNTB of 7 (95% CI 3 to 21), although this finding was not robust to the potential impact introduced by the inclusion of skewed data from two of the three trials. Nevertheless one of these trials also found that topical NSAIDs were 1½ times more likely to result in treatment success in comparison with placebo (NNTB 4, 95% CI 2 to 25) (<LINK REF="SOF-01" TYPE="SOF">Summary of findings table 1</LINK>), and both trials that could not be included in the meta-analysis also reported positive results.</P>
<P>Although the tolerability of topical NSAIDs was generally excellent, with no withdrawals due to adverse effects and no differences in numbers of adverse events compared with placebo, mild transient skin rash occurred in 3/204 (1.5%) participants who received topical NSAIDs and in one participant (0.5%) who received topical placebo.</P>
<P>One trial that compared topical NSAIDs and manipulative therapy with manipulative therapy alone failed to demonstrate any between-group differences in benefit, and an additional trial that compared iontophoresis of topical sodium diclofenac or salicylate reported that the diclofenac preparation provided better reduction of pain on pressure but no other between-group differences in outcome. One trial that compared topical NSAIDs with application of leeches reported better overall pain scores at 7 days but not at 45 days in the leech group and better function at 45 days but not at 7 days. Local skin reactions occurred less frequently with topical NSAIDs (5% of cases vs 50% in the leech group).</P>
<P>Six of the included trials studied the effects of oral NSAIDs (382 participants). Very low- to low-quality evidence from two trials was conflicting with respect to the benefit of oral NSAIDs (<LINK REF="SOF-02" TYPE="SOF">Summary of findings table 2</LINK>). Only one of the two trials demonstrated that oral NSAIDs provided a small but statistically significantly greater improvement in pain compared with placebo, and the other trial reported no between-group differences in terms of pain, treatment success or time off paid employment. Neither trial demonstrated benefit in terms of function or maximum pain-free grip strength.</P>
<P>Very low-quality evidence from three trials that compared oral NSAIDs with glucocorticoid injection revealed conflicting results (<LINK REF="SOF-03" TYPE="SOF">Summary of findings table 3</LINK>). Based upon two trials (126 participants) for which data could be pooled, no difference between treatments was noted with respect to treatment success in the short term (2 to 4 weeks). However one of these trials&#65293;the only one that blinded participants to treatment allocation but was underpowered&#65293;reported no between-group differences across a range of outcomes at 2 weeks, and the other trial, which did not blind participants and therefore could have overestimated any treatment benefit, reported significant differences favouring glucocorticoid injection over a range of outcomes at 4 weeks, favouring oral NSAIDs at 6 months and showing generally similar results by 12 months. A third trial that incompletely reported results described mixed results, with between-group differences favouring glucocorticoid injection for pain with resisted wrist extension and grip strength, but no mean improvement in pain at rest at 3 weeks; however, it is unclear whether these findings were significant because no variance measures were reported.</P>
<P>Use of oral NSAIDs was associated with increased risk of gastrointestinal side effects compared with placebo in one trial in the review. Another trial reported discontinuation of treatment in four participants taking NSAIDs due to gastrointestinal side effects and in another participant who developed an allergic reaction in response to oral NSAIDs.</P>
<P>Two trials that compared two different NSAIDs (naproxen and diflunisal) (62 participants) demonstrated no significant between-group differences with respect to benefit or numbers of adverse effects. Adverse effects in those who received diflunisal included nausea (n = 2), vomiting (n = 1), nausea and stomach cramps (n = 1) and burning during urination (n = 1); one participant who received naproxen developed drowsiness.</P>
</SUMMARY_OF_RESULTS>
<APPLICABILITY_OF_FINDINGS MODIFIED="2013-04-22 13:07:17 -0400" MODIFIED_BY="[Empty name]">
<P>Lateral elbow pain is a self-limiting but painful condition, and adequate pain relief is a high priority for people with the condition. Topical and oral NSAIDs continue to be commonly used to treat this condition, but the overall balance of benefits and harms associated with topical and oral NSAIDs remains a key issue.</P>
<P>Although most of the studies included in this review were performed between 1979 and 1999, and additional trials were published in 2005 and 2011, it is likely that results remain applicable to people with lateral elbow pain in the current era. Trial participants appeared typical of patients seen in routine care. Of note, we were unable to identify any published trials directly comparing topical with oral NSAIDs.</P>
<P>Outcomes reported in the trials varied widely, as did their method of measurement, and many trials inadequately reported important outcomes. For example, although seven trials have compared topical NSAIDs with placebo, we were able to draw conclusions about reduced pain and increased risk of adverse events based upon only three trials and treatment success based upon only one trial. In addition, none of the trials included a dichotomous measure of pain, as recommended by IMMPACT (<LINK REF="REF-Dworkin-2008" TYPE="REFERENCE">Dworkin 2008</LINK>). It is therefore likely that further trials will change these treatment effect estimates. None of the trials included a measure of quality of life, and less than half included a measure of function; therefore we were unable to draw any conclusions regarding these outcomes.</P>
</APPLICABILITY_OF_FINDINGS>
<QUALITY_OF_EVIDENCE MODIFIED="2013-04-22 13:08:10 -0400" MODIFIED_BY="[Empty name]">
<P>Most of the thirteen trials included in this review were small (ten trials included 40 or fewer participants) and risk of bias was generally high, with only two trials adequately blinding trial participants. Methodological and reporting issues limited our ability to combine data.</P>
<P>At best, very low-quality evidence indicates benefit (in terms of pain relief and treatment success) of topical NSAIDs, and some patients may expect a transient mild rash with therapy. Evidence of the benefits of oral NSAIDs compared with both placebo and glucocorticoid injection was conflicting, and some patients may expect gastrointestinal and other side effects with oral NSAIDs.</P>
<P>Because of concerns about the potential risk of bias of all included trials and the risk of Type II error in many trials, further high-quality randomised controlled trials are needed to establish the true effects of both topical and oral NSAIDs for lateral elbow pain and their comparative effectiveness.</P>
</QUALITY_OF_EVIDENCE>
<POTENTIAL_BIASES MODIFIED="2013-04-22 13:09:26 -0400" MODIFIED_BY="[Empty name]">
<P>Upon completion of a thorough search of all major databases with no language restrictions, we believe that all relevant studies were identified. Two review authors assessed the trials for inclusion in the review and the risk of bias, and a third review author adjudicated whether there was any discrepancy. The biggest limitation of the review process was that many trials did not provide enough published data, or did not provide data in a form that could be extracted for meta-analysis.</P>
</POTENTIAL_BIASES>
<AGREEMENT MODIFIED="2013-04-22 13:09:53 -0400" MODIFIED_BY="[Empty name]">
<P>Results of this updated review are in general agreement with those of our original review (<LINK REF="REF-Green-2002" TYPE="REFERENCE">Green 2002</LINK>), although we excluded three trials erroneously included in the previous review and included an additional two trials. Our results are also in keeping with those of <LINK REF="REF-Boisaubert-2004" TYPE="REFERENCE">Boisaubert 2004</LINK>&#65293;a review that found no additional trials on this topic.</P>
</AGREEMENT>
</DISCUSSION>
<CONCLUSIONS MODIFIED="2013-04-22 13:11:35 -0400" MODIFIED_BY="[Empty name]">
<IMPLICATIONS_PRACTICE MODIFIED="2013-04-22 13:10:56 -0400" MODIFIED_BY="[Empty name]">
<P>Limited evidence is available from which to draw firm conclusions about the benefits or harms of topical or oral NSAIDs in treating lateral elbow pain. Although data from five placebo-controlled trials suggest that topical NSAIDs may be beneficial in improving pain (for up to 4 weeks), non-normal distribution of data and other methodological issues preclude drawing of firm conclusions. Some people may expect a mild transient skin rash. Evidence of the benefits of oral NSAIDs is conflicting, although use of oral NSAIDs may result in gastrointestinal adverse effects in some people. No direct comparisons between oral and topical NSAIDs were available. Some trials demonstrated greater benefit from glucocorticoid injection than has been seen with NSAIDs in the short term, but this was not apparent in all studies and was not apparent by 6 months in the only study that included longer-term outcomes.</P>
</IMPLICATIONS_PRACTICE>
<IMPLICATIONS_RESEARCH MODIFIED="2013-04-22 13:11:35 -0400" MODIFIED_BY="[Empty name]">
<P>Further high-quality randomised controlled trials are needed to establish the true benefits and risks of both oral and topical NSAIDs for lateral elbow pain. Future trials should have adequate power for the research question posed, and should include strategies designed to minimise the potential for bias, including adequate randomisation methods, treatment allocation concealment and blinding of participants and outcome assessment. Development of a core set of outcomes for trials of lateral elbow pain would enhance this endeavour and improve our ability to synthesise the evidence. If the benefits of topical and/or oral NSAIDs become established, trials directly comparing topical with oral NSAIDs to determine which therapy has a better risk-benefit profile may be worthwhile.</P>
</IMPLICATIONS_RESEARCH>
</CONCLUSIONS>
</BODY>
<ACKNOWLEDGEMENTS MODIFIED="2013-04-23 09:29:09 -0400" MODIFIED_BY="[Empty name]">
<P>This update was partially supported by a fellowship granted to the first author by the SEA-ORCHID Project (www.seaorchid.org), funded by the Wellcome Trust (UK) and the Australian National Health and Medical Research Council (NHMRC). RB is partially supported by an Australian NHMRC Practitioner Fellowship.</P>
<P>Drs Les Barnsley, Stephen Hall, Nynke Smidt, and Willem Assendelft as well as Millicent White, were authors of the original review.</P>
</ACKNOWLEDGEMENTS>
<CONFLICT_OF_INTEREST>
<P>None known.</P>
</CONFLICT_OF_INTEREST>
<CONTRIBUTIONS MODIFIED="2013-04-22 13:12:00 -0400" MODIFIED_BY="[Empty name]">
<P>All authors were responsible for all components of the review, including selection of trials for the update of the review, appraisal of the risk of bias of included trials, extraction and analysis of data, interpretation of the results and writing of the manuscript.</P>
</CONTRIBUTIONS>
<PRO_REV_DIFF MODIFIED="2013-04-22 13:13:57 -0400" MODIFIED_BY="[Empty name]">
<P>In the original review we limited inclusion of trials to those with study participants who had lateral elbow pain of greater than 3 weeks' duration but removed this criterion in the updated review, as NSAIDs are most commonly used for acute symptoms.</P>
<P>We updated the outcomes that were considered in this review according to the Initiative on Methods, Measurement, and Pain Assessment in Clinical Trials (IMMPACT), which has published consensus recommendations for determining clinically important changes in outcome measures in clinical trials of interventions for chronic pain (<LINK REF="REF-Dworkin-2008" TYPE="REFERENCE">Dworkin 2008</LINK>).</P>
<P>We excluded three trials that were included in the original review (<LINK REF="STD-F_x00f6_rster-1997" TYPE="STUDY">Förster 1997</LINK>; <LINK REF="STD-Percy-1981" TYPE="STUDY">Percy 1981</LINK>; <LINK REF="STD-Primbs-1983" TYPE="STUDY">Primbs 1983</LINK>). <LINK REF="STD-F_x00f6_rster-1997" TYPE="STUDY">Förster 1997</LINK> was excluded because the published paper was a subgroup analysis of an unpublished RCT. Only data for 48/116 participants who had acute epicondylitis (&lt; 48 hours) due to squash, tennis, golf or other sporting activities were presented, and data were not presented separately for lateral elbow pain. <LINK REF="STD-Percy-1981" TYPE="STUDY">Percy 1981</LINK> was excluded because it was not clear what proportion of participants labelled as having tennis elbow had lateral versus medial epicondylitis. <LINK REF="STD-Primbs-1983" TYPE="STUDY">Primbs 1983</LINK> was excluded because it clearly was not an RCT, as described in the translated report.</P>
<P>Changes to the risk of bias table and sensitivity analysis sections in this updated review reflect advances in systematic review methodology.</P>
<P>In the original review we performed a sensitivity analysis excluding trials published in languages other than English. We did not perform this sensitivity analysis in this update because of reduced concerns about publication and outcome assessment bias in non-English studies.</P>
<P>We corrected some errors in the previous analyses. For example, in the original review, <LINK REF="STD-Burton-1988" TYPE="STUDY">Burton 1988</LINK> was listed under topical NSAIDs versus placebo, but review of the article clearly revealed that the trial compared topical NSAIDs with no topical treatment, although both groups also received manipulative therapy.</P>
</PRO_REV_DIFF>
<PUBLIC_NOTES/>
</MAIN_TEXT>
<STUDIES_AND_REFERENCES MODIFIED="2013-04-22 14:10:07 -0400" MODIFIED_BY="Porjai Pattanittum">
<STUDIES MODIFIED="2013-04-22 14:10:07 -0400" MODIFIED_BY="[Empty name]">
<INCLUDED_STUDIES MODIFIED="2013-04-22 13:48:59 -0400" MODIFIED_BY="[Empty name]">
<STUDY DATA_SOURCE="PUB" ID="STD-Adelaar-1987" MODIFIED="2013-03-11 03:18:30 -0400" MODIFIED_BY="[Empty name]" NAME="Adelaar 1987" YEAR="1987">
<REFERENCE MODIFIED="2013-03-11 03:18:30 -0400" MODIFIED_BY="[Empty name]" NOTES="&lt;p&gt;Adelaar R, Maddy L, Emroch L. Diflunisal vs Naproxen in the Management of Mild to Moderate Pain Associated with Epicondylitis. Advances in Therapy, 1987; 4(6):317-327.&lt;/p&gt;" NOTES_MODIFIED="2013-03-11 03:18:30 -0400" NOTES_MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Adelaar R, Maddy L, Emroch L</AU>
<TI>Diflunisal versus naproxen in the management of mild to moderate pain associated with epicondylitis</TI>
<SO>Advances in Therapy</SO>
<YR>1987</YR>
<VL>4</VL>
<NO>6</NO>
<PG>317-27</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-B_x00e4_cker-2011" MODIFIED="2013-04-22 13:48:41 -0400" MODIFIED_BY="[Empty name]" NAME="Bäcker 2011" YEAR="2011">
<REFERENCE MODIFIED="2013-04-22 13:48:41 -0400" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Bäcker M, Ludtke R, Afra D, Cesur O, Langhorst J, Fink M, et al</AU>
<TI>Effectiveness of leech therapy in chronic lateral epicondylitis: a randomized controlled trial</TI>
<SO>Clinical Journal of Pain</SO>
<YR>2011</YR>
<VL>27</VL>
<NO>5</NO>
<PG>442-7</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Burnham-1998" NAME="Burnham 1998" YEAR="1998">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Burnham R, Gregg R, Healy P, Steadward R</AU>
<TI>The effectiveness of topical diclofenac for lateral epicondylitis</TI>
<SO>Clinical Journal of Sports Medicine</SO>
<YR>1998</YR>
<VL>8</VL>
<PG>78-81</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Burton-1988" MODIFIED="2012-08-28 01:22:38 -0400" MODIFIED_BY="[Empty name]" NAME="Burton 1988" YEAR="1988">
<REFERENCE MODIFIED="2012-08-28 01:22:38 -0400" MODIFIED_BY="[Empty name]" NOTES="&lt;p&gt;Burton A. A comparative trial of forearm strap and topical anti-inflammatory as adjuncts to manual therapy in tennis elbow. Manual Medicine. 1988; 3:141-143&lt;/p&gt;" NOTES_MODIFIED="2012-08-28 01:22:38 -0400" NOTES_MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Burton A</AU>
<TI>A comparative trial of forearm strap and topical anti-inflammatory as adjuncts to manual therapy in tennis elbow</TI>
<SO>Manual Medicine</SO>
<YR>1988</YR>
<VL>3</VL>
<PG>141-3</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Demirtas-1998" MODIFIED="2013-04-21 20:38:28 -0400" MODIFIED_BY="[Empty name]" NAME="Demirtas 1998" YEAR="1998">
<REFERENCE MODIFIED="2013-04-21 20:38:28 -0400" MODIFIED_BY="[Empty name]" NOTES="&lt;p&gt;Demirtas RN, Oner C. The treatment of lateral epicondylitis by iontophoresis of sodium salicylate and sodium diclofenac. Clinical Rehabilitation 1998;12:23-29.&lt;/p&gt;" NOTES_MODIFIED="2013-04-21 20:38:28 -0400" NOTES_MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Demirtas RN, Oner C</AU>
<TI>The treatment of lateral epicondylitis by iontophoresis of sodium salicylate and sodium diclofenac</TI>
<SO>Clinical Rehabilitation</SO>
<YR>1998</YR>
<VL>12</VL>
<PG>23-9</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Erturk-1997" NAME="Erturk 1997" YEAR="1997">
<REFERENCE NOTES="&lt;p&gt;collected&lt;/p&gt;" PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>Erturk H, Celiker R, Sivri A, Cetin A, Cindas A</AU>
<TI>The efficacy of different treatment regiments that are commonly used in tennis elbow</TI>
<SO>Journal of Rheumatology and Medical Rehabilitation</SO>
<YR>1997</YR>
<VL>8</VL>
<PG>298-301</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Hay-1999" MODIFIED="2012-08-28 01:23:11 -0400" MODIFIED_BY="[Empty name]" NAME="Hay 1999" YEAR="1999">
<REFERENCE MODIFIED="2012-08-28 01:23:11 -0400" MODIFIED_BY="[Empty name]" PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>Hay E, Paterson S, Lewis M, Hosie G, Croft P</AU>
<TI>Pragmatic randomised controlled trial of local corticosteroid injection and naproxen for treatment of lateral epicondylitis of elbow in primary care</TI>
<SO>BMJ</SO>
<YR>1999</YR>
<VL>319</VL>
<PG>964-8</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Jenoure-1997" MODIFIED="2013-04-22 13:48:50 -0400" MODIFIED_BY="[Empty name]" NAME="Jenoure 1997" YEAR="1997">
<REFERENCE MODIFIED="2013-04-22 13:48:50 -0400" MODIFIED_BY="[Empty name]" NOTES="&lt;p&gt;collected&lt;/p&gt;" NOTES_MODIFIED="2013-04-22 13:48:50 -0400" NOTES_MODIFIED_BY="[Empty name]" PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>Jenoure P, Rostan A, Gremion G, Meier J, Grossen R, Bielinki R, et al</AU>
<TI>Multi-centre, double-blind, controlled clinical study on the efficacy of diclofenac epolamine tissugel plaster in patients with epicondylitis</TI>
<SO>Medicina Dello Sport</SO>
<YR>1997</YR>
<VL>50</VL>
<PG>285-92</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Labelle-1997" MODIFIED="2012-08-28 01:23:46 -0400" MODIFIED_BY="[Empty name]" NAME="Labelle 1997" YEAR="1997">
<REFERENCE MODIFIED="2012-08-28 01:23:46 -0400" MODIFIED_BY="[Empty name]" PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>Labelle H, Guibert R</AU>
<TI>Efficacy of diclofenac in lateral epicondylitis of the elbow also treated with immobilization</TI>
<SO>Archives of Family Medicine</SO>
<YR>1997</YR>
<VL>6</VL>
<PG>257-62</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Polat-2011" MODIFIED="2013-02-24 17:13:43 -0500" MODIFIED_BY="[Empty name]" NAME="Polat 2011" YEAR="2011">
<REFERENCE MODIFIED="2013-02-24 17:13:43 -0500" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Polat A, Ekinci O, Terzioglu B, Canbora M, Muftuoglu T, Gorgec M</AU>
<TI>Treatment of lateral epicondylitis using betahistine dihydrochloride</TI>
<SO>Journal of Musculoskeletal Pain</SO>
<YR>2011</YR>
<VL>19</VL>
<NO>4</NO>
<PG>201-6</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Saartok-1986" MODIFIED="2012-08-28 01:23:59 -0400" MODIFIED_BY="[Empty name]" NAME="Saartok 1986" YEAR="1986">
<REFERENCE MODIFIED="2012-08-28 01:23:59 -0400" MODIFIED_BY="[Empty name]" NOTES="&lt;p&gt;Saartok T, Eriksson E. Randomized trial of oral naproxen or local injection of betamethasone in lateral epicondylitis of the humerus. Orthopaedics 1986; 2:191-194&lt;/p&gt;" NOTES_MODIFIED="2012-08-28 01:23:59 -0400" NOTES_MODIFIED_BY="[Empty name]" PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>Saartok T, Eriksson E</AU>
<TI>Randomized trial of oral naproxen or local injection of betamethasone in lateral epicondylitis of the humerus</TI>
<SO>Orthopaedics</SO>
<YR>1986</YR>
<VL>2</VL>
<PG>191-4</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Schapira-1991" MODIFIED="2012-08-28 01:24:10 -0400" MODIFIED_BY="[Empty name]" NAME="Schapira 1991" YEAR="1991">
<REFERENCE MODIFIED="2012-08-28 01:24:10 -0400" MODIFIED_BY="[Empty name]" PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>Schapira D, Linn S, Scharf Y</AU>
<TI>A placebo-controlled evaluation of diclofenac diethylamine salt in the treatment of lateral epicondylitis of the elbow</TI>
<SO>Current Therapeutic Research</SO>
<YR>1991</YR>
<VL>49</VL>
<NO>2</NO>
<PG>162-8</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="MIX" ID="STD-Spacca-2005" MODIFIED="2012-01-15 19:17:23 -0500" MODIFIED_BY="[Empty name]" NAME="Spacca 2005" YEAR="2005">
<REFERENCE MODIFIED="2012-01-15 19:17:23 -0500" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Spacca G, Cacchio A, Forgacs A, Monteforte P, Rovetta G</AU>
<TI>Analgesic efficacy of a lecithin-vehiculated diclofenac epolamine gel in shoulder periarthritis and lateral epicondylitis: a placebo-controlled, multicenter, randomized, double-blind clinical trial</TI>
<SO>Drugs Under Experimental &amp; Clinical Research</SO>
<YR>2005</YR>
<VL>31</VL>
<NO>4</NO>
<PG>147-54</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Stull-1986" MODIFIED="2013-03-11 03:18:04 -0400" MODIFIED_BY="[Empty name]" NAME="Stull 1986" YEAR="1986">
<REFERENCE MODIFIED="2013-03-11 03:18:04 -0400" MODIFIED_BY="[Empty name]" NOTES="&lt;p&gt;Stull P, Jokl P. Comparison of Difunisal and Naproxen in the Treatment of Tennis Elbow. Clinical Therapeutics. 1986;9(Suppl C):62-66&lt;/p&gt;" NOTES_MODIFIED="2013-03-11 03:18:04 -0400" NOTES_MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Stull P, Jokl P</AU>
<TI>Comparison of diflunisal and naproxen in the treatment of tennis elbow</TI>
<SO>Clinical Therapeutics</SO>
<YR>1986</YR>
<VL>9</VL>
<NO>Suppl C</NO>
<PG>62-6</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Tsuyama-1979" MODIFIED="2013-04-22 13:48:59 -0400" MODIFIED_BY="[Empty name]" NAME="Tsuyama 1979" YEAR="1979">
<REFERENCE MODIFIED="2013-04-22 13:48:59 -0400" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Tsuyama N, Nichikawa K, Tsujimoto M, Miyanaga Y, Mizushima H, Nakajima A</AU>
<TI>Clinical evaluation of non-steroidal anti-inflammation/analgesics for external use &#65293; Indomethacin ointment &#65293; in the orthopaedic field</TI>
<SO>Clinical Evaluation</SO>
<YR>1979</YR>
<VL>7</VL>
<PG>285-309</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
</INCLUDED_STUDIES>
<EXCLUDED_STUDIES MODIFIED="2013-04-22 14:10:07 -0400" MODIFIED_BY="[Empty name]">
<STUDY DATA_SOURCE="PUB" ID="STD-Abbott-1980" MODIFIED="2013-03-11 03:19:29 -0400" MODIFIED_BY="[Empty name]" NAME="Abbott 1980" YEAR="1980">
<REFERENCE MODIFIED="2013-03-11 03:19:29 -0400" MODIFIED_BY="[Empty name]" NOTES="&lt;p&gt;collected&lt;/p&gt;" NOTES_MODIFIED="2013-03-11 03:19:29 -0400" NOTES_MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Abbott C, Bouchier-Hayes T, Hunt H</AU>
<TI>A comparison of the efficacy of naproxen sodium and a paracetamol/dextropropoxyphene combination in the treatment of soft-tissue disorders</TI>
<SO>British Journal of Sports Medicine</SO>
<YR>1980</YR>
<VL>14</VL>
<PG>213-8</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Auvinet-1995" MODIFIED="2013-04-22 14:05:14 -0400" MODIFIED_BY="[Empty name]" NAME="Auvinet 1995" YEAR="1995">
<REFERENCE MODIFIED="2013-04-22 14:05:14 -0400" MODIFIED_BY="[Empty name]" NOTES="&lt;p&gt;collected&lt;/p&gt;" NOTES_MODIFIED="2013-04-22 14:05:14 -0400" NOTES_MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Auvinet B, Crielaard J, Manteuffel GE, Müller P, Multicenter Piroxicam FDDF European Study Group </AU>
<TI>A double-blind comparison of fast dissolving dosage form and diclofenac enteric-coated tablets in the treatment of patients with acute musculoskeletal disorders</TI>
<SO>Current Therapeutic Research</SO>
<YR>1995</YR>
<VL>56</VL>
<PG>1142-53</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Baskurt-2003" MODIFIED="2012-03-18 22:35:47 -0400" MODIFIED_BY="[Empty name]" NAME="Baskurt 2003" YEAR="2003">
<REFERENCE MODIFIED="2012-03-18 22:35:47 -0400" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Baskurt F, Ozcan A, Algun C</AU>
<TI>Comparison of effects of phonophoresis and iontophoresis of naproxen in the treatment of lateral epicondylitis</TI>
<SO>Clinical Rehabilitation</SO>
<YR>2003</YR>
<VL>17</VL>
<NO>1</NO>
<PG>96-100</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Bolten-1991" MODIFIED="2013-04-22 13:49:08 -0400" MODIFIED_BY="[Empty name]" NAME="Bolten 1991" YEAR="1991">
<REFERENCE MODIFIED="2013-04-22 13:49:08 -0400" MODIFIED_BY="[Empty name]" NOTES="&lt;p&gt;collected&lt;/p&gt;" NOTES_MODIFIED="2013-04-22 13:49:08 -0400" NOTES_MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Bolten W</AU>
<TI>Felbinac gel for treatment of localized extra-articular rheumatic diseases &#65293; a multicenter, placebo controlled, randomized study</TI>
<TO>Felbinac-Gel zur Behandlung lokalisierter extraartikularer rheumatischer Beschwerden &#65293; eine multizentrische, placebokontrollierte, randomisierte studie</TO>
<SO>Zeitschrift für Rheumatologie</SO>
<YR>1991</YR>
<VL>50</VL>
<PG>109-13</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Bono-1983" MODIFIED="2013-04-22 13:49:15 -0400" MODIFIED_BY="[Empty name]" NAME="Bono 1983" YEAR="1983">
<REFERENCE MODIFIED="2013-04-22 13:49:15 -0400" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Bono RF, Finkel S, Goodman H, Hanna C</AU>
<TI>A multicenter, double-blind comparison of oxaprozin, phenylbutazone, and placebo therapy in patients with tendinitis and bursitis</TI>
<SO>Clinical Therapeutics</SO>
<YR>1983</YR>
<VL>6</VL>
<NO>1</NO>
<PG>79-85</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Boussina-1983" NAME="Boussina 1983" YEAR="1983">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Boussina I, Gunthner W, Marti Masso R</AU>
<TI>Double-blind multicenter study comparing meclofenamate sodium with indomethacin and placebo in the treatment of extra-articular rheumatic disease</TI>
<SO>Arzneimittel-Forschung</SO>
<YR>1983</YR>
<VL>33</VL>
<NO>4A</NO>
<PG>649-52</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Buckwalter-1995" MODIFIED="2012-08-28 02:03:48 -0400" MODIFIED_BY="[Empty name]" NAME="Buckwalter 1995" YEAR="1995">
<REFERENCE MODIFIED="2012-08-28 02:03:48 -0400" MODIFIED_BY="[Empty name]" NOTES="&lt;p&gt;collected&lt;/p&gt;" NOTES_MODIFIED="2012-08-28 02:03:48 -0400" NOTES_MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Buckwalter JA</AU>
<TI>Pharmacological treatment of soft-tissue injuries</TI>
<SO>The Journal of Bone and Joint Surgery</SO>
<YR>1995</YR>
<VL>77A</VL>
<NO>12</NO>
<PG>1902-14</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Burgos-2001" NAME="Burgos 2001" YEAR="2001">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Burgos A, Busquier MP, Reino JG, Ferreiro JL, Navarro F, Valverde J, et al</AU>
<TI>Double-blind, double-dummy comparative study of local action transcutaneous flurbiprofen (flurbiprofen LAT) versus piketoprofen cream in the treatment of extra-articular rheumatism</TI>
<SO>Clinical Drug Investigation</SO>
<YR>2001</YR>
<VL>21</VL>
<NO>2</NO>
<PG>95-102</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Castro-DeTolosa-1994" MODIFIED="2012-08-28 03:05:47 -0400" MODIFIED_BY="[Empty name]" NAME="Castro DeTolosa 1994" YEAR="1994">
<REFERENCE MODIFIED="2012-08-28 03:05:47 -0400" MODIFIED_BY="[Empty name]" NOTES="&lt;p&gt;collected&lt;/p&gt;" NOTES_MODIFIED="2012-08-28 03:05:47 -0400" NOTES_MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Castro De Tolosa E, Bueno Pereira P, Barreto Reis J, Hideo Hori A</AU>
<TI>Comparative evaluation of two non-steroidal anti-inflammatory drugs in patients with acute tendinitis or bursitis</TI>
<SO>Arquivos Brasileiros de Medicina</SO>
<YR>1994</YR>
<VL>68</VL>
<PG>203-7</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Commandre-1983" MODIFIED="2012-08-28 02:04:21 -0400" MODIFIED_BY="[Empty name]" NAME="Commandre 1983" YEAR="1983">
<REFERENCE MODIFIED="2012-08-28 02:04:21 -0400" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Commandre F</AU>
<TI>Double-blind comparative study of piroxicam and indomethacin in acute locomotor affections linked with sports activity</TI>
<SO>European Journal of Rheumatology and Inflammation</SO>
<YR>1983</YR>
<VL>6</VL>
<PG>113-8</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Commandre-1993" MODIFIED="2012-08-28 02:04:33 -0400" MODIFIED_BY="[Empty name]" NAME="Commandre 1993" YEAR="1993">
<REFERENCE MODIFIED="2012-08-28 02:04:33 -0400" MODIFIED_BY="[Empty name]" NOTES="&lt;p&gt;collected&lt;/p&gt;" NOTES_MODIFIED="2012-08-28 02:04:33 -0400" NOTES_MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Commandre F, Zakarian H, Corriol-Rohou S</AU>
<TI>Comparison of the analgesic effects of topical niflumic acid gel versus piroxicam gel in the treatment of musculoskeletal disorders</TI>
<SO>Current Therapeutic Research, Clinical and Experimental</SO>
<YR>1993</YR>
<VL>53</VL>
<PG>113-21</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Dreiser-1988" MODIFIED="2012-08-28 02:04:42 -0400" MODIFIED_BY="[Empty name]" NAME="Dreiser 1988" YEAR="1988">
<REFERENCE MODIFIED="2012-08-28 02:04:42 -0400" MODIFIED_BY="[Empty name]" NOTES="&lt;p&gt;collected&lt;/p&gt;" NOTES_MODIFIED="2012-08-28 02:04:42 -0400" NOTES_MODIFIED_BY="[Empty name]" PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>Dreiser RL</AU>
<TI>Clinical trial of efficacy and tolerability of topical ibuprofen in the treatment of tendinitis</TI>
<SO>Le Journal International de Medicine</SO>
<YR>1988</YR>
<VL>119</VL>
<PG>70-3</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Dreiser-1991" MODIFIED="2012-08-28 02:04:46 -0400" MODIFIED_BY="[Empty name]" NAME="Dreiser 1991" YEAR="1991">
<REFERENCE MODIFIED="2012-08-28 02:04:46 -0400" MODIFIED_BY="[Empty name]" NOTES="&lt;p&gt;received&lt;/p&gt;" NOTES_MODIFIED="2012-08-28 02:04:46 -0400" NOTES_MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Dreiser R, Ditisheim A, Charlot J, Lopez A</AU>
<TI>A double-blind, placebo controlled study of niflumic acid gel in the treatment of acute tendinitis</TI>
<SO>European Journal of Rheumatology and Inflammation</SO>
<YR>1991</YR>
<VL>11</VL>
<PG>38-45</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Fauchald-1978" MODIFIED="2013-04-22 13:49:26 -0400" MODIFIED_BY="[Empty name]" NAME="Fauchald 1978" YEAR="1978">
<REFERENCE MODIFIED="2013-04-22 13:49:26 -0400" MODIFIED_BY="[Empty name]" NOTES="&lt;p&gt;collected&lt;/p&gt;" NOTES_MODIFIED="2013-04-22 13:49:26 -0400" NOTES_MODIFIED_BY="[Empty name]" PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>Fauchald N, Ronning F, Saxegaard E, Sjolyst R</AU>
<TI>Naproxen and phenylbutazone in acute tendinitis: a multi-center double-blind comparison</TI>
<SO>Tidsskrift for Den Norske Laegeforening</SO>
<YR>1978</YR>
<VL>98</VL>
<PG>1004-6</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Fiszman-1985" MODIFIED="2012-08-28 02:05:10 -0400" MODIFIED_BY="[Empty name]" NAME="Fiszman 1985" YEAR="1985">
<REFERENCE MODIFIED="2012-08-28 02:05:10 -0400" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Fiszman P, Perpetuo J, Sidi A</AU>
<TI>Ro 12-0068 (Tenoxicam) in the treatment of extra-articular inflammatory processes</TI>
<SO>European Journal of Rheumatology and Inflammation</SO>
<YR>1985</YR>
<VL>8</VL>
<PG>15-20</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-F_x00f6_rster-1997" MODIFIED="2012-08-28 03:05:19 -0400" MODIFIED_BY="[Empty name]" NAME="Förster 1997" YEAR="1997">
<REFERENCE MODIFIED="2012-08-28 03:05:03 -0400" MODIFIED_BY="[Empty name]" NOTES="&lt;p&gt;collected&lt;/p&gt;" NOTES_MODIFIED="2012-08-28 03:05:03 -0400" NOTES_MODIFIED_BY="[Empty name]" PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>Förster KK, Schmid K, Reichelt A</AU>
<TI>Sports-induced acute epicondylitis of the elbow and conservative therapy</TI>
<TO>Sportbedingte akute epikondylitis des ellenbogens und ihre konservative therapie</TO>
<SO>Sportverletz Sportschaden</SO>
<YR>1997</YR>
<VL>11</VL>
<PG>16-20</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Furberg-1985" MODIFIED="2013-04-22 13:53:14 -0400" MODIFIED_BY="Dolores Matthews" NAME="Furberg 1985" YEAR="1985">
<REFERENCE MODIFIED="2013-04-22 13:53:14 -0400" MODIFIED_BY="Dolores Matthews" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Furberg B, Lerner A, Nystrom B, Rosen M, Willig P</AU>
<TI>Antiphlogistics in acute inflammatory conditions in the soft tissues of the musculo-skeletal system &#65293; a double blind comparison of diclofenac and indomethacin</TI>
<SO>Current Therapeutic Research, Clinical &amp; Experimental</SO>
<YR>1985</YR>
<VL>38</VL>
<NO>3</NO>
<PG>523-7</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Gallacchi-1990" MODIFIED="2013-04-22 13:53:23 -0400" MODIFIED_BY="[Empty name]" NAME="Gallacchi 1990" YEAR="1990">
<REFERENCE MODIFIED="2013-04-22 13:53:23 -0400" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Gallacchi G, Mautone G, Lualdi P</AU>
<TI>Painful inflammatory conditions: topical treatment with diclofenac hydroxyethylpyrrolidine ((R)Flector gel 1%)</TI>
<SO>Clinical Trials Journal</SO>
<YR>1990</YR>
<VL>27</VL>
<NO>1</NO>
<PG>58-64</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Geiger-1995" MODIFIED="2012-08-27 22:11:29 -0400" MODIFIED_BY="[Empty name]" NAME="Geiger 1995" YEAR="1995">
<REFERENCE MODIFIED="2012-08-27 22:11:29 -0400" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Geiger L, Elsasser R, Bias P, Haag RF</AU>
<TI>Placebo-controlled clinical study with Dolobene (R) gel in the treatment of epicondylitis</TI>
<SO>Deutsche Zeitschrift fur Sportmedizin</SO>
<YR>1995</YR>
<VL>46</VL>
<NO>4</NO>
<PG>221-7</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Ginsberg-1994" MODIFIED="2012-08-28 02:08:24 -0400" MODIFIED_BY="[Empty name]" NAME="Ginsberg 1994" YEAR="1994">
<REFERENCE MODIFIED="2012-08-28 02:08:24 -0400" MODIFIED_BY="[Empty name]" NOTES="&lt;p&gt;collected&lt;/p&gt;" NOTES_MODIFIED="2012-08-28 02:08:24 -0400" NOTES_MODIFIED_BY="[Empty name]" PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>Ginsberg F, Famaey J</AU>
<TI>Double-blind, randomized cross over study of the percutaneous efficacy and tolerability of a topical indomethacin spray versus placebo in the treatment of tendinitis</TI>
<SO>Journal of Musculoskeletal Pain</SO>
<YR>1994</YR>
<VL>2</VL>
<NO>1</NO>
<PG>127-8</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Goldberg-1985" NAME="Goldberg 1985" YEAR="1985">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Goldberg D, Rondier J, Oberlin F, Cayla J, Parier J</AU>
<TI>Preliminary study of the local injection of superoxide dismutase in epicondylitis</TI>
<TO>Etude preliminarie de l'injection locale de superoxyde dismutase au cours des epicondylites</TO>
<SO>Revue du Rhumatisme et des Maladies Osteo-Articulaires</SO>
<YR>1985</YR>
<VL>52</VL>
<NO>4</NO>
<PG>291</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Grossi-1986" MODIFIED="2013-04-22 13:53:36 -0400" MODIFIED_BY="[Empty name]" NAME="Grossi 1986" YEAR="1986">
<REFERENCE MODIFIED="2013-04-22 13:53:36 -0400" MODIFIED_BY="[Empty name]" NOTES="&lt;p&gt;Grossi, E., Monza, G. C., Pollavini, S., &amp;amp; Bona, L. (1986). NSAID ionisation in the management of soft-tissue rheumatism Role played by the drug, electrical stimulation and suggestion. Clinical and Experimental Rheumatology, 4, 265-267.&lt;/p&gt;" NOTES_MODIFIED="2013-04-22 13:53:36 -0400" NOTES_MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Grossi E, Monza GC, Pollavini S, Bona L</AU>
<TI>NSAID ionisation in the management of soft-tissue rheumatism: role played by the drug, electrical stimulation and suggestion</TI>
<SO>Clinical and Experimental Rheumatology</SO>
<YR>1986</YR>
<VL>4</VL>
<NO>3</NO>
<PG>265-7</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Gui-1982" MODIFIED="2013-04-22 13:53:43 -0400" MODIFIED_BY="[Empty name]" NAME="Gui 1982" YEAR="1982">
<REFERENCE MODIFIED="2013-04-22 13:53:43 -0400" MODIFIED_BY="[Empty name]" NOTES="&lt;p&gt;docdel&lt;/p&gt;" NOTES_MODIFIED="2013-04-22 13:53:43 -0400" NOTES_MODIFIED_BY="[Empty name]" PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>Gui L, Pellacci F, Ghirardini G</AU>
<TI>Use of ibuprofen cream in ambulatory orthopaedic patients: double-blind comparison with placebo</TI>
<SO>Clinica Terapeutica</SO>
<YR>1982</YR>
<VL>101</VL>
<PG>363-9</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Halle-1986" NAME="Halle 1986" YEAR="1986">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Halle J, Franklin RJ, Karalfa L</AU>
<TI>Comparison of four treatment approaches for lateral epicondylitis of the elbow</TI>
<SO>Journal Orthopaedic Sports Physical Medicine</SO>
<YR>1986</YR>
<VL>8</VL>
<NO>2</NO>
<PG>62-9</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Hofman-2000" MODIFIED="2013-04-22 13:54:00 -0400" MODIFIED_BY="[Empty name]" NAME="Hofman 2000" YEAR="2000">
<REFERENCE MODIFIED="2013-04-22 13:54:00 -0400" MODIFIED_BY="[Empty name]" NOTES="&lt;p&gt;docdel 14/11&lt;/p&gt;" NOTES_MODIFIED="2013-04-22 13:54:00 -0400" NOTES_MODIFIED_BY="[Empty name]" PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>Hofman J, Nasswetter G, Cayetti LM</AU>
<TI>Lysine clonixinate gel in soft tissue injuries: controlled randomized prospective double-blind clinical trial with diclofenac</TI>
<SO>Presna Medica Argentina</SO>
<YR>2000</YR>
<VL>87</VL>
<PG>513-20</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Hughes-1969" NAME="Hughes 1969" YEAR="1969">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Hughes GR, Currey HL</AU>
<TI>Hypospray treatment of tennis elbow</TI>
<SO>Annals of the Rheumatic Diseases</SO>
<YR>1969</YR>
<VL>28</VL>
<NO>1</NO>
<PG>58-62</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Jakobsen-1988" MODIFIED="2012-08-28 02:11:41 -0400" MODIFIED_BY="[Empty name]" NAME="Jakobsen 1988" YEAR="1988">
<REFERENCE MODIFIED="2012-08-28 02:11:41 -0400" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Jakobsen T, Petersen L, Christiansen S, Haarbo J, Munch M, Larsen P, et al</AU>
<TI>Double-blind comparative study of tenoxicam, piroxicam, and placebo in acute soft-tissue injuries</TI>
<SO>Current Therapeutic Research, Clinical and Experimental</SO>
<YR>1988</YR>
<VL>44</VL>
<NO>4</NO>
<PG>516-27</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Jakobsen-1991" MODIFIED="2013-04-22 14:07:09 -0400" MODIFIED_BY="[Empty name]" NAME="Jakobsen 1991" YEAR="1991">
<REFERENCE MODIFIED="2013-04-22 14:07:09 -0400" MODIFIED_BY="[Empty name]" NOTES="&lt;p&gt;docdel&lt;/p&gt;" NOTES_MODIFIED="2013-04-22 14:07:09 -0400" NOTES_MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Jakobsen T, Petersen L, Christiansen S, Haarbo J, Munch M, Larsen PB, et al</AU>
<TI>Should athletic injuries be treated with non-steroidal anti-rheumatic agents (NSAID)?</TI>
<SO>Ugeskrift for Laeger</SO>
<YR>1991</YR>
<VL>153</VL>
<PG>2003-5</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Jensen-2001" MODIFIED="2012-03-18 22:33:14 -0400" MODIFIED_BY="[Empty name]" NAME="Jensen 2001" YEAR="2001">
<REFERENCE MODIFIED="2012-03-18 22:33:12 -0400" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Jensen B, Bliddal H, Danneskiold-Samsoe B</AU>
<TI>Comparison of two different treatments for lateral epicondylitis</TI>
<SO>Ugeskrift for Laeger</SO>
<YR>2001</YR>
<VL>163</VL>
<NO>10</NO>
<PG>1427-31</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Karinen-1999" MODIFIED="2012-03-18 22:34:45 -0400" MODIFIED_BY="[Empty name]" NAME="Karinen 1999" YEAR="1999">
<REFERENCE MODIFIED="2012-03-18 22:34:42 -0400" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="CONFERENCE_PROC">
<AU>Karinen P, Kemola T, Pienimaki T, Koivukangas P, Vanharanta H</AU>
<TI>Economic evaluation of two different treatments of the tennis elbow</TI>
<SO>15th Annual Meeting of the International Society of Technology Assessment in Health Care</SO>
<YR>1999</YR>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Kneer-1994" MODIFIED="2013-04-22 14:08:08 -0400" MODIFIED_BY="[Empty name]" NAME="Kneer 1994" YEAR="1994">
<REFERENCE MODIFIED="2013-04-22 14:08:08 -0400" MODIFIED_BY="[Empty name]" NOTES="&lt;p&gt;received&lt;/p&gt;" NOTES_MODIFIED="2013-04-22 14:08:08 -0400" NOTES_MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Kneer W, Kuhnau S, Bias P, Haag RF</AU>
<TI>Dimethylsulfoxide (DMSO) gel for the treatment of acute tendinopathy. A multicentre placebo-controlled randomized study</TI>
<SO>Fortschritte der Medizin</SO>
<YR>1994</YR>
<VL>112</VL>
<PG>142-6</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Kroll-1989" MODIFIED="2013-04-22 13:54:15 -0400" MODIFIED_BY="[Empty name]" NAME="Kroll 1989" YEAR="1989">
<REFERENCE MODIFIED="2013-04-22 13:54:15 -0400" MODIFIED_BY="[Empty name]" NOTES="&lt;p&gt;Kroll, M., Wiseman, R., Guttadauria, M. A clinical evaluation of piroxicam gel: an open comparative trial with diclofenac gel in the treatment of acute musculoskeletal disorders.  Clinical Therapeutics 1989;11:3 382 - 391&lt;/p&gt;" NOTES_MODIFIED="2013-04-22 13:54:15 -0400" NOTES_MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Kroll M, Wiseman R, Guttadauria M</AU>
<TI>A clinical evaluation of piroxicam gel: an open comparative trial with diclofenac gel in the treatment of acute musculoskeletal disorders</TI>
<SO>Clinical Therapeutics</SO>
<YR>1989</YR>
<VL>11</VL>
<PG>382-91</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Lecomte-1994" MODIFIED="2013-04-22 13:54:37 -0400" MODIFIED_BY="[Empty name]" NAME="Lecomte 1994" YEAR="1994">
<REFERENCE MODIFIED="2013-04-22 13:54:37 -0400" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Lecomte J, Buyse H, Taymans J, Monti T</AU>
<TI>Treatment of tendinitis and bursitis: a comparison of nimesulide and naproxen sodium in a double-blind parallel trial</TI>
<SO>European Journal of Rheumatology and Inflammation</SO>
<YR>1994</YR>
<VL>14</VL>
<PG>29-32</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Lopez-1997" MODIFIED="2013-04-22 13:57:54 -0400" MODIFIED_BY="[Empty name]" NAME="Lopez 1997" YEAR="1997">
<REFERENCE MODIFIED="2013-04-22 13:57:54 -0400" MODIFIED_BY="[Empty name]" NOTES="&lt;p&gt;collected, at translator&lt;/p&gt;" NOTES_MODIFIED="2013-04-22 13:57:54 -0400" NOTES_MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Lopez A, Auguste P, Maurandy P, Tamisier S, Wullaert P, Martin C, et al</AU>
<TI>Efficacy and safety of oral niflumic acid in the treatment of acute tendinitis of the limbs (a multicenter, randomised, double-blind, placebo-controlled trial)</TI>
<SO>Les Semaines des Hôpitaux Thérapeutique</SO>
<YR>1997</YR>
<VL>73</VL>
<PG>953-60</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-McGuinness-1969" NAME="McGuinness 1969" YEAR="1969">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>McGuinness BW, Lloyd-Jones M, Fowler PD</AU>
<TI>A double-blind comparative trial of 'parazolidin' and paracetamol</TI>
<SO>British Journal of Clinical Practice</SO>
<YR>1969</YR>
<VL>23</VL>
<NO>11</NO>
<PG>542-5</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Meloni-1995" MODIFIED="2013-04-22 14:09:00 -0400" MODIFIED_BY="[Empty name]" NAME="Meloni 1995" YEAR="1995">
<REFERENCE MODIFIED="2013-04-22 14:09:00 -0400" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Meloni P, Demuro G, Cara L, Garau D, Uras G, Suddu L</AU>
<TI>Evaluation of the effectiveness and tolerability of MED 15 vs piroxicam in patients with acute epicondylitis</TI>
<SO>Clinica Terapeutica</SO>
<YR>1995</YR>
<VL>146</VL>
<NO>6-7</NO>
<PG>453-6</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Menkes-1990" MODIFIED="2012-08-28 02:57:03 -0400" MODIFIED_BY="[Empty name]" NAME="Menkes 1990" YEAR="1990">
<REFERENCE MODIFIED="2012-08-28 02:57:03 -0400" MODIFIED_BY="[Empty name]" NOTES="&lt;p&gt;collected&lt;/p&gt;" NOTES_MODIFIED="2012-08-28 02:57:03 -0400" NOTES_MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Menkes C, Laoussadi S, Kac-Ohana, Lasserre O</AU>
<TI>Controlled trial of injectable diclofenac in mesotherapy for the treatment of tendinitis</TI>
<TO>Essai controle du diclofenac injectable en mesotherapie dans le traitement des tendinites</TO>
<SO>Revue du Rhumatisme et des Maladies Osteo-Articulaires</SO>
<YR>1990</YR>
<VL>57</VL>
<PG>589-91</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Nilsson-2012" MODIFIED="2013-04-22 13:58:18 -0400" MODIFIED_BY="[Empty name]" NAME="Nilsson 2012" YEAR="2012">
<REFERENCE MODIFIED="2013-04-22 13:58:18 -0400" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Nilsson P, Baigi A, Sward L, Moller M, Mansson J</AU>
<TI>Lateral epicondylalgia: a structured programme better than corticosteroids and NSAID</TI>
<SO>Scandinavian Journal of Occupational Therapy</SO>
<YR>2012</YR>
<VL>19</VL>
<NO>5</NO>
<PG>404-10</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Percy-1981" MODIFIED="2012-08-28 02:16:14 -0400" MODIFIED_BY="[Empty name]" NAME="Percy 1981" YEAR="1981">
<REFERENCE MODIFIED="2012-08-28 02:16:14 -0400" MODIFIED_BY="[Empty name]" NOTES="&lt;p&gt;collected&lt;/p&gt;" NOTES_MODIFIED="2012-08-28 02:16:14 -0400" NOTES_MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Percy EC, Carson JD</AU>
<TI>The use of DMSO in tennis elbow and rotator cuff tendinitis: a double-blind study</TI>
<SO>Medicine and Science in Sports and Exercise</SO>
<YR>1981</YR>
<VL>13</VL>
<NO>4</NO>
<PG>215-9</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Primbs-1983" MODIFIED="2012-08-28 02:16:22 -0400" MODIFIED_BY="[Empty name]" NAME="Primbs 1983" YEAR="1983">
<REFERENCE MODIFIED="2012-08-28 02:16:22 -0400" MODIFIED_BY="[Empty name]" NOTES="&lt;p&gt;collected&lt;/p&gt;" NOTES_MODIFIED="2012-08-28 02:16:22 -0400" NOTES_MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Primbs P, Tomasi M</AU>
<TI>Results of a double-blind study with Amuno gelo vs. placebo</TI>
<SO>Fortschritte der Medizin</SO>
<YR>1983</YR>
<VL>101</VL>
<PG>242-4</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Ritchie-1996a" MODIFIED="2012-08-28 02:16:33 -0400" MODIFIED_BY="[Empty name]" NAME="Ritchie 1996a" YEAR="1996">
<REFERENCE MODIFIED="2012-08-28 02:16:33 -0400" MODIFIED_BY="[Empty name]" NOTES="&lt;p&gt;Ritchie, L.D., Johnson, N., on behalf of the General Practice Research Group. A willingness to pay analysis: comparison of the patient preference for topical flurbiprofen local action cutaneous patches and piroxicam gel. 1996; 10: 291 - 302.&lt;/p&gt;" NOTES_MODIFIED="2012-08-28 02:16:33 -0400" NOTES_MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Ritchie LD, Johnson N</AU>
<TI>A willingness to pay analysis: comparison of the patient preference for topical flurbiprofen local action cutaneous patches and piroxicam gel</TI>
<SO>British Journal of Medical Economics</SO>
<YR>1996</YR>
<VL>10</VL>
<PG>291-302</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Ritchie-1996b" NAME="Ritchie 1996b" YEAR="1996">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Ritchie LD</AU>
<TI>A clinical evaluation of flurbiprofen LAT and piroxicam gel: a multicentre study in general practice</TI>
<SO>Clinical Rheumatology</SO>
<YR>1996</YR>
<VL>15</VL>
<NO>3</NO>
<PG>243-7</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Rosenthal-1982" MODIFIED="2012-08-28 02:17:28 -0400" MODIFIED_BY="[Empty name]" NAME="Rosenthal 1982" YEAR="1982">
<REFERENCE MODIFIED="2012-08-28 02:17:28 -0400" MODIFIED_BY="[Empty name]" NOTES="&lt;p&gt;Rosenthal M. The application of an extract of human placenta in the treatment of rheumatic affections. Int J Tiss Reac 1982: 4(2);147-151.&lt;/p&gt;" NOTES_MODIFIED="2012-08-28 02:17:28 -0400" NOTES_MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Rosenthal M</AU>
<TI>The application of an extract of human placenta in the treatment of rheumatic affections</TI>
<SO>International Journal of Tissue Reactions</SO>
<YR>1982</YR>
<VL>4</VL>
<NO>2</NO>
<PG>147-51</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Rosenthal-1984" MODIFIED="2012-08-28 02:17:57 -0400" MODIFIED_BY="[Empty name]" NAME="Rosenthal 1984" YEAR="1984">
<REFERENCE MODIFIED="2012-08-28 02:17:57 -0400" MODIFIED_BY="[Empty name]" NOTES="&lt;p&gt;Rosenthal M. The efficacy of flurbiprofen versus piroxicam in the treatment of acute soft tissue rheumatism. 1984; 9(5), 304-309.&lt;/p&gt;" NOTES_MODIFIED="2012-08-28 02:17:57 -0400" NOTES_MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Rosenthal M</AU>
<TI>The efficacy of flurbiprofen versus piroxicam in the treatment of acute soft tissue rheumatism</TI>
<SO>Current Medical Research and Opinion</SO>
<YR>1984</YR>
<VL>9</VL>
<NO>5</NO>
<PG>304-9</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Saggini-1997" MODIFIED="2013-04-22 14:10:07 -0400" MODIFIED_BY="[Empty name]" NAME="Saggini 1997" YEAR="1997">
<REFERENCE MODIFIED="2013-04-22 14:10:07 -0400" MODIFIED_BY="[Empty name]" NOTES="&lt;p&gt;Saggini R, Zoppi M, Vecchier F, Gatteschi L. Comparison of Electromotive Drug Administration with Ketorolac or Placebo in Patients with Patients with Pain from Rheumatic Disease: a Double Masked Study.   1997; 18:6, 1169-1174.&lt;/p&gt;" NOTES_MODIFIED="2013-04-22 14:10:07 -0400" NOTES_MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Saggini R, Zoppi M, Vecchiet F, Gatteschi L, Obletter G, Giamberardino MA</AU>
<TI>Comparison of electromotive drug administration with ketorolac or placebo in patients with pain from rheumatic disease</TI>
<SO>Clinical Therapeutics</SO>
<YR>1997</YR>
<VL>18</VL>
<NO>6</NO>
<PG>1169-74</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Saudan-1977" MODIFIED="2012-03-18 22:37:44 -0400" MODIFIED_BY="[Empty name]" NAME="Saudan 1977" YEAR="1977">
<REFERENCE MODIFIED="2012-03-18 22:37:42 -0400" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Saudan Y</AU>
<TI>Non-surgical treatment of the acute and chronic epicondylitis (tennis elbow)</TI>
<SO>Therapeutische Umschau</SO>
<YR>1977</YR>
<VL>34</VL>
<NO>2</NO>
<PG>81-7</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Schorn-1986" MODIFIED="2012-08-28 02:19:19 -0400" MODIFIED_BY="[Empty name]" NAME="Schorn 1986" YEAR="1986">
<REFERENCE MODIFIED="2012-08-28 02:19:19 -0400" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Schorn D</AU>
<TI>Tenoxicam in soft tissue rheumatism</TI>
<SO>South African Medical Journal</SO>
<YR>1986</YR>
<VL>69</VL>
<PG>301-3</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Seligra-1990" MODIFIED="2013-04-22 13:59:11 -0400" MODIFIED_BY="[Empty name]" NAME="Seligra 1990" YEAR="1990">
<REFERENCE MODIFIED="2013-04-22 13:59:11 -0400" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Seligra A, Ingles F</AU>
<TI>A comparative study of naproxen gel and flufenamic acid gel in the treatment of soft tissue injuries</TI>
<SO>Current Medical Research and Opinion</SO>
<YR>1990</YR>
<VL>12</VL>
<NO>4</NO>
<PG>249-54</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Sileghem-1991" MODIFIED="2012-08-28 02:20:08 -0400" MODIFIED_BY="[Empty name]" NAME="Sileghem 1991" YEAR="1991">
<REFERENCE MODIFIED="2012-08-28 02:20:08 -0400" MODIFIED_BY="[Empty name]" NOTES="&lt;p&gt;Sileghem A, Verstraeten A, Dequeker J. Double-blind, randomised, parallel-group study of the efficacy and safety of Proglumetacin and Naproxen in Periarthritis of the shoulder or Elbow. Current Therapeutic Research 1991; 50 (1): 93-100.&lt;/p&gt;" NOTES_MODIFIED="2012-08-28 02:20:08 -0400" NOTES_MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Sileghem A, Verstraeten A, Dequeker J</AU>
<TI>Double-blind, randomised, parallel-group study of the efficacy and safety of poglumetacin and naproxen in periarthritis of the shoulder or elbow</TI>
<SO>Current Therapeutic Research</SO>
<YR>1991</YR>
<VL>1</VL>
<PG>93-100</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Thorling-1990" MODIFIED="2012-08-28 02:20:21 -0400" MODIFIED_BY="[Empty name]" NAME="Thorling 1990" YEAR="1990">
<REFERENCE MODIFIED="2012-08-28 02:20:21 -0400" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Thorling J, Linden B, Berg R, Sandahl A</AU>
<TI>A double blind comparison of naproxen gel and placebo in treatment of soft tissue injuries</TI>
<SO>Current Medical Research and Opinion</SO>
<YR>1990</YR>
<VL>12</VL>
<NO>4</NO>
<PG>242-8</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Turbio-1993" MODIFIED="2012-08-28 02:20:33 -0400" MODIFIED_BY="[Empty name]" NAME="Turbio 1993" YEAR="1993">
<REFERENCE MODIFIED="2012-08-28 02:20:33 -0400" MODIFIED_BY="[Empty name]" NOTES="&lt;p&gt;docdel&lt;/p&gt;" NOTES_MODIFIED="2012-08-28 02:20:33 -0400" NOTES_MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Turbio F, Ishida A, Laredo F</AU>
<TI>Etodolac versus diclofenac in acute tendinitis and bursitis</TI>
<SO>Arquivos Brasilieiros de Medicina</SO>
<YR>1993</YR>
<VL>67</VL>
<PG>217-23</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Vecchini-1984" MODIFIED="2013-04-22 13:59:20 -0400" MODIFIED_BY="[Empty name]" NAME="Vecchini 1984" YEAR="1984">
<REFERENCE MODIFIED="2013-04-22 13:59:20 -0400" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Vecchini L, Grossi E</AU>
<TI>Ionisation with diclofenac sodium in rheumatic disorders: a double blind placebo controlled trial</TI>
<SO>Journal of International Medical Research</SO>
<YR>1984</YR>
<VL>12</VL>
<PG>346-50</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Venerando-1973" NAME="Venerando 1973" YEAR="1973">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Venerando A, Santilli G</AU>
<TI>Use of 2-(4-isobutylphenyl)-propionic acid (brufen) in the treatment of some diseases of athletes</TI>
<TO>Sull'impiego dell'acido 2-(4-isobutilfenil)-propionico (Brufen) nel trattamento di alcune atlopatie</TO>
<SO>Minerva Medica</SO>
<YR>1973</YR>
<VL>64</VL>
<NO>48</NO>
<PG>2537-9</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Wiseman-1987" MODIFIED="2013-04-22 13:59:32 -0400" MODIFIED_BY="[Empty name]" NAME="Wiseman 1987" YEAR="1987">
<REFERENCE MODIFIED="2013-04-22 13:59:32 -0400" MODIFIED_BY="[Empty name]" PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>Wiseman R, Sodergren J, Guttadauria M, Ryan A</AU>
<TI>Treatment of acute musculoskeletal disorders with piroxicam: results of a double-blind multicenter comparison with naproxen</TI>
<SO>Current Therapeutic Research, Clinical and Experimental</SO>
<YR>1987</YR>
<VL>42</VL>
<PG>974-87</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
</EXCLUDED_STUDIES>
<AWAITING_STUDIES/>
<ONGOING_STUDIES MODIFIED="2013-02-03 21:35:45 -0500" MODIFIED_BY="[Empty name]"/>
</STUDIES>
<OTHER_REFERENCES MODIFIED="2013-04-22 14:01:36 -0400" MODIFIED_BY="Porjai Pattanittum">
<ADDITIONAL_REFERENCES MODIFIED="2013-04-22 14:01:36 -0400" MODIFIED_BY="Porjai Pattanittum">
<REFERENCE ID="REF-Alizadehkhaiyat-2007" MODIFIED="2012-08-28 02:45:00 -0400" MODIFIED_BY="[Empty name]" NAME="Alizadehkhaiyat 2007" TYPE="JOURNAL_ARTICLE">
<AU>Alizadehkhaiyat O, Fisher AC, Kemp GJ, Frostick SP</AU>
<TI>Pain, functional disability, and psychologic status in tennis elbow</TI>
<SO>Clinical Journal of Pain</SO>
<YR>2007</YR>
<VL>23</VL>
<PG>482-9</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Allander-1974" MODIFIED="2013-04-22 13:59:46 -0400" MODIFIED_BY="[Empty name]" NAME="Allander 1974" TYPE="JOURNAL_ARTICLE">
<AU>Allander E</AU>
<TI>Prevalence, incidence and remission rates of some common rheumatic diseases and syndromes</TI>
<SO>Scandinavian Journal of Rheumatology</SO>
<YR>1974</YR>
<VL>3</VL>
<PG>145-53</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Biskupiak-2006" MODIFIED="2012-08-28 02:46:10 -0400" MODIFIED_BY="[Empty name]" NAME="Biskupiak 2006" TYPE="JOURNAL_ARTICLE">
<AU>Biskupiak JE, Brixner DI, Howard K, Oderda GM</AU>
<TI>Gastrointestinal complications of over-the-counter nonsteroidal antiinflammatory drugs</TI>
<SO>Journal of Pain &amp; Palliative Care Pharmacotherapy</SO>
<YR>2006</YR>
<VL>20</VL>
<NO>3</NO>
<PG>7-14</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Bisset-2005" MODIFIED="2012-08-28 02:46:32 -0400" MODIFIED_BY="[Empty name]" NAME="Bisset 2005" TYPE="JOURNAL_ARTICLE">
<AU>Bisset L, Paungmali A, Vicenzino B, Beller E</AU>
<TI>A systematic review and meta-analysis of clinical trials on physical interventions for lateral epicondylalgia</TI>
<SO>British Journal of Sports Medicine</SO>
<YR>2005</YR>
<VL>39</VL>
<NO>7</NO>
<PG>411-22</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Boisaubert-2004" MODIFIED="2012-05-26 00:54:50 -0400" MODIFIED_BY="[Empty name]" NAME="Boisaubert 2004" TYPE="JOURNAL_ARTICLE">
<AU>Boisaubert B, Brousse C, Zaoui A, Montigny JP</AU>
<TI>Nonsurgical treatment of tennis elbow</TI>
<TO>Analyse de la littérature: Les traitements non chirurgicaux de la tendinopathie des épicondyliens</TO>
<SO>Annales de Readaptation et de Medecine Physique</SO>
<YR>2004</YR>
<VL>47</VL>
<NO>6</NO>
<PG>346-55</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Bot-2005" MODIFIED="2013-04-22 14:00:06 -0400" MODIFIED_BY="[Empty name]" NAME="Bot 2005" TYPE="JOURNAL_ARTICLE">
<AU>Bot SD, van der Waal JM, Terwee CB, van der Windt DA, Schellevis FG, Bouter LM, et al</AU>
<TI>Incidence and prevalence of complaints of the neck and upper extremity in general practice</TI>
<SO>Annals of the Rheumatic Diseases</SO>
<YR>2005</YR>
<VL>64</VL>
<NO>1</NO>
<PG>118-23</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Cates-2008" MODIFIED="2012-08-28 02:41:53 -0400" MODIFIED_BY="[Empty name]" NAME="Cates 2008" TYPE="COMPUTER_PROGRAM">
<AU>Cates C</AU>
<TI>Visual Rx</TI>
<YR>2008</YR>
<EN>3</EN>
<PB>Dr Christopher Cates</PB>
<MD>http://www.nntonline.net/visualrx/</MD>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Clarke-2010" MODIFIED="2012-08-28 02:47:18 -0400" MODIFIED_BY="[Empty name]" NAME="Clarke 2010" TYPE="JOURNAL_ARTICLE">
<AU>Clarke AW, Ahmad M, Curtis M, Connell DA</AU>
<TI>Lateral elbow tendinopathy: correlation of ultrasound findings with pain and functional disability</TI>
<SO>American Journal of Sports Medicine</SO>
<YR>2010</YR>
<VL>38</VL>
<PG>1209-14</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Deeks-2009" MODIFIED="2013-04-22 14:00:20 -0400" MODIFIED_BY="[Empty name]" NAME="Deeks 2009" TYPE="BOOK_SECTION">
<AU>Deeks JJ, Higgins JPT, Altman DG, on behalf of the Cochrane Statistical Methods Group (Editors)</AU>
<TI>Chapter 9:  Analysing data and undertaking meta-analyses</TI>
<SO>Higgins JFT, Green S (editors). Cochrane Handbook for Systematic Reviews of Interventions Version 5.0.2 [updated September 2009]</SO>
<YR>2009. Available from www.cochrane-handbook.org</YR>
<PB>The Cochrane Collaboration</PB>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Dworkin-2008" MODIFIED="2012-12-23 00:57:57 -0500" MODIFIED_BY="[Empty name]" NAME="Dworkin 2008" TYPE="JOURNAL_ARTICLE">
<AU>Dworkin RH, Turk DC, Wyrwich KW, Beaton D, CleelandCS, Farrar JT, et al</AU>
<TI>Interpreting the clinical importance of treatment outcomes in chronic pain clinical trials: IMMPACT recommendations</TI>
<SO>The Journal of Pain</SO>
<YR>2008</YR>
<VL>9</VL>
<NO>2</NO>
<PG>105&#8211;21</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Garcia-2001" MODIFIED="2009-10-30 01:15:06 -0400" MODIFIED_BY="[Empty name]" NAME="Garcia 2001" TYPE="JOURNAL_ARTICLE">
<AU>Garcia Rodriguez LA, Hernandez-Diaz S</AU>
<TI>Relative risk of upper gastrointestinal complications among users of acetaminophen and nonsteroidal anti-inflammatory drugs</TI>
<SO>Epidemiology</SO>
<YR>2001</YR>
<VL>12</VL>
<NO>5</NO>
<PG>570-6</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Green-2002" MODIFIED="2010-02-14 23:36:50 -0500" MODIFIED_BY="Porjai Pattanittum" NAME="Green 2002" TYPE="COCHRANE_REVIEW">
<AU>Green S, Buchbinder R, Barnsley L, Hall S, White M, Smidt N, Assendelft W</AU>
<TI>Acupuncture for lateral elbow pain</TI>
<SO>Cochrane Database of Systematic Reviews</SO>
<YR>2002</YR>
<NO>1</NO>
<IDENTIFIERS MODIFIED="2010-02-14 23:36:50 -0500" MODIFIED_BY="Porjai Pattanittum">
<IDENTIFIER MODIFIED="2010-02-14 23:36:50 -0500" MODIFIED_BY="Porjai Pattanittum" TYPE="DOI" VALUE="10.1002/14651858.CD003527"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Higgins-2011" MODIFIED="2013-04-22 14:01:00 -0400" MODIFIED_BY="Porjai Pattanittum" NAME="Higgins 2011" TYPE="OTHER">
<AU>Higgins JPT, Altman DG, Sterne JAC (editors)</AU>
<TI>Chapter 8: Assessing risk of bias in included studies</TI>
<SO>In: Higgins JPT, Green S (editors). Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 [updated March 2011]. The Cochrane Collaboration, 2011. Available from www.cochrane-handbook.org</SO>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Hume-2006" MODIFIED="2012-01-18 21:16:11 -0500" MODIFIED_BY="[Empty name]" NAME="Hume 2006" TYPE="JOURNAL_ARTICLE">
<AU>Hume PA, Reid D, Edwards T</AU>
<TI>Epicondylar injury in sport: epidemiology, type, mechanisms, assessment, management and prevention</TI>
<SO>Sports Medicine</SO>
<YR>2006</YR>
<VL>36</VL>
<PG>151-70</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Kearney-2006" MODIFIED="2012-03-18 21:52:44 -0400" MODIFIED_BY="[Empty name]" NAME="Kearney 2006" TYPE="JOURNAL_ARTICLE">
<AU>Kearney P, Baigent C, Godwin J, Halls H, Emberson J, Patrono C</AU>
<TI>Do selective cyclo-oxygenase-2 inhibitors and traditional non-steroidal anti-inflammatory drugs increase the risk of atherothrombosis? Meta-analysis of randomised trials</TI>
<SO>BMJ</SO>
<YR>2006</YR>
<VL>332</VL>
<PG>1302-8</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Mallen-2009" MODIFIED="2012-08-28 02:48:08 -0400" MODIFIED_BY="[Empty name]" NAME="Mallen 2009" TYPE="JOURNAL_ARTICLE">
<AU>Mallen CD, Chesterton LS, Hay EM</AU>
<TI>Tennis elbow</TI>
<SO>BMJ</SO>
<YR>2009</YR>
<VL>339</VL>
<PG>b3180</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Moore-2010a" MODIFIED="2012-12-23 01:02:14 -0500" MODIFIED_BY="[Empty name]" NAME="Moore 2010a" TYPE="JOURNAL_ARTICLE">
<AU>Moore RA, Eccleston C, Derry S, Wiffen P, Bell RF, Straube S, et al</AU>
<TI>"Evidence" in chronic pain-establishing best practice in the reporting of systematic reviews</TI>
<SO>Pain</SO>
<YR>2010</YR>
<VL>150</VL>
<NO>3</NO>
<PG>386-9</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Nirschl-1979" MODIFIED="2013-04-22 14:01:12 -0400" MODIFIED_BY="[Empty name]" NAME="Nirschl 1979" TYPE="JOURNAL_ARTICLE">
<AU>Nirschl RP, Pettrone FA</AU>
<TI>Tennis elbow: the surgical treatment of lateral epicondylitis</TI>
<SO>Journal of Bone and Joint Surgery</SO>
<YR>1979</YR>
<VL>61</VL>
<NO>6A</NO>
<PG>832-9</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Ranney-1995" MODIFIED="2012-01-18 21:15:01 -0500" MODIFIED_BY="[Empty name]" NAME="Ranney 1995" TYPE="JOURNAL_ARTICLE">
<AU>Ranney D, Wells R, Moore A</AU>
<TI>Upper limb musculoskeletal disorders in highly repetitive industries: precise anatomical physical findings</TI>
<SO>Ergonomics</SO>
<YR>1995</YR>
<VL>38</VL>
<PG>1408-23</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-RevMan2011" MODIFIED="2012-08-28 02:50:28 -0400" MODIFIED_BY="Porjai Pattanittum" NAME="RevMan2011" TYPE="COMPUTER_PROGRAM">
<TI>Review Manager (RevMan)</TI>
<SO>http://www.cc-ims.net/revman/download</SO>
<YR>2011</YR>
<EN>5.1</EN>
<PB>The Nordic Cochrane Centre, The Cochrane Collaboration</PB>
<CY>Copenhagen</CY>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Rompe-2007" MODIFIED="2012-12-23 01:19:48 -0500" MODIFIED_BY="[Empty name]" NAME="Rompe 2007" TYPE="JOURNAL_ARTICLE">
<AU>Rompe JD, Overend TJ, MacDermid JC</AU>
<TI>Validation of the Patient-rated Tennis Elbow Evaluation Questionnaire</TI>
<SO>Journal Hand Therapy</SO>
<YR>2007</YR>
<VL>20</VL>
<PG>3-10</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Roquelaure-2006" MODIFIED="2013-04-22 14:01:22 -0400" MODIFIED_BY="[Empty name]" NAME="Roquelaure 2006" TYPE="JOURNAL_ARTICLE">
<AU>Roquelaure Y, Ha C, Leclerc A, Touranchet A, Sauteron M, Melchior M, et al</AU>
<TI>Epidemiologic surveillance of upper-extremity musculoskeletal disorders in the working population</TI>
<SO>Arthritis and Rheumatism</SO>
<YR>2006</YR>
<VL>55</VL>
<NO>5</NO>
<PG>765-78</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Sch_x00fc_nemann-2011a" MODIFIED="2013-04-22 14:01:30 -0400" MODIFIED_BY="[Empty name]" NAME="Schünemann 2011a" TYPE="OTHER">
<AU>Schünemann HJ, Oxman AD, Higgins JPT, Vist GE, Glasziou P, Guyatt GH</AU>
<TI>Chapter 11: Presenting results and 'Summary of findings' tables</TI>
<SO>In: Higgins JPT, Green S (editors). Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 [updated March 2011]. The Cochrane Collaboration, 2011. Available from www.cochrane-handbook.org</SO>
<IDENTIFIERS MODIFIED="2012-01-18 22:02:50 -0500" MODIFIED_BY="[Empty name]">
<IDENTIFIER MODIFIED="2012-01-18 22:02:50 -0500" MODIFIED_BY="[Empty name]" TYPE="OTHER" VALUE="Available from www.cochrane-handbook.org"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Sch_x00fc_nemann-2011b" MODIFIED="2013-04-22 14:01:36 -0400" MODIFIED_BY="[Empty name]" NAME="Schünemann 2011b" TYPE="OTHER">
<AU>Schünemann HJ, Oxman AD, Vist GE, Higgins JPT, Deeks JJ, Glasziou P, et al</AU>
<TI>Chapter 12: Interpreting results and drawing conclusions</TI>
<SO>In: Higgins JPT, Green S (editors). Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 [updated March 2011]. The Cochrane Collaboration, 2011. Available from www.cochrane-handbook.org</SO>
<IDENTIFIERS MODIFIED="2012-01-18 22:04:09 -0500" MODIFIED_BY="[Empty name]">
<IDENTIFIER MODIFIED="2012-01-18 22:04:09 -0500" MODIFIED_BY="[Empty name]" TYPE="OTHER" VALUE="Available from www.cochrane-handbook.org"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Shiri-2006" MODIFIED="2012-08-28 02:34:15 -0400" MODIFIED_BY="[Empty name]" NAME="Shiri 2006" TYPE="JOURNAL_ARTICLE">
<AU>Shiri R, Viikari-Juntura E, Varonen H, Heliovaara M</AU>
<TI>Prevalence and determinants of lateral and medial epicondylitis: a population study</TI>
<SO>American Journal of Epidemiology</SO>
<YR>2006</YR>
<VL>164</VL>
<NO>11</NO>
<PG>1065-74</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Walker_x002d_Bone-2004" MODIFIED="2012-08-28 02:33:51 -0400" MODIFIED_BY="[Empty name]" NAME="Walker-Bone 2004" TYPE="JOURNAL_ARTICLE">
<AU>Walker-Bone K, Palmer KT, Reading I, Coggon D, Cooper C</AU>
<TI>Prevalence and impact of musculoskeletal disorders of the upper limb in the general population</TI>
<SO>Arthritis and Rheumatism</SO>
<YR>2004</YR>
<VL>51</VL>
<NO>4</NO>
<PG>642-51</PG>
<IDENTIFIERS/>
</REFERENCE>
</ADDITIONAL_REFERENCES>
<OTHER_VERSIONS_REFERENCES MODIFIED="2012-08-28 02:29:13 -0400" MODIFIED_BY="[Empty name]">
<REFERENCE ID="REF-Green-2002a" MODIFIED="2012-08-28 02:29:13 -0400" MODIFIED_BY="[Empty name]" NAME="Green 2002a" TYPE="COCHRANE_REVIEW">
<AU>Green S, Buchbinder R, Barnsley L, Hall S, White M, Smidt N, Assendelft WJJ</AU>
<TI>Non-steroidal anti-inflammatory drugs (NSAIDs) for treating lateral elbow pain in adults</TI>
<SO>Cochrane Database of Systematic Reviews</SO>
<YR>2002</YR>
<NO>4</NO>
<IDENTIFIERS MODIFIED="2012-08-28 02:29:13 -0400" MODIFIED_BY="[Empty name]">
<IDENTIFIER MODIFIED="2012-08-28 02:29:13 -0400" MODIFIED_BY="[Empty name]" TYPE="DOI" VALUE="10.1002/14651858.CD003686"/>
</IDENTIFIERS>
</REFERENCE>
</OTHER_VERSIONS_REFERENCES>
<PENDING_REFERENCES MODIFIED="2009-06-15 01:48:41 -0400" MODIFIED_BY="[Empty name]"/>
</OTHER_REFERENCES>
</STUDIES_AND_REFERENCES>
<CHARACTERISTICS_OF_STUDIES MODIFIED="2013-04-22 21:45:57 -0400" MODIFIED_BY="[Empty name]">
<CHARACTERISTICS_OF_INCLUDED_STUDIES MODIFIED="2013-04-22 21:45:57 -0400" MODIFIED_BY="[Empty name]" SORT_BY="STUDY" USER_DEF_1_ENABLED="NO" USER_DEF_2_ENABLED="NO" USER_DEF_3_ENABLED="NO">
<INCLUDED_CHAR MODIFIED="2013-04-22 21:37:02 -0400" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Adelaar-1987">
<CHAR_METHODS MODIFIED="2013-04-22 13:14:14 -0400" MODIFIED_BY="[Empty name]">
<P>
<B>Design:</B> randomised controlled trial.</P>
<P>
<B>Blinding: </B>outcome assessment not blinded.</P>
<P>
<B>Primary endpoint and sample size calculation: </B>not described.</P>
<P>
<B>Withdrawals:</B> Three participants were not evaluated as they were reported to be non-compliant with study medication regimen; a fourth participant was excluded for not meeting inclusion criteria.</P>
<P>
<B>Statistical analysis:</B> Non-compliant participants were excluded from the analysis and no measures of variance were reported.</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2013-04-22 21:37:02 -0400" MODIFIED_BY="[Empty name]">
<P>
<B>Number of participants:</B> 22 but data reported only for the 18 'evaluable' participants.</P>
<P>
<B>Mean age:</B> 34.5 years, range 20 to 49 years.</P>
<P>
<B>Gender:</B> 6 M, 12 F.</P>
<P>
<B>Duration of symptoms: </B>All participants had symptoms for at least 6-7 days; pain was at least mild and functional capacity was at least moderately inhibited.</P>
<P>
<B>Inclusion criteria: </B>males or females between ages 18 and 65 years with medial, lateral or posterior epicondylitis of mild to moderate severity.</P>
<P>
<BR/>
<B>Exclusion criteria:</B> allergic to study medication, taking other medication, pregnant or lactating, history of peptic ulcer or gastrointestinal bleeding, history of bleeding disorder, hypertension, cardiovascular, renal or hepatic disease, sustained injury to the elbow other than epicondylitis, surgery to elbow, glucocorticoid injection to elbow less than 4 weeks before study entry, abnormal elbow x-ray.</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2013-04-22 13:14:36 -0400" MODIFIED_BY="[Empty name]">
<P>
<B>Group 1</B>: Rehabilitation program of rest, electrotherapy, ice/heat, exercises and bracing PLUS oral NSAID &#65293; diflunisal 1000 mg followed by 500 mg every 12 hours for 15 days.<BR/>
<B>Group 2:</B> Rehabilitation program of rest, electrotherapy, ice/heat, exercises and bracing PLUS oral NSAID &#65293; naproxen 500 mg followed by 250 mg every 6-8 hours as required for 15 days.</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2013-04-22 13:15:33 -0400" MODIFIED_BY="[Empty name]">
<P>Outcomes were assessed at baseline and at 5, 10 and 15 days or on the day the study medication was discontinued and no primary outcome specified:</P>
<P>1. Work simulation testing (for details refer to study report).</P>
<P>2. Investigator-rated pain (scale 0-3 where 0 = none, 1 = mild, 2 = moderate, 3 = severe).</P>
<P>3. Investigator-rated tenderness (scale 0-3 where 0 = none, 1 = tenderness present, 2 = tenderness present and participant winces, 3 = tenderness present and participant winces and withdraws).</P>
<P>4. Investigator-rated swelling (scale 0-3 where 0 = no swelling, 1 = detectable swelling, 2 = up to and including 50% increase in size, 3 = &gt; 50% increase in size)</P>
<P>5. Limitation of motion &#65293; degree of ease by which flexion, extension, pronation and supination could be carried out during passive and active motion.</P>
<P>6. Patient-rated pain (same scale as investigator-rated pain).</P>
<P>7. Patient-rated functional capacity (0-3 scale where 0 = no discomfort, 1 = mild discomfort and difficulty, 2 = great discomfort and difficulty, 3 = usual activity cannot be performed).</P>
<P>8. Patient-rated overall post-treatment assessment includes post-treatment symptoms (no remaining symptoms, improved, no changed, worse) and medication as pain-relieving symptoms (excellent, very good, good, fair, poor).</P>
<P>9. Tolerability of study medication (scale not described).</P>
<P>10. Adverse reactions recorded on adverse experience report form (format not described).</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2013-04-22 13:16:06 -0400" MODIFIED_BY="[Empty name]">
<P>Conflicting data were reported for the condition being treated. At one point the paper states that all 22 participants had lateral epicondylitis. The results report that 15/18 (83%) participants had lateral epicondylitis including one participant who also had medial epicondylitis, and three participants had medial epicondylitis. At best all participants had lateral elbow pain, and at worst 15/18 (83%) had the condition; therefore we made the decision to include the trial.</P>
<P>The interim assessments were not reported for any outcome.</P>
<P>Only means before and after treatment were presented with no measure of variance, so no data could be pooled.</P>
<P>Study investigators reported no significant between-group differences for any outcome. They also reported that both NSAIDs were well tolerated. One participant who received diflunisal developed transient nausea and stomach cramps.</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2013-04-22 13:17:56 -0400" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Burnham-1998">
<CHAR_METHODS MODIFIED="2013-04-22 13:17:43 -0400" MODIFIED_BY="[Empty name]">
<P>
<B>Design:</B> randomised, crossover study.</P>
<P>
<B>Blinding:</B> 'double-blind' (participants and researchers blinded).</P>
<P>
<B>Primary endpoint and sample size:</B> not described.</P>
<P>
<B>Withdrawals:</B> none reported.</P>
<P>
<B>Statistical analysis: </B>intention to treat.</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2013-04-22 13:17:50 -0400" MODIFIED_BY="[Empty name]">
<P>
<B>Number of participants: </B>14.</P>
<P>
<B>Setting:</B> Edmonton Sport Institute, Canada.<BR/>
</P>
<P>
<B>Mean (SD) age:</B> 41.5 (6.8) years; range 20 to 49 years.</P>
<P>
<B>Gender:</B> 8 M, 6 F.</P>
<P>
<B>Mean duration of symptoms: </B>8.3 months (range 2 to 23 months).</P>
<P>
<B>Inclusion criteria: </B>chronic lateral epicondylitis = point tenderness, aggravation with wrist extension, symptoms for longer than 2 months.<BR/>
</P>
<P>
<B>Exclusion criteria: </B>concomitant treatment.</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2013-04-22 13:17:52 -0400" MODIFIED_BY="[Empty name]">
<P>
<B>Initial week:</B> applied a pluronic lecithin liposome organo gel over the affected lateral elbow 3 times daily.<BR/>
<B>Second week:</B> no gel "washout period".<BR/>
<B>Third week:</B> second application of the pluronic lecithin liposome organo gel.<BR/>
<BR/>Only one of the gels contained diclofenac.</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2013-04-22 13:17:53 -0400" MODIFIED_BY="[Empty name]">
<P>Assessment at baseline and after 1, 2, 3 weeks:</P>
<P>1. Pain using a visual analogue scale.<BR/>2. Isometric wrist extension strength (dynamometer).</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2013-04-22 13:17:56 -0400" MODIFIED_BY="[Empty name]">
<P>A 1-week washout period for wrist extension strength may not have excluded carryover effects. Data for pain 10 cm VAS appeared skewed.</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2013-04-22 13:19:14 -0400" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Burton-1988">
<CHAR_METHODS MODIFIED="2013-04-22 13:18:42 -0400" MODIFIED_BY="[Empty name]">
<P>
<B>Design:</B> randomised, controlled trial (four groups).<BR/>
<B>Blinding: </B>unclear whether blinded or not.<BR/>
<B>Loss to follow-up: </B>none reported.<BR/>
<B>Statistical analysis: </B>appropriate.</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2013-04-22 13:18:51 -0400" MODIFIED_BY="[Empty name]">
<P>
<B>Number of participants: </B>33 (n = 17 for the two relevant groups for this review).<BR/>
</P>
<P>
<B>Mean (SD) age:</B> 45.1 years.</P>
<P>
<B>Gender:</B> 17 M; 16 F.</P>
<P>
<B>Mean duration of symptoms: </B>4.8 weeks.</P>
<P>
<B>Inclusion criteria: </B>diagnosis of tennis elbow &lt; 3 months' duration, with pain, tenderness over lateral epicondylitis, with at least 2 of increased pain on grip/twist/lift, resisted 3rd-digit extension or pronation, wrist flexion.</P>
<P>
<B>Exclusion criteria: </B>none specified.</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2013-04-22 13:19:03 -0400" MODIFIED_BY="[Empty name]">
<P>
<B>Group 1:</B> manipulative treatment, a forearm strap and a topical NSAID &#65293; benzydamine (Difflam) cream applied 5 times daily for 3 weeks (n = 8).<BR/>
<B>Group 2:</B> manipulative treatment and topical NSAID (same as for Group 1) (n = 9).</P>
<P>
<B>Group 3:</B> manipulative treatment and a forearm strap (n = 8).</P>
<P>
<B>Group 4:</B> manipulation only (n = 8).</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2013-04-22 13:19:13 -0400" MODIFIED_BY="[Empty name]">
<P>Assessment at baseline, 3 days, 1 week, 3 weeks:<BR/>1. Painfree grip strength using sphygmomanometer cuff.<BR/>2. 6-Point categorical scale for pain with the participant's chosen function, rated from 0 (no pain/difficulty) to 5 (severe pain/impossible).</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2013-04-22 13:19:14 -0400" MODIFIED_BY="[Empty name]">
<P>For the purposes of this review, we compared Group 2 with Group 4. We converted the 6-point categorical scale for pain to a 10-point scale for meta-analysis. The data are likely to be skewed.</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2013-04-22 21:37:24 -0400" MODIFIED_BY="[Empty name]" STUDY_ID="STD-B_x00e4_cker-2011">
<CHAR_METHODS MODIFIED="2013-04-22 13:19:24 -0400" MODIFIED_BY="[Empty name]">
<P>
<B>Design: </B>randomised controlled trial.<BR/>
<B>Blinding: </B>none.<BR/>
</P>
<P>
<B>Withdrawals: </B>No withdrawals were reported.<BR/>
<B>Appropriate statistical analysis: </B>Sample size calculation was specified, and there was a predefined stopping rule for an interim analysis after 40 participants.</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2013-04-22 21:37:24 -0400" MODIFIED_BY="[Empty name]">
<P>
<B>Number of participants: </B>40.</P>
<P>
<B>Mean (SD) age: </B>47.9 (9.5) years in the leech group and 50.2 (11.8) years in the diclofenac group.</P>
<P>
<B>Gender:</B> 13 F, 7 M in the leech group and 9 F, 11 M in the diclofenac group.</P>
<P>
<B>Mean duration of symptoms: </B>17.8 months (range 3 to 84) in the leech group and 30.9 months (range 3 to 180) in the diclofenac group.<BR/>
</P>
<P>
<B>Inclusion criteria: </B>18-70 years old; met the following diagnostic criteria: (1) typical history of lateral elbow pain of at least 3 months' duration, presence of pain for more than 50% of the last 30 days, aggravated by gripping or exertion, especially active extension of the wrist and alleviated by rest; (2) pressure pain on the radial epicondyle of the humerus; (3) aggravation of pain during extension of the wrist against resistance and (4) a positive middle finger test.<BR/>
</P>
<P>
<B>Exclusion criteria: </B>signs, such as dorsal elbow pain and cervical radiculopathy, not primarily attributable to lateral epicondylitis; systemic rheumatic disease, acute psychotic disorder, local injection at elbow in past 3 weeks, anticoagulation or haemophilia, diabetes mellitus, anaemia, polyneuropathy, systemic glucocorticoids or immune suppressants, coexisting serious illness.<BR/>
</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2013-04-22 13:19:33 -0400" MODIFIED_BY="[Empty name]">
<P>
<B>Group 1: </B>Two to four medicinal leeches applied once to the radial insertion of the extensor muscles of the wrist with preferences for maximum pain points. Leeches were left in place until they detached themselves (mean approximately 45 minutes).<BR/>
<B>Group 2:</B> Diclofenac 10 mg/g gel applied at least twice daily for 30 days.<BR/>
</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2013-04-22 13:19:39 -0400" MODIFIED_BY="[Empty name]">
<P>Outcomes were assessed at days -3, 0 (intervention), 7 and 45:</P>
<P>1.Total pain score from days 0 to 7 was derived from the sum of three single 100-mm VAS pain scales (pain at rest, pain in motion, pain during grip).</P>
<P>2. Functional impairment (DASH questionnaire).</P>
<P>3. Quality of life (SF-36).</P>
<P>4. Grip strength (maximum peak strength of three consecutive efforts).</P>
<P>5. Adverse effects (participant diary).</P>
<P>6. Use of oral rescue medication.</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2013-04-22 13:19:42 -0400" MODIFIED_BY="[Empty name]">
<P>Outcome expectation was rated on a 5-point Likert scale ranging from 4 (expecting considerable pain relief) to 0 (expecting no pain relief). An additional analysis adjusting for outcome expectation did not alter the results. The authors state that total pain score was adjusted for 'prior treatment', but no information was provided as to how this was measured.</P>
<P>Workload (Do you inevitably have to perform movements with your arm in your job or during daily living that augment your elbow pain? Yes/no) and the level of chronicity as determined by a multidimensional German pain questionnaire were monitored as possible confounders.</P>
<P>We extracted mean overall pain score and standard deviation (0 to 300 VAS; 0 = no pain) at day 7 from the text; and at day 45 as an estimate from the graph.</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2013-04-22 21:34:31 -0400" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Demirtas-1998">
<CHAR_METHODS MODIFIED="2013-04-22 13:19:56 -0400" MODIFIED_BY="[Empty name]">
<P>
<B>Design: </B>Randomised, controlled trial.<BR/>
<B>Blinding:</B> unclear.<BR/>
<B>Loss to follow-up:</B> none reported.<BR/>
<B>Appropriate statistical analysis: </B>not described.</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2013-04-22 21:34:31 -0400" MODIFIED_BY="[Empty name]">
<P>
<B>Number of participants:</B> 40.</P>
<P>
<B>Mean (SD) age: </B>45.35 (1.71) years (Group 1); 42.65 (2.12) years (Group 2).</P>
<P>
<B>Gender: </B>9 M, 11 F (Group 1); 5 M, 15 F (Group 2).</P>
<P>
<B>Mean duration of symptoms: </B>5.2 months (Group 1); 4.8 months (Group 2).</P>
<P>
<BR/>
<B>Inclusion criteria: </B>Lateral epicondylitis.<BR/>
</P>
<P>
<B>Exclusion criteria: </B>Markedly abnormal laboratory tests, skin disease contraindicating ionization use, concomitant treatment with anti-inflammatories/glucocorticosteroids.</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2013-04-22 13:20:03 -0400" MODIFIED_BY="[Empty name]">
<P>
<B>Group 1: </B>Topical NSAID &#65293; iontophoresis of sodium diclofenac.<BR/>
<B>Group 2: </B>Topical NSAID &#65293; iontophoresis of sodium salicylate.<BR/>Both groups received infrared treatment.<BR/>
<BR/>Treatment was carried out once a day, 5 days a week, up to a maximum of 18 days (mean duration of treatment 17 (0.91) days (Group 1) and 16.3 (1.04) days (Group 2)).</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2013-04-22 13:20:06 -0400" MODIFIED_BY="[Empty name]">
<P>Assessment baseline and at completion:<BR/>1. Pain scores in four categories: palpation, resisted wrist extension, during function and at rest on 4-point scale; pain evaluations made 7 days after treatment.</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2012-05-21 20:25:09 -0400" MODIFIED_BY="[Empty name]"/>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2013-04-22 13:20:27 -0400" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Erturk-1997">
<CHAR_METHODS MODIFIED="2013-04-22 13:20:12 -0400" MODIFIED_BY="[Empty name]">
<P>
<B>Design: </B>randomised controlled trial.<BR/>
<B>Blinding: </B>unclear.<BR/>
<B>Loss to follow-up:</B> unclear.<BR/>
<B>Appropriate statistical analysis: </B>unclear.</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2013-04-22 13:20:17 -0400" MODIFIED_BY="[Empty name]">
<P>
<B>Number of participants:</B> 36 (N = 27 for the three relevant groups for this review).</P>
<P>
<B>Mean age: </B>47.64 years (range 33-66 years).</P>
<P>
<B>Gender: </B>not specified</P>
<P>
<B>Mean duration of symptoms: </B>17.69 weeks (range 3-156).</P>
<P>
<B>Inclusion criteria: </B>lateral epicondyle pain on palpation and gripping.<BR/>
</P>
<P>
<B>Exclusion criteria: </B>systemic illness.</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2013-04-22 13:20:23 -0400" MODIFIED_BY="[Empty name]">
<P>
<B>Group 1: </B>oral NSAID &#65293; acemetacin 90 mg daily dose and epicondylitis bandage (aircast pneumatic armband).<BR/>
<B>Group 2: </B>local injection with 20 mg triamcinolone acetate and 0.5 mL 2% lidocaine.<BR/>
<B>Group 3:</B> local injection plus bandaging.<BR/>
<B>Group 4:</B> bandage only.</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2013-04-22 13:20:24 -0400" MODIFIED_BY="[Empty name]">
<P>Assessment at baseline and at 3 weeks:<BR/>
</P>
<P>1. Pain at rest and during resisted wrist extension (100 mm VAS).</P>
<P>2. Grip strength (kg).</P>
<P>3. Local tenderness (graded 0-3).</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2013-04-22 13:20:27 -0400" MODIFIED_BY="[Empty name]">
<P>For the purposes of this review, we compared Group 1 with Group 3 and Group 1 with Group 4.</P>
<P>No SD reported nor any data from which it could be imputed.</P>
<P>Data not included in meta-analysis; means of results included in additional tables (VAS converted to 10).</P>
<P>The number of participants in Group 4: bandaging was reportedas 8 in the text and as only 7 in Table 1 (n = 7). We assumed it was 8.</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2013-04-22 21:34:47 -0400" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Hay-1999">
<CHAR_METHODS MODIFIED="2013-04-22 13:20:38 -0400" MODIFIED_BY="[Empty name]">
<P>
<B>Design:</B> randomised controlled trial.<BR/>
<B>Blinding:</B> participants only partially blinded; blinded single outcome assessor.<BR/>
<B>Loss to follow-up: </B>only 151 participants had complete information.<BR/>
<B>Appropriate statistical analysis:</B> did not use intention-to-treat analysis.</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2013-04-22 13:20:44 -0400" MODIFIED_BY="[Empty name]">
<P>
<B>Number of participants: </B>164.</P>
<P>
<B>Number (%) age &#8805; 45 years:</B> Group 1: 37 (70); Group 2: 36 (68); Group 3: 36 (62).</P>
<P>
<B>Gender:</B> 86 M; 78 F.</P>
<P>
<B>Number (%) duration of symptoms &gt; 3 months: </B>Group 1: 19 (36); Group 2: 13 (25); Group 3: 18 (31).</P>
<P>
<B>Inclusion criteria:</B> patients aged between 18 and 70 years with new episode of acute lateral epicondylitis.<BR/>
</P>
<P>
<B>Exclusion criteria: </B>inflammatory arthritis, structural abnormalities, contraindications to NSAID or cortisone, pregnancy and breast-feeding.</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2013-04-22 21:34:47 -0400" MODIFIED_BY="[Empty name]">
<P>
<B>Group 1:</B> oral NSAID &#65293; naproxen 500 mg (enteric-coated) twice daily for 2 weeks.<BR/>
<B>Group 2:</B> local glucocorticoid injection of methylprednisolone 20 mg and 0.5 mL 1% lignocaine.<BR/>
<B>Group 3:</B> oral placebo (unmarked vitamin C tablets) twice daily for 2 weeks.</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2013-04-22 13:21:00 -0400" MODIFIED_BY="[Empty name]">
<P>Outcomes assessed at 4 weeks, 6 months, 12 months, collected by a blinded study nurse (most outcomes were participant-reported):</P>
<P>1. Participant-reported global assessment of change (5-point scale: complete recovery, improved, no change, worse, much worse) (4-week time point was primary endpoint).</P>
<P>2. Pain severity (10-point Likert scale).</P>
<P>3. Impairment of function (10-point Likert scale).</P>
<P>4. Severity of 'main complaint' (10-point Likert scale).</P>
<P>5. Disability measured with the tennis elbow disability questionnaire.</P>
<P>6. Pain-free grip strength (average of two readings with hand-held dynomanometer).</P>
<P>7. Local tenderness of lateral epicondyle (3-point scale: none, some, definite with flinch).</P>
<P>8. Pain on resisted extension of the middle finger and the wrist with arm extended (3-point scale: none, some, definite with flinch).</P>
<P>9. Numbers and types of co-interventions.</P>
<P>10. Time off paid employment.</P>
<P>11. Complications of treatment (post-intervention exacerbation of pain (daily 10-point pain scale measured for 5 days).</P>
<P>12. Local skin atrophy.</P>
<P>13. Gastrointestinal side effects.</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2013-04-22 13:21:10 -0400" MODIFIED_BY="[Empty name]">
<P>Pain and function data were reported as median and interquartile ranges (as data reported to be skewed by the authors); therefore could not be included in pooled analysis. We have reported these data separately (see Additional <LINK REF="TBL-01" TYPE="TABLE">Table 1</LINK>).</P>
<P>The authors compared pain scores and participants' global assessment of change at 4 weeks and found that 89% of participants who had a pain score &#8804; 3 reported that they were either completely better or improved, and none had become worse. They then performed a post hoc analysis comparing pain between groups at 4 weeks and 6 and 12 months as a dichotomous variable ('better' = pain &#8804; 3 vs pain 'not better' = pain &#8805; 4).</P>
<P>Pain-free grip strength was reported as the number of participants with grip strength &gt; 300 mm Hg.</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2013-04-22 13:22:04 -0400" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Jenoure-1997">
<CHAR_METHODS MODIFIED="2013-04-22 13:21:35 -0400" MODIFIED_BY="[Empty name]">
<P>
<B>Design: </B>randomised placebo-controlled trial.<BR/>
<B>Blinding: </B>double-blind, participant and treating practitioner.<BR/>
<B>Loss to follow-up:</B> none reported.<BR/>
<B>Appropriate statistical analysis:</B> intention to treat (ITT).</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2013-04-22 13:21:44 -0400" MODIFIED_BY="[Empty name]">
<P>
<B>Number of participants:</B> 85.</P>
<P>
<B>Setting: </B>not specified, Switzerland.</P>
<P>
<B>Mean (SD) age:</B> Group 1: 46.2 (1.7) years; Group 2: 44.9 (1.8) years.</P>
<P>
<B>Gender: </B>Group 1:<B> </B>27 M, 17 F; Group 2: 27 M, 14 F.</P>
<P>
<B>Duration of symptoms: </B>not specified.<BR/>
</P>
<P>
<B>Inclusion criteria:</B> tennis elbow not defined.</P>
<P>
<B>Exclusion criteria:</B> patients with pre-existing muscular injuries or bone avulsions, intra-articular elbow effusions or evident muscle contraction were excluded, as were patients already using NSAIDs or oral glucocorticoids &lt; 1 week before trial commencement; pregnant or breast-feeding patients; uncooperative patients; and patients with skin injuries in area where patch was to be applied, or who were hypersensitive to the product being tested.</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2013-04-22 13:21:46 -0400" MODIFIED_BY="[Empty name]">
<P>
<B>Group 1: </B>topical NSAID &#65293; diclofenac tissugel patch worn BD for 14 days (185.5 mg diclofenac hydroxyethylpyrrolidine salt at concentration of 1.32 mg/cm<SUP>3</SUP>).<BR/>
<B>Group 2:</B> identical placebo patch worn BD for 14 days.</P>
<P>No NSAID, analgesia, physiotherapy or ice packs were to be used during the trial.</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2013-04-22 13:22:03 -0400" MODIFIED_BY="[Empty name]">
<P>Outcomes assessed at baseline, 7, 14, 28 days:<BR/>1. Spontaneous pain (5-point verbal scale).</P>
<P>2. Spontaneous pain (10-cm VAS).</P>
<P>3. Pain in response to pressure (5-point verbal scale).</P>
<P>4. Pain on muscular testing (5-point verbal scale).</P>
<P>5. Tolerance assessment scale (verbal 5-point scale).</P>
<P>6. Overall effectiveness of treatment (verbal 5-point scale: 0 = no effect, 1 = minor effect, 2 = positive effect but not enough, 3 = good effect, but less than would have been expected, relative to the severity of the condition and 4 = excellent response).</P>
<P>7. Overall effectiveness of treatment (verbal 5-point scale: 0 = none, 1 = poor, 2 = fair, 3 = good, 4 = excellent).</P>
<P>8. Side effects.</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2013-04-22 13:22:04 -0400" MODIFIED_BY="[Empty name]">
<P>Translated from Italian. Data were likely to be skewed.</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2013-04-22 21:34:55 -0400" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Labelle-1997">
<CHAR_METHODS MODIFIED="2013-04-22 13:41:40 -0400" MODIFIED_BY="[Empty name]">
<P>
<B>Design: </B>randomised placebo-controlled trial.<BR/>
<B>Blinding: </B>double-blind (participant and assessor).<BR/>
<B>Loss to follow-up: </B>1 withdrawal due to side effects and not included in analysis.<BR/>
<B>Appropriate statistical analysis: </B>did not use intention-to-treat analysis.</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2013-04-22 21:34:55 -0400" MODIFIED_BY="[Empty name]">
<P>
<B>Number of participants: </B>129 (1 withdrew).</P>
<P>
<B>Mean age: </B>43.7 years (range 22-59).</P>
<P>
<B>Gender: </B>69 M, 59 F.</P>
<P>
<B>Mean duration of symptoms: </B>number with symptoms &lt; 6 weeks: 55 (43.3%); 56 (44.1%) had symptoms for longer than 6 months.<BR/>
</P>
<P>
<B>Inclusion criteria: </B>adults aged 18-60 years presenting with painful lateral elbow syndrome; pain on palpation, pain on wrist pronation and resisted dorsiflexion, pain on static stretching of flexed wrist in pronation/elbow extension and normal AP/lateral X-ray.<BR/>
</P>
<P>
<B>Exclusion criteria: </B>history of polyarthralgia in preceding month, history of cervical/cervicobrachial pain, wound/skin lesion over lateral elbow, history of glucocorticoid use during 6 weeks before commencement of trial, reduced elbow range of movement, paraesthesia in territory of radial nerve, bilateral epicondylitis, contraindications to NSAID use.</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2013-04-22 13:41:50 -0400" MODIFIED_BY="[Empty name]">
<P>
<B>Group 1: </B>75 mg diclofenac sodium (slow-release form) twice daily for 28 days.<BR/>
<B>Group 2: </B>placebo administered as above.<BR/>
<BR/>Both groups were also immobilised in a long arm cast for 14 days.<BR/>
</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2013-04-22 13:42:02 -0400" MODIFIED_BY="[Empty name]">
<P>Outcomes were assessed at baseline and at 28 days:<BR/>1. Maximum pain-free grip strength (MPFGS) measured in kg using a squeeze dynamometer with elbow flexed at 90 degrees (primary outcome).<BR/>2. MPFGS ratio (MPFGS affected side/normal side).</P>
<P>3. Maximum grip strength (MGS) measured in kg using a squeeze dynamometer with elbow flexed at 90 degrees.</P>
<P>4. MGS ratio (MGS affected side/normal side).</P>
<P>5. Pain on a 100-mm vertical VAS (0 = no pain to 100 = maximal pain).</P>
<P>6. Function on a 100-mm vertical VAS (0 = no function to 100 = normal function).<BR/>7. Pain-free function index (eight items that measure presence or absence of discomfort in following activities of daily living (ADLs): dressing, eating, washing, cleaning the house, opening a door, lifting an object, working, and practicing sports or normal activities) (scored from 0 (full function for ADLs) to 8 (no function)).<BR/>8. Number of days missed from work (at 3-month follow-up telephone interview).</P>
<P>9. Symptom recurrence (at 3-month follow-up telephone interview).</P>
<P>10. Adverse events.</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2013-04-22 13:42:03 -0400" MODIFIED_BY="[Empty name]">
<P>Data may be skewed but reported as means and standard deviations so included in meta-analysis.</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2013-04-22 13:44:17 -0400" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Polat-2011">
<CHAR_METHODS MODIFIED="2013-04-22 13:43:55 -0400" MODIFIED_BY="[Empty name]">
<P>
<B>Design: </B>randomised controlled trial.<BR/>
<B>Blinding: </B>double-blind (participant and physician).<BR/>
<B>Primary endpoint and sample size estimation:</B> not reported.</P>
<P>
<B>Loss to follow-up: </B>none reported.<BR/>
<B>Appropriate statistical analysis: </B>yes.</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2013-04-22 13:44:00 -0400" MODIFIED_BY="[Empty name]">
<P>
<B>Number of participants: </B>55: 33 in the betahistidine group and 22 in the naproxen group.</P>
<P>
<B>Mean age: </B>41.4 years in the betahistidine group and 39.8 years in the naproxen group.</P>
<P>
<B>Gender: </B>14 M, 41 F.</P>
<P>
<B>Mean duration of symptoms: </B>3 months.<BR/>
</P>
<P>
<B>Inclusion criteria: </B>lateral epicondylitis diagnosed with pain over the lateral epicondyle with palpation and pain increase with resistance applied against wrist extension. Anatomical structure normal on X-ray.<BR/>
</P>
<P>
<B>Exclusion criteria: </B>younger than 18 years of age, pregnant or lactating women, patients with history or complaint of cervical radiculopathy, entrapment neuropathy, diabetes, rheumatological disease, or hepatitis and those receiving oncology treatment.<BR/>
</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2013-04-22 13:44:02 -0400" MODIFIED_BY="[Empty name]">
<P>
<B>Group 1: </B>48 mg/day betahistine dihydrochloride for 10 days &#65293; this drug is a centrally acting histamine receptor agonist with partial histamine antagonistic activity, which results in vasodilatation.<BR/>
<B>Group 2: </B>750 mg/day naproxen sodium for 10 days.<BR/>
</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2013-04-22 13:44:16 -0400" MODIFIED_BY="[Empty name]">
<P>Outcomes were assessed at baseline, day 10 and 3 and 6 months unless otherwise specified. Evaluations were performed by two different orthopaedic surgeons:</P>
<P>1. Pain measured on a on a VAS (0 = no pain and 10 = maximum pain).</P>
<P>2. Physician assessment of severity using Verhaar criteria for pain on lateral epicondyle, participant's satisfaction for the results of treatment, subjective loss of grip and pain on resisted dorsiflexion of the wrist; each assessed as 1 = poor, 2 = fair, 3 = good, 4 = excellent, at baseline and day 10; presented as overall mean score of severity.</P>
<P>3. At each follow-up, the following items were assessed as yes/no:</P>
<P>a. Pain and sensitivity over the external elbow.</P>
<P>b. Pain during hand and wrist extension.</P>
<P>c. Increase in pain during heavy lifting.</P>
<P>d. Pain when making a fist.</P>
<P>e. Pain extending from the elbow to the forearm.</P>
<P>4.  Adverse effects.</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2013-04-22 13:44:17 -0400" MODIFIED_BY="[Empty name]">
<P>We extracted pain at day 10 (1 to 6-week subgroup) and 6 months (&gt; 6-week subgroup). No adverse events were reported.</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2013-04-22 21:45:57 -0400" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Saartok-1986">
<CHAR_METHODS MODIFIED="2013-04-22 21:45:57 -0400" MODIFIED_BY="[Empty name]">
<P>
<B>Design: </B>randomised placebo-controlled trial.<BR/>
<B>Blinding:</B> participants were blinded (not outcome assessor).<BR/>
<B>Loss to follow-up:</B> none reported.<BR/>
<B>Appropriate statistical analysis: </B>appears to be appropriate.</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2013-04-22 13:44:42 -0400" MODIFIED_BY="[Empty name]">
<P>
<B>Number of participants: </B>21.<BR/>
<B>Mean age: </B>45 years.</P>
<P>
<B>Gender: </B>16 M; 5 F.</P>
<P>
<B>Duration of symptoms: </B>equal distribution between cases considered to be acute, recurrent or chronic.</P>
<P>
<B>Inclusion criteria:</B> typical history and signs of tennis elbow (e.g. pain during extension of the wrist) and impaired mobility. Previous treatment ceased 5 weeks before baseline.</P>
<P>
<B>Exclusion criteria:</B> none specified.</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2013-04-22 13:44:47 -0400" MODIFIED_BY="[Empty name]">
<P>
<B>Group 1:</B> oral NSAID &#65293; naproxen (250 mg bd, initial dose 500 mg, for 2 weeks) plus local saline injection (1.5 mL).<BR/>
<B>Group 2:</B> 6 mg (1 mL) betamethasone injection (comprising equal amounts of both a short- and a long-acting ester of betamethasone) and 0.5 mL prilocaine plus placebo tablet.</P>
<P>No other treatment during trial period.</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2013-04-22 13:44:51 -0400" MODIFIED_BY="[Empty name]">
<P>Outcomes were assessed at baseline and at days 15-16:<BR/>1. Pain at rest (9-point scale).</P>
<P>2. Pain with movement (9-point scale).</P>
<P>3. Pain with isometric contraction (9-point scale).</P>
<P>4. Presence or absence of limited extension (method not described).</P>
<P>5. Grip strength (three successive measures on Vigorimeter).<BR/>6. Overall evaluation of change in condition by assessor (cured, markedly improved, somewhat improved, unchanged, somewhat worse, markedly worse).</P>
<P>7. Overall evaluation of change in condition by participant (cured, markedly improved, somewhat improved, unchanged, somewhat worse, markedly worse).</P>
<P>8. Adverse effects.</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2012-08-21 02:58:28 -0400" MODIFIED_BY="[Empty name]"/>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2012-12-17 20:21:50 -0500" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Schapira-1991">
<CHAR_METHODS MODIFIED="2012-01-15 19:23:43 -0500" MODIFIED_BY="[Empty name]">
<P>
<B>Design:</B> Randomised, placebo controlled trial .<BR/>Allocation concealment ensured.<BR/>
<B>Blinding:</B> double blind<BR/>
<B>Loss to follow up: </B>None reported<BR/>
<B>Appropriate statistical analysis: </B>Appears to be</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2012-05-31 20:51:22 -0400" MODIFIED_BY="[Empty name]">
<P>
<B>Number of participants: </B>32 (number per group not specified)<BR/>
<B>Setting:</B> Not specified, Israel</P>
<P>
<B>Age range: </B>34-78 years</P>
<P>
<B>Gender: </B>11 M, 21 F</P>
<P>
<B>Duration of symptoms: </B>&lt;4 weeks</P>
<P>
<B>Inclusion criteria:</B> Acute lateral epicondyle pain (&lt;4 weeks) but most appeared to be &gt; 3 weeks duration); 7-day washout for previous NSAID treatment.<BR/>
</P>
<P>
<B>Exclusion criteria: </B>History of systemic or local glucocorticoid treatment,<B> </B>cutaneous lesions, asthma, allergic rhinitis, urticaria, anaphylactic reactions, hepatic/renal insufficiencies</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2012-01-15 19:23:56 -0500" MODIFIED_BY="[Empty name]">
<P>
<B>Group 1:</B> 2 weeks treatment with topical NSAID - diclofenac diethylamine salt (gel form),<BR/>4 times daily application to painful areas<BR/>
<B>Group 2:</B> 2 weeks identical regimen of treatment with placebo gel</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2012-12-17 20:21:50 -0500" MODIFIED_BY="[Empty name]">
<P>Assessment day 1, 4, 8, 14:<BR/>1. Pain in 5 different categories according to 4 point scale and visual analogue scale<BR/>2. Grip strength (inflated sphygmomanometer at 30 mmHg)<BR/>3. Functional capacity of affected limb according to 4 point scale<BR/>
</P>
<P>4. Tolerability of drug according to 4 point scale</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2012-05-24 00:46:16 -0400" MODIFIED_BY="[Empty name]">
<P>Unclear from report if randomised therefore author contacted and confirmation given that study was an RCT. Number per treatment group not specified.</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2013-04-22 13:45:37 -0400" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Spacca-2005">
<CHAR_METHODS MODIFIED="2013-04-22 13:45:14 -0400" MODIFIED_BY="[Empty name]">
<P>
<B>Design:</B> randomised controlled trial.</P>
<P>
<B>Blinding: </B>described as 'double-blind': participants were blind, unclear who else was blind.</P>
<P>
<B>Sample size calculation: </B>not specified.</P>
<P>
<B>Withdrawals:</B> three people (2%) were not included in analysis; condition, treatment group and reasons not specified.</P>
<P>
<B>Statistical analysis:</B> intention-to-treat analysis not specified.</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2013-04-22 13:45:19 -0400" MODIFIED_BY="[Empty name]">
<P>
<B>Number of participants:</B> 40 with lateral epicondylitis and 115 with shoulder periarthritis; another three participants were said to be enrolled, but no baseline or outcome data were provided.</P>
<P>
<B>Setting: </B>two clinical centres in Italy and one clinical centre in Hungary.</P>
<P>
<B>Mean (SD) age:</B> Group 1: 51 (13.0) years; Group 2: 50 (10.2) years, but data not reported separately by condition.</P>
<P>
<B>Gender: </B>Group 1: 79 M, 38 F; Group 2: 76 M, 26 F, but data not reported separately by condition.</P>
<P>
<B>Symptom duration:</B> not specified.</P>
<P>
<B>Inclusion criteria: </B>lateral epicondylitis in an acute phase (pain present for less than 5 days).</P>
<P>
<B>Exclusion criteria: </B>none specified.</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2013-04-22 13:45:23 -0400" MODIFIED_BY="[Empty name]">
<P>
<B>Group 1: </B>lecithin-enriched diclofenac epolamine (2-hydroxyethyl-pyrrolidine) (DHEP) 1.3% gel 5 g three times daily applied to painful area by gentle massage until complete absorption of gel for 10 days.</P>
<P>
<B>Group 2: p</B>lacebo gel administered in the same way.</P>
<P>
<B>Both groups: </B>treatment could be stopped before the end of the 10-day treatment period if the pain disappeared. Forty tablets paracetamol (500 mg) were given to all participants, who were instructed to take these only when the pain was unbearable. No other analgesics or NSAIDs were allowed for duration of trial.</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2013-04-22 13:45:36 -0400" MODIFIED_BY="[Empty name]">
<P>Outcomes measured at baseline and at day 10. Outcome assessor not specified. Participant diaries completed at same time of day each day and at follow-up visit on day 10.</P>
<P>
<B>Primary outcome:</B>
</P>
<P>1. Pain while performing a specific standardised movement, selected by the participant and physician as the most painful movement to be done according to the underlying condition, measured on 100 mm VAS (for lateral epicondylitis, movements chosen were 'shake hands' (n = 13), 'turn a key' (n = 7), 'open a heavy door' (n = 8), 'lift a weight upward' (n = 2) or other (n = 10). In addition to baseline and day 10, this was assessed daily by participants at the same time of day and recorded in a participant diary.</P>
<P>
<B>Secondary outcomes:</B>
</P>
<P>2. Intake of rescue medication (paracetamol) and any other kinds of medications taken.</P>
<P>3. Disabilities of the Arm, Shoulder and Hand (DASH) questionnaire: appears that only part of the questionnaire was used. Part B is a 30-item disability/symptom scale, but only 21 items (the disability items) were measured and reported individually.</P>
<P>4. Adverse events.</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2013-04-22 13:45:37 -0400" MODIFIED_BY="[Empty name]">
<P>First author was contacted and provided separate outcome data for the primary endpoint at days 3, 6 and 10 for the lateral epicondylitis group. For the purpose of the meta-analysis, the final day 10 mean (SD) scores for pain were included. The data included in the review are unpublished data.</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2013-04-22 13:45:53 -0400" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Stull-1986">
<CHAR_METHODS MODIFIED="2013-04-22 13:45:42 -0400" MODIFIED_BY="[Empty name]">
<P>
<B>Design:</B> Randomised, controlled trial.<BR/>
<B>Blinding:</B> No.<BR/>
<B>Loss to follow-up:</B> two participants did not complete the study.<BR/>
<B>Appropriate statistical analysis: </B>completers analysis.</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2013-04-22 13:45:48 -0400" MODIFIED_BY="[Empty name]">
<P>
<B>Number of participants:</B> 40.</P>
<P>
<B>Mean age: </B>not reported.</P>
<P>
<B>Gender: </B>21 M; 17 F (provided only for the 38 participants who completed the study).</P>
<P>
<B>Duration of symptoms: </B>not reported.</P>
<P>
<B>Inclusion criteria: </B>adult participants (&gt; 18 years) with tennis elbow and mild to moderate pain. Diagnosis based upon history and physical examination (no further details provided).</P>
<P>
<B>Exclusion criteria: </B>none specified.</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2013-04-22 13:45:49 -0400" MODIFIED_BY="[Empty name]">
<P>
<B>Group 1:</B> Oral NSAID &#65293; 1000 mg diflunisal followed by 500 mg BD for 15 days.<BR/>
<B>Group 2:</B> Oral NSAID &#65293; 500 mg naproxen followed by 250 mg QID for 15 days.</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2013-04-22 13:45:53 -0400" MODIFIED_BY="[Empty name]">
<P>Assessed at baseline, day 5, 10, 15:</P>
<P>1. Pain severity measured four times daily for 15 days.</P>
<P>2. Limitation of function/movement measured four times daily for 15 days.<BR/>3. Participant-reported overall degree of pain relief (excellent, very good, good, fair, poor).</P>
<P>4. Participant-reported overall elbow condition after treatment (no symptoms, improved, no change, worse).</P>
<P>5. Participant-reported overall elbow condition after treatment (none, mild, moderate, severe).</P>
<P>6. Adverse effects.</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2012-01-15 21:07:16 -0500" MODIFIED_BY="[Empty name]"/>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2013-04-22 21:40:20 -0400" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Tsuyama-1979">
<CHAR_METHODS MODIFIED="2013-04-22 13:46:06 -0400" MODIFIED_BY="[Empty name]">
<P>
<B>Design:</B> randomised placebo-controlled trial.<BR/>
<B>Blinding:</B> no.<BR/>
<B>Loss to follow-up:</B> two participants did not complete the study.<BR/>
<B>Appropriate statistical analysis: </B>completers analysis.</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2013-04-22 13:46:13 -0400" MODIFIED_BY="[Empty name]">
<P>
<B>Number of participants:</B> 187 (33 participants with lateral elbow pain: 20 in the active group and 13 in the placebo group).<BR/>
<B>Setting: </B>17 orthopaedic hospital clinics, 1 rheumatism clinic and 1 plastic surgery clinic, Japan.</P>
<P>
<B>Mean age: </B>wide range from 6-80+ years, but no overall difference between groups (data not reported separately for participants with lateral elbow pain).</P>
<P>
<B>Gender: </B>Group 1: 30 M, 62 F; Group 2: 28 M, 67 F (data not presented separately for participants with lateral elbow pain).</P>
<P>
<B>Duration of symptoms: </B>not specified.</P>
<P>
<B>Inclusion criteria: </B>"patients that suffered from 'non-external injuries of the tendon/muscle' such as tendonitis/tenosynovitis, who received treatment in institutions such as orthopaedic clinics, during the period of April to July 1978".<BR/>
</P>
<P>
<B>Exclusion criteria: </B>skin wounds at the site the medication was to be applied or sensitive skin; serious comorbidities including serious liver, kidney, hematopoietic problems; elderly patients with bad skin conditions; pregnant and breast-feeding women; allergic to medication; others whom the doctor in charge deemed inappropriate to participate.</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2013-04-22 13:46:14 -0400" MODIFIED_BY="[Empty name]">
<P>
<B>Group 1: </B>Topical NSAID &#65293; 1% indomethacin ointment applied three to four times daily for 2 weeks.<BR/>
<B>Group 2:</B> Placebo ointment applied three to four times daily for 2 weeks.</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2013-04-22 21:40:20 -0400" MODIFIED_BY="[Empty name]">
<P>Outcome was assessed at baseline and at 1 and 2 weeks:</P>
<P>1. Spontaneous pain (categorical scale: severity of symptoms high, medium, light or non-symptoms).</P>
<P>2. Pain on pressure (scale as above).</P>
<P>3. Pain on motion (scale as above).</P>
<P>4. Swelling (scale as above).</P>
<P>5. Localised warmth (scale as above).</P>
<P>6. Limitation of motion (scale as above).</P>
<P>7. Doctor-assessed improvement (great, medium or mild improvement, no change or worsened).</P>
<P>8. Participant-assessed improvement (improved a lot, improved slightly, no change, worsened).</P>
<P>9. Adverse effects.</P>
<P>10. Full blood examination, renal and liver function and urinanalysis.</P>
<P>11. General improvement level and overall safety (extremely useful, very useful, slightly useful, can't say, not good).</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2013-04-22 13:46:27 -0400" MODIFIED_BY="[Empty name]">
<P>Translated from Japanese.<BR/>Three dropouts from the topical NSAID group and one dropout from the topical placebo group were reported.</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<FOOTNOTES/>
</CHARACTERISTICS_OF_INCLUDED_STUDIES>
<CHARACTERISTICS_OF_EXCLUDED_STUDIES MODIFIED="2013-04-22 13:47:29 -0400" MODIFIED_BY="[Empty name]" SORT_BY="STUDY">
<EXCLUDED_CHAR MODIFIED="2012-01-15 21:19:34 -0500" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Abbott-1980">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2012-01-15 21:19:34 -0500" MODIFIED_BY="[Empty name]">
<P>RCT but not specific to lateral elbow pain and data not presented separately.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2012-01-15 21:19:43 -0500" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Auvinet-1995">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2012-01-15 21:19:43 -0500" MODIFIED_BY="[Empty name]">
<P>Not specific to lateral elbow pain and data not presented separately.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2012-03-18 22:43:11 -0400" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Baskurt-2003">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2012-03-18 22:43:11 -0400" MODIFIED_BY="[Empty name]">
<P>Comparison of two topical applications of NSAID (phonophoresis and iontophoresis).</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2012-01-15 22:47:22 -0500" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Bolten-1991">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2012-01-15 22:47:22 -0500" MODIFIED_BY="[Empty name]">
<P>Not specific to lateral elbow pain.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2012-01-15 21:36:23 -0500" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Bono-1983">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2012-01-15 21:36:23 -0500" MODIFIED_BY="[Empty name]">
<P>Not specific to lateral elbow pain and data not presented separately.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2012-01-15 22:47:26 -0500" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Boussina-1983">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2012-01-15 22:47:26 -0500" MODIFIED_BY="[Empty name]">
<P>Not specific to lateral elbow pain and data not presented separately.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2012-01-15 21:36:26 -0500" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Buckwalter-1995">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2012-01-15 21:36:26 -0500" MODIFIED_BY="[Empty name]">
<P>Not RCT, not specific to lateral elbow pain.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2012-01-15 22:47:29 -0500" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Burgos-2001">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2012-01-15 22:47:29 -0500" MODIFIED_BY="[Empty name]">
<P>Not specific to lateral elbow pain and data not presented separately.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2012-01-15 21:36:16 -0500" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Castro-DeTolosa-1994">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2012-01-15 21:36:16 -0500" MODIFIED_BY="[Empty name]">
<P>Not specific to lateral elbow pain and data not presented separately.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2012-01-15 21:36:20 -0500" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Commandre-1983">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2012-01-15 21:36:20 -0500" MODIFIED_BY="[Empty name]">
<P>RCT but not restricted to lateral elbow pain.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2012-01-15 21:36:33 -0500" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Commandre-1993">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2012-01-15 21:36:33 -0500" MODIFIED_BY="[Empty name]">
<P>RCT but not restricted to lateral elbow pain and data not presented separately.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2013-04-22 13:46:58 -0400" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Dreiser-1988">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2013-04-22 13:46:58 -0400" MODIFIED_BY="[Empty name]">
<P>Not specific to lateral elbow pain and data not presented separately.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2012-01-15 21:36:40 -0500" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Dreiser-1991">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2012-01-15 21:36:40 -0500" MODIFIED_BY="[Empty name]">
<P>Not specific to lateral elbow pain and data not presented separately.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2013-04-22 13:46:58 -0400" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Fauchald-1978">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2013-04-22 13:46:58 -0400" MODIFIED_BY="[Empty name]">
<P>Not specific to lateral elbow pain and data not separated.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2013-04-22 13:46:59 -0400" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Fiszman-1985">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2013-04-22 13:46:59 -0400" MODIFIED_BY="[Empty name]">
<P>Population not specific to lateral elbow pain. Included bursitis, tendonitis and epicondylitis, and results not presented separately.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2013-04-22 13:47:00 -0400" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Furberg-1985">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2013-04-22 13:47:00 -0400" MODIFIED_BY="[Empty name]">
<P>Study population included 28 participants with periarthritis of the shoulder and two with epicondylitis. Data not presented separately.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2013-04-22 13:47:01 -0400" MODIFIED_BY="[Empty name]" STUDY_ID="STD-F_x00f6_rster-1997">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2013-04-22 13:47:01 -0400" MODIFIED_BY="[Empty name]">
<P>Subgroup analysis of RCT (48/116 participants who had acute epicondylitis (&lt; 48 hours) due to squash, tennis, golf or other sporting activities). Trial results for whole study population published only in abstract. Data not presented separately for lateral elbow pain (translated from German to confirm).</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2012-01-15 22:47:59 -0500" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Gallacchi-1990">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2012-01-15 22:47:59 -0500" MODIFIED_BY="[Empty name]">
<P>Not specific to lateral elbow pain and data not presented separately.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2012-03-18 22:42:58 -0400" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Geiger-1995">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2012-03-18 22:42:58 -0400" MODIFIED_BY="[Empty name]">
<P>Not NSAIDs.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2012-01-15 21:38:11 -0500" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Ginsberg-1994">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2012-01-15 21:38:11 -0500" MODIFIED_BY="[Empty name]">
<P>Not specific to lateral elbow pain and data not presented separately.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2012-01-15 22:48:01 -0500" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Goldberg-1985">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2012-01-15 22:48:01 -0500" MODIFIED_BY="[Empty name]">
<P>Not an RCT (translated from French to confirm).</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2013-04-22 13:47:03 -0400" MODIFIED_BY="Dolores Matthews" STUDY_ID="STD-Grossi-1986">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2013-04-22 13:47:03 -0400" MODIFIED_BY="Dolores Matthews">
<P>Seventy-three patients with lateral epicondylitis or adhesive capsulitis (numbers for each individual diagnosis not given). Not possible to separate lateral epicondylitis from adhesive capsulitis data.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2012-01-15 21:38:15 -0500" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Gui-1982">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2012-01-15 21:38:15 -0500" MODIFIED_BY="[Empty name]">
<P>Not isolated to lateral elbow pain.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2012-01-15 22:48:04 -0500" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Halle-1986">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2012-01-15 22:48:04 -0500" MODIFIED_BY="[Empty name]">
<P>Not NSAIDs.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2012-01-15 21:38:19 -0500" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Hofman-2000">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2012-01-15 21:38:19 -0500" MODIFIED_BY="[Empty name]">
<P>RCT but not specific to lateral elbow pain and data not presented separately.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2012-01-15 22:44:57 -0500" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Hughes-1969">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2012-01-15 22:44:57 -0500" MODIFIED_BY="[Empty name]">
<P>*Not NSAIDs.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2013-04-22 13:47:03 -0400" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Jakobsen-1988">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2013-04-22 13:47:03 -0400" MODIFIED_BY="[Empty name]">
<P>Includes only one participant with lateral elbow pain.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2012-01-15 22:48:06 -0500" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Jakobsen-1991">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2012-01-15 22:48:06 -0500" MODIFIED_BY="[Empty name]">
<P>Not specific to lateral elbow pain (only 1/212 had epicondylitis).</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2012-03-18 22:43:24 -0400" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Jensen-2001">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2012-03-18 22:43:24 -0400" MODIFIED_BY="[Empty name]">
<P>Not NSAIDs.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2012-03-18 22:43:30 -0400" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Karinen-1999">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2012-03-18 22:43:30 -0400" MODIFIED_BY="[Empty name]">
<P>Not NSAIDs.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2012-01-15 21:38:33 -0500" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Kneer-1994">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2012-01-15 21:38:33 -0500" MODIFIED_BY="[Empty name]">
<P>Not specific to lateral elbow pain and data not presented separately.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2013-04-22 13:47:06 -0400" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Kroll-1989">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2013-04-22 13:47:06 -0400" MODIFIED_BY="[Empty name]">
<P>RCT of topical NSAID but mixed population including epicondylitis, and data not presented separately. Population included shoulder, ankle and elbow sprains and tendonitis; more than 50% of participants had ankle sprain.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2012-01-15 21:38:40 -0500" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Lecomte-1994">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2012-01-15 21:38:40 -0500" MODIFIED_BY="[Empty name]">
<P>RCT but not restricted to lateral elbow pain.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2013-04-22 13:47:07 -0400" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Lopez-1997">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2013-04-22 13:47:07 -0400" MODIFIED_BY="[Empty name]">
<P>RCT but not restricted to lateral elbow pain (all tendonitis of upper and lower limb).</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2012-01-15 22:48:09 -0500" MODIFIED_BY="[Empty name]" STUDY_ID="STD-McGuinness-1969">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2012-01-15 22:48:09 -0500" MODIFIED_BY="[Empty name]">
<P>Study population included patients with acute painful conditions of the locomotor system such as lumbago, shoulder pain, fibrositis, osteoarthritis and sprains. Not specific to lateral elbow pain and data not presented separately by condition.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2011-10-17 20:27:06 -0400" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Meloni-1995">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2011-10-17 20:27:06 -0400" MODIFIED_BY="[Empty name]">
<P>Not randomised (translated from Italian to confirm).</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2013-04-22 13:47:09 -0400" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Menkes-1990">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2013-04-22 13:47:09 -0400" MODIFIED_BY="[Empty name]">
<P>Results not presented separately, general tendonitis grouped together.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2013-04-22 13:47:21 -0400" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Nilsson-2012">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2013-04-22 13:47:21 -0400" MODIFIED_BY="[Empty name]">
<P>Not an RCT.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2013-04-22 13:47:22 -0400" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Percy-1981">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2013-04-22 13:47:22 -0400" MODIFIED_BY="[Empty name]">
<P>Results for tennis elbow and rotator cuff tendonitis presented separately; however 'tennis elbow' included participants with both medial and lateral epicondylitis. It is not clear what proportion of participants labelled as having tennis elbow had lateral versus medial epicondylitis. At best all participants had lateral elbow pain, and at worst none of them had the condition. We therefore made the decision to exclude the trial.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2012-01-15 22:48:13 -0500" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Primbs-1983">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2012-01-15 22:48:13 -0500" MODIFIED_BY="[Empty name]">
<P>Not an RCT (translated from German to confirm).</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2013-04-22 13:47:24 -0400" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Ritchie-1996a">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2013-04-22 13:47:24 -0400" MODIFIED_BY="[Empty name]">
<P>Study population included participants with medial or epicondylitis, supraspinatus tendonitis, bicipital tendonitis, subacromial bursitis or adhesive capsulitis). Participants with elbow complaints constituted 47% of the study population. Data for participants with lateral elbow pain not presented separately.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Ritchie-1996b">
<CHAR_REASON_FOR_EXCLUSION>
<P>Excluded as includes multiple soft tissue conditions and results not presented separately.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2013-04-22 13:47:25 -0400" MODIFIED_BY="Dolores Matthews" STUDY_ID="STD-Rosenthal-1982">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2013-04-22 13:47:25 -0400" MODIFIED_BY="Dolores Matthews">
<P>Double-blind trial but not clear whether randomised. Intervention was iontophoresis of extract of human placenta versus placebo and so not directly relevant to this review.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2013-04-22 13:47:26 -0400" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Rosenthal-1984">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2013-04-22 13:47:26 -0400" MODIFIED_BY="[Empty name]">
<P>Study population included participants with adhesive capsulitis (n = 38) and medial or lateral epicondylitis (n = 12). Data for participants with lateral elbow pain not presented separately.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2012-01-15 21:37:46 -0500" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Saggini-1997">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2012-01-15 21:37:46 -0500" MODIFIED_BY="[Empty name]">
<P>RCT but not restricted to lateral elbow pain and data not presented separately.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2012-03-18 22:43:43 -0400" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Saudan-1977">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2012-03-18 22:43:43 -0400" MODIFIED_BY="[Empty name]">
<P>Not an RCT.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2012-01-15 21:39:04 -0500" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Schorn-1986">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2012-01-15 21:39:04 -0500" MODIFIED_BY="[Empty name]">
<P>RCT but lateral elbow pain data not presented separately.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2013-04-22 13:47:27 -0400" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Seligra-1990">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2013-04-22 13:47:27 -0400" MODIFIED_BY="[Empty name]">
<P>RCT but of a population with varying disorders and not able to separate data for lateral elbow pain patients (n = 4; 2 in group 1, 2 in group 2).</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2013-04-22 13:47:27 -0400" MODIFIED_BY="Dolores Matthews" STUDY_ID="STD-Sileghem-1991">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2013-04-22 13:47:27 -0400" MODIFIED_BY="Dolores Matthews">
<P>RCT but population included both shoulder and elbow disorder, and the results not presented separately.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2012-01-15 21:39:16 -0500" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Thorling-1990">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2012-01-15 21:39:16 -0500" MODIFIED_BY="[Empty name]">
<P>Population of 120 participants with soft tissue injury. Included 3 participants with lateral elbow pain (2 in active group and 1 in placebo), but results not reported separately.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2013-04-22 13:47:28 -0400" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Turbio-1993">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2013-04-22 13:47:28 -0400" MODIFIED_BY="[Empty name]">
<P>Not specific to lateral elbow pain; included tendonitis and bursitis at multiple body sites.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2013-04-22 13:47:29 -0400" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Vecchini-1984">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2013-04-22 13:47:29 -0400" MODIFIED_BY="[Empty name]">
<P>Study population included participants with adhesive capsulitis (n = 12) and epicondylitis (n = 12). Data for participants with lateral elbow pain not presented separately.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2012-01-15 22:48:27 -0500" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Venerando-1973">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2012-01-15 22:48:27 -0500" MODIFIED_BY="[Empty name]">
<P>Not an RCT (translated from Italian to confirm).</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2013-04-22 13:47:29 -0400" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Wiseman-1987">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2013-04-22 13:47:29 -0400" MODIFIED_BY="[Empty name]">
<P>RCT but did not present data separately for different conditions, not specific for lateral elbow pain.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<FOOTNOTES/>
</CHARACTERISTICS_OF_EXCLUDED_STUDIES>
<CHARACTERISTICS_OF_AWAITING_STUDIES SORT_BY="STUDY" USER_DEF_1_ENABLED="NO" USER_DEF_2_ENABLED="NO" USER_DEF_3_ENABLED="NO">
<FOOTNOTES/>
</CHARACTERISTICS_OF_AWAITING_STUDIES>
<CHARACTERISTICS_OF_ONGOING_STUDIES MODIFIED="2013-02-03 21:35:45 -0500" MODIFIED_BY="[Empty name]" SORT_BY="STUDY" USER_DEF_1_ENABLED="NO" USER_DEF_2_ENABLED="NO" USER_DEF_3_ENABLED="NO">
<FOOTNOTES/>
</CHARACTERISTICS_OF_ONGOING_STUDIES>
</CHARACTERISTICS_OF_STUDIES>
<QUALITY_ITEMS MODIFIED="2013-04-22 21:39:44 -0400" MODIFIED_BY="Porjai Pattanittum">
<QUALITY_ITEM CORE_ITEM="YES" ID="QIT-01" LEVEL="STUDY" MODIFIED="2013-04-22 13:46:34 -0400" MODIFIED_BY="[Empty name]" NO="1">
<NAME>Random sequence generation (selection bias)</NAME>
<DESCRIPTION>
<P>Selection bias (biased allocation to interventions) due to inadequate generation of a randomised sequence</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2013-04-22 13:16:13 -0400" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Adelaar-1987">
<DESCRIPTION>
<P>"A randomisation process was used by the nurse coordinator to assign each participant into either Group A or B".</P>
<P>No further description of this process was provided.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2013-04-22 13:18:10 -0400" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Burnham-1998">
<DESCRIPTION>
<P>"The study was administered in a double-blind, randomised cross-over fashion". "The content code was known by the pharmacist who established the treatment randomisation schedule".<BR/>
<BR/>So although randomisation appears to be independent of the investigators, the way the sequence was generated was not described. It also was not clear what was randomised. as it appears that all participants were using gel from Jar A for the first week and from Jar B during the third week. "For the first week, participants used PLO from jar A. This was followed by a 1-week washout period. during which no PLO was used. During the third week, gel from jar B was used". However in the abstract, the authors state that "Treatment order was randomised". We have therefore interpreted this to mean that some of the participants received diclofenac in Jar A and some received it in Jar B.<BR/>
</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2013-04-22 13:19:15 -0400" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Burton-1988">
<DESCRIPTION>
<P>Participants "were randomly allocated to two treatment groups"; however sequence generation was not described.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2013-04-22 13:19:44 -0400" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-B_x00e4_cker-2011">
<DESCRIPTION>
<P>"Participants were randomly allocated to the treatments by a non-stratified block randomisation with varying block lengths. The independent biometrician draws random numbers from the "ranuni" random number generator of the SAS software".</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2013-04-22 13:20:07 -0400" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Demirtas-1998">
<DESCRIPTION>
<P>Authors state, "Participants were randomly separated into two groups"; however, no further details were provided.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2013-04-22 13:20:28 -0400" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Erturk-1997">
<DESCRIPTION>
<P>Participants were randomly divided into four groups.<BR/>No further details provided.<BR/>
</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2013-04-22 13:21:11 -0400" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Hay-1999">
<DESCRIPTION>
<P>"Numbers were used in a predetermined random sequence in blocks of six by general practice and generated with a random number table".</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2013-04-22 13:22:04 -0400" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Jenoure-1997">
<DESCRIPTION>
<P>Not described.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2013-04-22 13:42:03 -0400" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Labelle-1997">
<DESCRIPTION>
<P>"Allocation of the participants to the experimental or control group was done by block randomisation in 4 groups (i.e., 1 for each participating hospital). The order of allocation was pre-established with a table of random numbers".</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2013-04-22 13:44:18 -0400" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Polat-2011">
<DESCRIPTION>
<P>Not described.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2013-04-22 13:44:52 -0400" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Saartok-1986">
<DESCRIPTION>
<P>"The participants were randomly allocated to receive either naproxen tablets or betamethasone injection". Sequence generation was not described.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2013-04-22 13:45:04 -0400" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Schapira-1991">
<DESCRIPTION>
<P>Not described.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2012-01-15 19:55:10 -0500" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Spacca-2005">
<DESCRIPTION>
<P>Method of random sequence generation not specified.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2013-04-22 13:45:55 -0400" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Stull-1986">
<DESCRIPTION>
<P>"The participants were randomly assigned to two groups".<BR/>Method of sequence generation not described.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2013-04-22 13:46:34 -0400" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Tsuyama-1979">
<DESCRIPTION>
<P>"Allocation of medication was done as follows. One box contained four 25-g tubes, and this was used for one case. Six cases were put together as one group. The first controller allocated (these) randomly. Then the second controller allocated (these) randomly. This was called <I>the double-controller method</I>. The key codes were kept by each controller".<BR/>
<BR/>"The controllers made sure that the (two) medications could not be distinguished, conducted random allocation of the medication, stored the key code, made sure that the data were not changed and analysed the data".<BR/>
<BR/>Method of sequence generation was not specifically described.<BR/>
</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
</QUALITY_ITEM_DATA>
</QUALITY_ITEM>
<QUALITY_ITEM CORE_ITEM="YES" ID="QIT-02" LEVEL="STUDY" MODIFIED="2013-04-22 13:46:37 -0400" MODIFIED_BY="[Empty name]" NO="2">
<NAME>Allocation concealment (selection bias)</NAME>
<DESCRIPTION>
<P>Selection bias (biased allocation to interventions) due to inadequate concealment of allocations prior to assignment</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2013-04-22 13:16:22 -0400" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Adelaar-1987">
<DESCRIPTION>
<P>Not described. We know that randomisation was undertaken by the nurse coordinator, and the role of the nurse coordinator in the rest of the study was unclear. Baseline assessment was undertaken before randomisation, and so baseline data were available to potentially influence allocation.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2013-04-22 13:18:13 -0400" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Burnham-1998">
<DESCRIPTION>
<P>"Both jars were identical, and neither the participants nor the researchers were aware of which contained the diclofenac until after the study had ended. The content code was known by the pharmacist who established the treatment randomisation schedule". Thus it seems likely that allocation was concealed.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2012-05-21 19:46:13 -0400" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Burton-1988">
<DESCRIPTION>
<P>Not described.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2013-04-22 13:19:47 -0400" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-B_x00e4_cker-2011">
<DESCRIPTION>
<P>"The biometrician prepared, sealed and sequentially numbered opaque envelopes containing the treatment assignments. When a participant fulfilled all the enrolment criteria, the study physician opened the lowest numbered envelope to show that participant's assignment".</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2013-04-22 13:20:08 -0400" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Demirtas-1998">
<DESCRIPTION>
<P>Not described.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2009-06-11 23:49:12 -0400" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Erturk-1997">
<DESCRIPTION>
<P>Not described.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2013-04-22 13:21:13 -0400" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Hay-1999">
<DESCRIPTION>
<P>"Treatment allocation was according to the study number given to the participant at the baseline assessment". "The number corresponded with that on identical treatment packs kept in the general practitioners' surgeries".</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2013-04-22 13:22:04 -0400" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Jenoure-1997">
<DESCRIPTION>
<P>Not described.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2013-04-22 13:42:04 -0400" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Labelle-1997">
<DESCRIPTION>
<P>"The medication and the placebo were available as pills of identical shape, taste, and colour prepared by the manufacturer and delivered in identical containers of 5 pills that were identified only by a code number. The key to the code numbers was kept by the manufacturer, and a sealed copy was available to 1 investigator (RG) for emergency purposes".</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2013-04-22 13:44:20 -0400" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Polat-2011">
<DESCRIPTION>
<P>"Participants were randomised to groups by drawing lots from a closed envelope". No explanation was given for the much greater number of participants in the betahistine group (n = 33) compared with the number in the naproxen group (n = 22).</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2013-04-22 13:44:52 -0400" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Saartok-1986">
<DESCRIPTION>
<P>Not described. Seems unlikely, as no attempt was made to blind the treating physician.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2013-04-22 13:45:04 -0400" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Schapira-1991">
<DESCRIPTION>
<P>Not described.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2012-01-15 19:55:40 -0500" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Spacca-2005">
<DESCRIPTION>
<P>It was not specified whether or not treatment allocation was concealed.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2013-04-22 13:45:55 -0400" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Stull-1986">
<DESCRIPTION>
<P>Not described. Seems unlikely given open-label nature of trial.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2013-04-22 13:46:37 -0400" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Tsuyama-1979">
<DESCRIPTION>
<P>See above. Allocation concealment was not specified but seems likely.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
</QUALITY_ITEM_DATA>
</QUALITY_ITEM>
<QUALITY_ITEM CORE_ITEM="YES" ID="QIT-03" LEVEL="GROUP" MODIFIED="2013-04-22 21:39:44 -0400" MODIFIED_BY="Porjai Pattanittum" NO="3">
<NAME>Blinding (performance bias and detection bias)</NAME>
<DESCRIPTION>
<P>Performance bias or detection bias due to knowledge of the allocated interventions after assignment</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA_ENTRY_GROUP ID="QIG-03.01" NO="1">
<NAME>All outcomes</NAME>
</QUALITY_ITEM_DATA_ENTRY_GROUP>
<QUALITY_ITEM_DATA>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.01" MODIFIED="2013-04-22 13:16:24 -0400" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Adelaar-1987">
<DESCRIPTION>
<P>"Open label".</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.01" MODIFIED="2013-04-22 13:18:17 -0400" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Burnham-1998">
<DESCRIPTION>
<P>"Both jars were identical, and neither the participants nor the researchers were aware of which contained the diclofenac until after the study. The content code was known by the pharmacist who established the treatment randomisation schedule". Thus it seems likely that participants, investigators and outcome assessment (which appears to have been undertaken by the researchers) were blinded.<BR/>
<BR/>Eight of the fourteen participants correctly identified the diclofenac gel.<BR/>
</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.01" MODIFIED="2013-04-22 13:19:15 -0400" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Burton-1988">
<DESCRIPTION>
<P>Not described. Blinding of participants was unlikely, as interventions included a forearm strap for which there was no sham and a topical anti-inflammatory cream for which there was no placebo. Blinding of investigators or outcome assessment was not mentioned and was unlikely.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.01" MODIFIED="2013-04-22 13:19:51 -0400" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-B_x00e4_cker-2011">
<DESCRIPTION>
<P>Participants were not blinded, and all outcomes other than grip strength were participant assessed. All self-reported data were collected by study assistants, who were blinded to treatment allocation. The risk of detection bias for measurement of grip strength was unclear.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.01" MODIFIED="2013-04-22 13:20:08 -0400" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Demirtas-1998">
<DESCRIPTION>
<P>Not described.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.01" MODIFIED="2012-05-21 20:38:46 -0400" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Erturk-1997">
<DESCRIPTION>
<P>Unlikely to be blinded as interventions included injection and bandage and NSAIDs. </P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.01" MODIFIED="2013-04-22 21:39:44 -0400" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Hay-1999">
<DESCRIPTION>
<P>"Outcome assessments were performed by a blinded study nurse". However, nearly all outcomes were participant assessed and participants were only partially blinded. Although those who received oral medication were blinded to whether or not they received NSAID or placebo tablets, receipt of injection was not blinded. It was not clear whether the placebo tablets were identical to the active tablets, which were unmarked vitamin C tablets.<BR/>
</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.01" MODIFIED="2013-04-22 13:22:07 -0400" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Jenoure-1997">
<DESCRIPTION>
<P>"The placebo patch and the active patch (DIEP) were identical in appearance so that neither the participant nor the doctor could tell them apart". (quoted from translation)<BR/>
<BR/>It was unclear who was responsible for outcome assessment; however it seems this may have been the doctor, who would then have been blind.<BR/>
</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.01" MODIFIED="2013-04-22 13:42:07 -0400" MODIFIED_BY="Porjai Pattanittum" RESULT="YES" STUDY_ID="STD-Labelle-1997">
<DESCRIPTION>
<P>"The medication and the placebo were available as pills of identical shape, taste, and colour prepared by the manufacturer and delivered in identical containers of 5 pills that were identified only by a code number".<BR/>"The collaborating orthopaedists, the participants and the research assistant did not know what type of medication was being given to the participants".<BR/>So participants and investigators were blind.<BR/>
<BR/>"At each visit, all variables were monitored by an independent research assistant, who was not involved in the treatment process and, as stated above, completely blinded to the subject's treatment group".<BR/>So outcome assessment was blind.<BR/>
</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.01" MODIFIED="2013-04-22 13:44:23 -0400" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Polat-2011">
<DESCRIPTION>
<P>"The physicians were blind throughout the study. Participants did not know what medication they received. The tablets were removed from their original packages and were re-packaged without the drug name on it&#8221;. The authors noted in their discussion, "this method does not provide strong blindness". No details were provided as to whether the tablets were identical in appearance, or whether or not there were any identifying marks on the tablets.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.01" MODIFIED="2013-04-22 13:44:56 -0400" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Saartok-1986">
<DESCRIPTION>
<P>"To achieve blindness, the participants in the naproxen group also received a local saline injection (1.5 mL) and the betamethasone group received placebo tablets with the same appearance as naproxen tablets".<BR/>The treating physician (who was responsible for collection of outcome assessment) was not blind, although the only physician-reported outcomes were limitation of extension and doctor's evaluation of improvement. Nonetheless the physician could potentially influence participant report of other outcomes.<BR/>
</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.01" MODIFIED="2013-04-22 13:45:06 -0400" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Schapira-1991">
<DESCRIPTION>
<P>A placebo gel was used that was "identical in consistency, appearance, and odour with diclofenac gel" so it seems likely that participants were blind.<BR/>
<BR/>The study was described as "double-blind", and although it seems likely that investigators who were also responsible for outcome assessment were blind, this was not specifically mentioned and, in the absence of discussion of allocation concealment, cannot be confirmed.<BR/>
</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.01" MODIFIED="2013-04-22 13:45:38 -0400" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Spacca-2005">
<DESCRIPTION>
<P>Participants were blinded. Study described as 'double-blind' but unclear who else was blinded. Outcome assessor not specified but appears to be the physician treating the participant and most likely blinded.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.01" MODIFIED="2013-04-22 13:45:55 -0400" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Stull-1986">
<DESCRIPTION>
<P>"We performed an open-label, randomised clinical trial".<BR/>
</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.01" MODIFIED="2013-04-22 13:46:41 -0400" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Tsuyama-1979">
<DESCRIPTION>
<P>"The medication used were: yellow, transparent, gel-like ointment that contains 10 mg of indomethacin per 1 g (of medication); placebo that consists of medication used for this trial that does not contain the main ingredient of indomethacin. The controllers confirmed that it was not possible to distinguish the two medications from appearance".<BR/>
<BR/>It appears that the participants were blind to allocated intervention; however it was unclear whether treating doctors and outcome assessors were blind.<BR/>
<BR/>Data analysis was not blind, as this was carried out by the "controllers" who generated the allocation sequence.</P>
<P>Blinding was "Yes" for participants but "No" for data analysis.<BR/>
</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
</QUALITY_ITEM_DATA>
</QUALITY_ITEM>
<QUALITY_ITEM CORE_ITEM="YES" ID="QIT-04" LEVEL="GROUP" MODIFIED="2013-04-22 13:46:55 -0400" MODIFIED_BY="[Empty name]" NO="4">
<NAME>Incomplete outcome data (attrition bias)</NAME>
<DESCRIPTION>
<P>Attrition bias due to amount, nature or handling of incomplete outcome data</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA_ENTRY_GROUP ID="QIG-04.01" NO="1">
<NAME>All outcomes</NAME>
</QUALITY_ITEM_DATA_ENTRY_GROUP>
<QUALITY_ITEM_DATA>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2013-04-22 13:17:00 -0400" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Adelaar-1987">
<DESCRIPTION>
<P>22 participants were randomly assigned. Data were reported for 18 participants for "Investigator's assessment of pain, tenderness and swelling", "Patient's assessment of pain and functional capacity" and "Patients' overall post-treatment assessment". Three participants were not evaluated, as "they were non-compliant with the study medication regimen. A fourth patient was excluded because she failed to meet entry criteria". The group from which participants were excluded was not detailed. Non-compliant participants should have been included in the data analysis.<BR/>
</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2013-04-22 13:18:20 -0400" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Burnham-1998">
<DESCRIPTION>
<P>No missing data were reported for any outcomes.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2013-04-22 13:19:16 -0400" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Burton-1988">
<DESCRIPTION>
<P>Data for all included participants appear to be reported for all outcomes.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2013-04-22 13:19:52 -0400" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-B_x00e4_cker-2011">
<DESCRIPTION>
<P>All participants completed follow-up.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2013-04-22 13:20:08 -0400" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Demirtas-1998">
<DESCRIPTION>
<P>Complete outcome data reported for all included participants.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2013-04-22 13:20:30 -0400" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Erturk-1997">
<DESCRIPTION>
<P>Numbers of participants for whom data were reported for outcome measures were not specified.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2013-04-22 13:21:19 -0400" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Hay-1999">
<DESCRIPTION>
<P>Authors report that all but one participant (in the placebo group) completed the trial; however, complete data were not reported for all participants, and the proportion of missing data varies between outcomes. Authors note that case notes were not available for all participants; however, it was unclear which outcomes were assessed on the basis of the case notes. The number of participants included in the analysis was not reported for many outcomes. The proportion of missing data does not appear to be different between groups.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2013-04-22 13:22:11 -0400" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Jenoure-1997">
<DESCRIPTION>
<P>Small amounts (&lt; 10%) of missing data for all outcomes spread evenly between groups.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2013-04-22 13:42:08 -0400" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Labelle-1997">
<DESCRIPTION>
<P>"1 subject withdrew at 21 days because of secondary side effects".<BR/>It seems unlikely that this participant's data were included in the analysis. The number of participants for whom data was reported for each of the outcomes was not specified.<BR/>
</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2013-04-22 13:44:23 -0400" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Polat-2011">
<DESCRIPTION>
<P>Outcome data appear complete.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2013-04-22 13:45:01 -0400" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Saartok-1986">
<DESCRIPTION>
<P>Data from one participant were missing for changes in participant symptoms, doctor's evaluation of improvement and participant's evaluation of improvement. Data from three participants were missing for assessments of grip strength. The reasons for this loss to follow-up were not provided.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2013-04-22 13:45:08 -0400" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Schapira-1991">
<DESCRIPTION>
<P>The number of participants for whom data were reported for each of the outcomes was not specified. No loss to follow-up is mentioned.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2013-04-22 13:45:39 -0400" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Spacca-2005">
<DESCRIPTION>
<P>Data for all prespecified outcomes provided in the article but not presented separately for lateral epicondylitis.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2013-04-22 13:46:00 -0400" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Stull-1986">
<DESCRIPTION>
<P>"Of the 40 participants entered into the study, 38 completed it". "Participants failing to complete the study were excluded from data analysis".<BR/>In addition, data for the 38 who completed the study were missing. For example, for participant-reported overall degree of pain relief, data are missing for 3/19 participants in the diflunisal group and 2/17 in the naproxen group.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2013-04-22 13:46:55 -0400" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Tsuyama-1979">
<DESCRIPTION>
<P>"There were 187 cases where the test drug was administered. &#8230;Of these cases, 3 cases did not meet the experiment rules, hence were excluded. The exclusion reason was detailed in Table 2. 184 cases were analysed &#8230; Of these, 31 cases did not finish administration of medication; details were indicated in Table 3. Of the 31 cases, 7 cases were dropped because participants did not visit the hospital after their first visit. (With these cases), effectiveness could not be judged, but they were included as analysed cases of "No change and no side effects". For the 24 cases that were terminated within 2 weeks, evaluation made on the first week was moved to the second week and was regarded as the final evaluation. In terms of the number of cases that were dropped, reasons for dropping out and terminating, no significant differences were noted between the (two) groups.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
</QUALITY_ITEM_DATA>
</QUALITY_ITEM>
<QUALITY_ITEM CORE_ITEM="YES" ID="QIT-05" LEVEL="STUDY" MODIFIED="2013-04-22 13:46:57 -0400" MODIFIED_BY="[Empty name]" NO="5">
<NAME>Selective reporting (reporting bias)</NAME>
<DESCRIPTION>
<P>Reporting bias due to selective outcome reporting</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2013-04-22 13:17:27 -0400" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Adelaar-1987">
<DESCRIPTION>
<P>Prespecification of outcomes was not detailed. Data on investigator's assessment of limitation of motion and patient's assessment of swelling, although detailed in the methods, were not reported. In addition the interim assessments (at 5 and 10 days post-baseline) were not reported.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2013-04-22 13:18:23 -0400" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Burnham-1998">
<DESCRIPTION>
<P>Prespecification of outcomes was not detailed; however data were reported for all outcomes described in the methodology.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2013-04-22 13:19:17 -0400" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Burton-1988">
<DESCRIPTION>
<P>Prespecification of outcomes was not detailed; however data were reported for all outcomes described in the methodology.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2013-04-22 13:19:52 -0400" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-B_x00e4_cker-2011">
<DESCRIPTION>
<P>Prespecification of outcomes was not detailed; however data were reported for all outcomes described in the methods.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2013-04-22 13:20:09 -0400" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Demirtas-1998">
<DESCRIPTION>
<P>Prespecification of outcomes was not detailed; however data were reported for all outcomes described in methods.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2013-04-22 13:20:31 -0400" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Erturk-1997">
<DESCRIPTION>
<P>Prespecification of outcomes was not detailed; however data were reported for all outcomes described in methods.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2013-04-22 13:21:21 -0400" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Hay-1999">
<DESCRIPTION>
<P>All outcomes were reported in the article or on a BMJ Web appendix.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2012-05-24 00:29:33 -0400" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Jenoure-1997">
<DESCRIPTION>
<P>Prespecification of outcomes was not detailed and not all outcomes appear to have been reported.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2013-04-22 13:42:10 -0400" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Labelle-1997">
<DESCRIPTION>
<P>Prespecification of outcomes was not detailed; however data were reported for all outcomes described in the methodology.<BR/>Results were reported for some outcomes that were not described in the methods section, including adverse events and number of pills ingested.<BR/>
</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2013-04-22 13:44:24 -0400" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Polat-2011">
<DESCRIPTION>
<P>Data were reported for all outcomes describe in the methods. No reference was made to trial registration.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2013-04-22 13:45:03 -0400" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Saartok-1986">
<DESCRIPTION>
<P>Data were reported for a range of pain outcomes that were not specified in the methods. Detailed data were also not reported for several outcomes that were specified in the methods, including pain at rest and side effects.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2013-04-22 13:45:09 -0400" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Schapira-1991">
<DESCRIPTION>
<P>Prespecification of outcomes was not detailed; however data were reported for all outcomes described in the methodology.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2013-04-22 13:45:39 -0400" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Spacca-2005">
<DESCRIPTION>
<P>Three participants were not included in the analysis, but condition, treatment group and reasons were not specified.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2013-04-22 13:46:01 -0400" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Stull-1986">
<DESCRIPTION>
<P>Outcomes in the methods and results appeared to differ, but data were reported for all outcomes described in the methods.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2013-04-22 13:46:57 -0400" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Tsuyama-1979">
<DESCRIPTION>
<P>Prespecification of outcomes was not detailed; however data were reported for all outcomes described in the methodology.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
</QUALITY_ITEM_DATA>
</QUALITY_ITEM>
<QUALITY_ITEM CORE_ITEM="YES" ID="QIT-06" LEVEL="STUDY" MODIFIED="2013-04-22 13:46:57 -0400" MODIFIED_BY="[Empty name]" NO="6">
<NAME>Other bias</NAME>
<DESCRIPTION>
<P>Bias due to problems not covered elsewhere in the table</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2013-04-22 13:17:34 -0400" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Adelaar-1987">
<DESCRIPTION>
<P>"Supported by a grant from Merck Sharp &amp; Dohme, West Point, PA".</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2013-04-22 13:18:34 -0400" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Burnham-1998">
<DESCRIPTION>
<P>This study was a crossover trial; however within-participant data were not presented, and analysis of correlation between placebo and treatment results for each participant does not appear to have been undertaken.<BR/>
<BR/>Wrist extension strength in the washout period was greater than baseline or placebo levels, suggesting a carryover effect. A longer washout period may have been appropriate.<BR/>
</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2013-04-22 13:19:20 -0400" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Burton-1988">
<DESCRIPTION>
<P>Baseline details were not presented by group but were combined for all included participants, so it was unclear whether there were any differences between groups at baseline, although the authors report no differences in age, gender, duration of complaint or previous treatment. Mean grip strength does appear to vary somewhat between the groups at baseline (63.1 vs 60.5 vs 49.8 vs 52.1 mm Hg).<BR/>
</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2013-04-22 13:19:53 -0400" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-B_x00e4_cker-2011">
<DESCRIPTION>
<P>Outcome expectation was significantly higher in the leech group &#65293; adding expectation as a covariate in the analysis did not appreciably alter the results.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2012-08-21 02:55:35 -0400" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Demirtas-1998">
<DESCRIPTION>
<P>No other biases apparent.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2012-05-21 20:40:04 -0400" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Erturk-1997">
<DESCRIPTION>
<P>Very small numbers of participants in each group. At baseline pain at rest appears higher in Group 1 than in other groups, and pain on resisted wrist extension appears higher in Group 4 than in other groups.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2013-04-22 13:21:23 -0400" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Hay-1999">
<DESCRIPTION>
<P>Primary endpoint was outcome at 4 weeks after either a single glucocorticoid injection or a 2-week course of NSAID or placebo &#65293; it was unclear whether this was an appropriate length of treatment for comparison.<BR/>
</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2013-04-22 13:22:13 -0400" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Jenoure-1997">
<DESCRIPTION>
<P>At baseline a larger proportion of participants reported having moderate, strong or very strong pain in the placebo group than in the treatment group (89.5% vs 70.7%).</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2013-04-22 13:42:48 -0400" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Labelle-1997">
<DESCRIPTION>
<P>For the visual analogue scale of function at baseline, "The experimental group was slightly more affected than the control group (mean ± SD, 43 ± 24 vs 53 ± 27 mm)".</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2013-04-22 13:44:27 -0400" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Polat-2011">
<DESCRIPTION>
<P>The mean duration of symptoms was provided only for the overall study population, not by group, so it is not known whether any baseline differences were noted for this variable.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2013-04-22 13:45:04 -0400" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Saartok-1986">
<DESCRIPTION>
<P>Although text reports that groups were well matched at baseline, no table of baseline data was provided.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2013-04-22 13:45:11 -0400" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Schapira-1991">
<DESCRIPTION>
<P>Outcomes were quite subjective (pain at rest, pain on active movement, pain on passive movement, pain on firm pressure) and could easily be influenced by the outcome assessor &#65293; this would potentially introduce bias if outcome assessment was not blinded.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2012-02-20 19:57:38 -0500" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Spacca-2005">
<DESCRIPTION>
<P>First author was contacted and provided outcome data for the primary endpoint at days 3, 6 and 10 for the lateral epicondylitis group. </P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2013-04-22 13:46:02 -0400" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Stull-1986">
<DESCRIPTION>
<P>"This study was supported by a grant from Merck Sharp &amp; Dohme, West Point, Pennsylvania".</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2013-04-22 13:46:57 -0400" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Tsuyama-1979">
<DESCRIPTION>
<P>It was unclear whether the clinicians were blinded.<BR/>(Blinding was "No" for analyst to do data analysis.)</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
</QUALITY_ITEM_DATA>
</QUALITY_ITEM>
<QUALITY_ITEM CORE_ITEM="NO" ID="QIT-07" LEVEL="GROUP" MODIFIED="2012-08-22 00:18:43 -0400" MODIFIED_BY="[Empty name]" NO="7">
<NAME>Blinding of participants and personnel (performance bias)</NAME>
<DESCRIPTION>
<P>Performance bias due to knowledge of the allocated interventions by participants and personnel during the study</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA/>
</QUALITY_ITEM>
<QUALITY_ITEM CORE_ITEM="NO" ID="QIT-08" LEVEL="GROUP" MODIFIED="2012-08-22 00:18:43 -0400" MODIFIED_BY="[Empty name]" NO="8">
<NAME>Blinding of outcome assessment (detection bias)</NAME>
<DESCRIPTION>
<P>Detection bias due to knowledge of the allocated interventions by outcome assessors</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA/>
</QUALITY_ITEM>
</QUALITY_ITEMS>
<SOF_TABLES MODIFIED="2013-04-22 21:43:25 -0400" MODIFIED_BY="[Empty name]">
<SOF_TABLE ID="SOF-01" MODIFIED="2013-04-22 21:42:08 -0400" MODIFIED_BY="Porjai Pattanittum" NO="1" READONLY="YES">
<TITLE MODIFIED="2012-06-26 22:56:59 -0400" MODIFIED_BY="Grade Profiler">Topical NSAIDs compared to placebo for treating lateral elbow pain in adults</TITLE>
<TABLE COLS="7" ROWS="13">
<TR>
<TD COLSPAN="7">
<P>
<B>Topical NSAIDs compared with placebo for treating lateral elbow pain in adults</B>
</P>
</TD>
</TR>
<TR>
<TD COLSPAN="7">
<P>
<B>Patient or population:</B> Adults with lateral elbow pain<BR/>
<B>Settings: </B>Outpatient settings in high-income countries<BR/>
<B>Intervention:</B> Topical NSAIDs<BR/>
<B>Comparison: </B>Placebo</P>
</TD>
</TR>
<TR>
<TH ALIGN="LEFT" ROWSPAN="3" VALIGN="TOP">
<P>Outcomes</P>
</TH>
<TH ALIGN="LEFT" COLSPAN="2" VALIGN="TOP">
<P>Illustrative comparative risks* (95% CI)</P>
</TH>
<TH ALIGN="LEFT" ROWSPAN="3" VALIGN="TOP">
<P>Relative effect<BR/>(95% CI)</P>
</TH>
<TH ALIGN="LEFT" ROWSPAN="3" VALIGN="TOP">
<P>No of Participants<BR/>(studies)</P>
</TH>
<TH ALIGN="LEFT" ROWSPAN="3" VALIGN="TOP">
<P>Quality of the evidence<BR/>(GRADE)</P>
</TH>
<TH ALIGN="LEFT" ROWSPAN="3" VALIGN="TOP">
<P>Comments</P>
</TH>
</TR>
<TR>
<TH ALIGN="LEFT" VALIGN="TOP">
<P>Assumed risk</P>
</TH>
<TH ALIGN="LEFT" VALIGN="TOP">
<P>Corresponding risk</P>
</TH>
</TR>
<TR>
<TH ALIGN="LEFT" VALIGN="TOP">
<P>Placebo</P>
</TH>
<TH ALIGN="LEFT" VALIGN="TOP">
<P>
<B>Topical NSAIDs</B>
</P>
</TH>
</TR>
<TR>
<TD ALIGN="LEFT" ROWSPAN="1" VALIGN="TOP">
<P>
<B>Pain</B>
</P>
<P>0 to 10 visual analogue scale (0 = no pain)</P>
</TD>
<TD ROWSPAN="1" VALIGN="TOP">
<P>The median pain in the placebo groups was<BR/>
<B>3.78 points</B>
<SUP>1</SUP>
</P>
</TD>
<TD ROWSPAN="1" VALIGN="TOP">
<P>The mean pain in the intervention groups was<BR/>
<B>1.64 lower</B>
<BR/>(2.42 to 0.86 lower)</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="1" VALIGN="TOP">
<P/>
</TD>
<TD ALIGN="LEFT" ROWSPAN="1" VALIGN="TOP">
<P>153<BR/>(3 studies)</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="1" VALIGN="TOP">
<P>&#8853;&#8861;&#8861;&#8861;<BR/>
<B>very low</B>
<SUP>2,3,4</SUP>
</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="1" VALIGN="TOP">
<P>Absolute reduction in pain 16% (8% to 24%); relative percent reduction 32% (17% to 47%).</P>
<P>NNTB 7 (3 to 21).</P>
</TD>
</TR>
<TR>
<TD>
<P>
<B>Treatment success</B>
</P>
<P>Fair, good or excellent effectiveness</P>
</TD>
<TD>
<P>488 per 1000<SUP>5</SUP>
</P>
</TD>
<TD>
<P>
<B>727 per 1000</B> (507 to 1000)<SUP>6</SUP>
</P>
</TD>
<TD>
<P>
<B>RR 1.49</B> (1.04 to 2.14)</P>
</TD>
<TD>
<P>85</P>
<P>(1 study)</P>
</TD>
<TD>
<P>&#8853;&#8853;&#8861;&#8861;<BR/>
<B>low</B>
<SUP>2,7</SUP>
</P>
</TD>
<TD>
<P>Absolute risk difference 24% more success with NSAIDs (4% to 44%); relative change 49% improvement (4% to 114%).</P>
<P>NNTB 4 (2 to 25).</P>
</TD>
</TR>
<TR>
<TD ALIGN="LEFT" ROWSPAN="1" VALIGN="TOP">
<P>
<B>Function/disability</B>
</P>
</TD>
<TD ROWSPAN="1" VALIGN="TOP">
<P>See comment</P>
</TD>
<TD ROWSPAN="1" VALIGN="TOP">
<P>See comment</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="1" VALIGN="TOP">
<P>Not estimable</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="1" VALIGN="TOP">
<P>-<BR/>
</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="1" VALIGN="TOP">
<P>See comment</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="1" VALIGN="TOP">
<P>No studies reported this outcome.</P>
</TD>
</TR>
<TR>
<TD ALIGN="LEFT" ROWSPAN="1" VALIGN="TOP">
<P>
<B>Quality of life</B>
</P>
</TD>
<TD ROWSPAN="1" VALIGN="TOP">
<P>See comment</P>
</TD>
<TD ROWSPAN="1" VALIGN="TOP">
<P>See comment</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="1" VALIGN="TOP">
<P>Not estimable</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="1" VALIGN="TOP">
<P>-<BR/>
</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="1" VALIGN="TOP">
<P>See comment</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="1" VALIGN="TOP">
<P>No studies reported this outcome.</P>
</TD>
</TR>
<TR>
<TD>
<P>
<B>Withdrawal due to adverse events</B>
</P>
</TD>
<TD>
<P>See comment</P>
</TD>
<TD>
<P>See comment</P>
</TD>
<TD>
<P>Not estimable</P>
</TD>
<TD>
<P>185</P>
<P>(4 studies)</P>
</TD>
<TD>
<P>&#8853;&#8853;&#8861;&#8861;<BR/>
<B>low</B>
<SUP>2,3,4</SUP>
</P>
</TD>
<TD>
<P>No participants withdrew because of adverse effects with topical NSAIDs or placebo. Some studies reported infrequent and mild adverse effects such as rash.</P>
</TD>
</TR>
<TR>
<TD>
<P>
<B>Adverse events</B>
</P>
</TD>
<TD>
<P>12 per 1000</P>
</TD>
<TD>
<P>
<B>20 per 1000</B> (3 to 158)</P>
</TD>
<TD>
<P>
<B>RR 1.55</B> (0.20, 12.14)</P>
</TD>
<TD>
<P>153 (3 studies)</P>
</TD>
<TD>
<P>&#8853;&#8853;&#8861;&#8861;<BR/>
<B>low</B>
<SUP>2,3,4</SUP>
</P>
</TD>
<TD>
<P>Absolute risk difference 0% (5% fewer to 6% more); relative change 55% more events with NSAIDs (80% fewer to 114% more).</P>
<P>NNTH not applicable.</P>
</TD>
</TR>
<TR>
<TD COLSPAN="7">
<P>*The basis for the <B>assumed risk</B> (e.g. the median control group risk across studies) is provided in footnotes. The <B>corresponding risk</B> (and its 95% confidence interval) is based on the assumed risk in the comparison group and the <B>relative effect</B> of the intervention (and its 95% CI).<BR/>
<B>CI:</B> Confidence interval.</P>
</TD>
</TR>
<TR>
<TD COLSPAN="7">
<P>GRADE Working Group grades of evidence:<BR/>
<B>High quality:</B> Further research is very unlikely to change our confidence in the estimate of effect.<BR/>
<B>Moderate quality:</B> Further research is likely to have an important impact on our confidence in the estimate of effect and may change the estimate.<BR/>
<B>Low quality:</B> Further research is very likely to have an important impact on our confidence in the estimate of effect and is likely to change the estimate.<BR/>
<B>Very low quality:</B> We are very uncertain about the estimate.<BR/>
</P>
</TD>
</TR>
</TABLE>
<FOOTNOTES>
<P>
<SUP>1 </SUP>Median of reported mean pain in placebo group for three studies included in the meta-analysis.<BR/>
<SUP>2</SUP> Included studies were of low quality and small sample size.<BR/>
<SUP>3</SUP> Only one study used adequate concealment of allocation.<BR/>
<SUP>4</SUP> One crossover study did not present within-participant data; one RCT did not report baseline data by group and one RCT reported an imbalance of baseline data in terms of pain between treatment and control groups.<BR/>
<SUP>5</SUP> Risk of treatment success in the placebo group of the single study reporting this outcome.</P>
<P>
<SUP>6</SUP> Upper limit of the CI was rounded down to 1000 as the highest possible value for an absolute effect.<BR/>
<SUP>7</SUP> Imbalance of baseline data between treatment and control groups.</P>
</FOOTNOTES>
</SOF_TABLE>
<SOF_TABLE ID="SOF-02" MODIFIED="2013-04-22 13:48:09 -0400" MODIFIED_BY="Porjai Pattanittum" NO="2" READONLY="YES">
<TITLE MODIFIED="2012-06-26 22:58:17 -0400" MODIFIED_BY="Grade Profiler">Oral NSAIDs compared to placebo for treating lateral elbow pain in adults</TITLE>
<TABLE COLS="7" ROWS="13">
<TR>
<TD COLSPAN="7">
<P>
<B>Oral NSAIDs compared with placebo for treating lateral elbow pain in adults</B>
</P>
</TD>
</TR>
<TR>
<TD COLSPAN="7">
<P>
<B>Patient or population:</B> adults with lateral elbow pain<BR/>
<B>Settings: n</B>ot described<BR/>
<B>Intervention:</B> oral NSAIDs<BR/>
<B>Comparison: </B>placebo</P>
</TD>
</TR>
<TR>
<TH ALIGN="LEFT" ROWSPAN="3" VALIGN="TOP">
<P>Outcomes</P>
</TH>
<TH ALIGN="LEFT" COLSPAN="2" VALIGN="TOP">
<P>Illustrative comparative risks* (95% CI)</P>
</TH>
<TH ALIGN="LEFT" ROWSPAN="3" VALIGN="TOP">
<P>Relative effect<BR/>(95% CI)</P>
</TH>
<TH ALIGN="LEFT" ROWSPAN="3" VALIGN="TOP">
<P>No of Participants<BR/>(studies)</P>
</TH>
<TH ALIGN="LEFT" ROWSPAN="3" VALIGN="TOP">
<P>Quality of the evidence<BR/>(GRADE)</P>
</TH>
<TH ALIGN="LEFT" ROWSPAN="3" VALIGN="TOP">
<P>Comments</P>
</TH>
</TR>
<TR>
<TH ALIGN="LEFT" VALIGN="TOP">
<P>Assumed risk</P>
</TH>
<TH ALIGN="LEFT" VALIGN="TOP">
<P>Corresponding risk</P>
</TH>
</TR>
<TR>
<TH ALIGN="LEFT" VALIGN="TOP">
<P>Placebo</P>
</TH>
<TH ALIGN="LEFT" VALIGN="TOP">
<P>
<B>Oral NSAID</B>
</P>
</TH>
</TR>
<TR>
<TD ALIGN="LEFT" ROWSPAN="1" VALIGN="TOP">
<P>
<B>Pain </B>
</P>
<P>0 to 100 visual analogue scale and 10-point Likert scale (lower score = less pain)</P>
</TD>
<TD ROWSPAN="1" VALIGN="TOP">
<P>See comment</P>
</TD>
<TD ROWSPAN="1" VALIGN="TOP">
<P>See comment</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="1" VALIGN="TOP">
<P>Not estimable</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="1" VALIGN="TOP">
<P>292<BR/>(2 studies)</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="1" VALIGN="TOP">
<P>&#8853;&#8861;&#8861;&#8861;<BR/>
<B>very low</B>
<SUP>1,2,3,4</SUP>
</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="1" VALIGN="TOP">
<P>Results were conflicting. One trial found significant improvement in pain with NSAIDs. The other reported no between-group difference. Could not be pooled because one trial reported medians.</P>
</TD>
</TR>
<TR>
<TD>
<P>
<B>Treatment success</B>
</P>
<P>Fair, good or excellent effectiveness</P>
</TD>
<TD>
<P>483 per 1000<SUP>5</SUP>
</P>
</TD>
<TD>
<P>
<B>565 per 1000 </B>(396 to 806)</P>
</TD>
<TD>
<P>
<B>RR 1.17 </B>(0.82 to 1.67)</P>
</TD>
<TD>
<P>111</P>
<P>(1 study)</P>
</TD>
<TD>
<P>&#8853;&#8853;&#8853;&#8861;<BR/>
<B>low</B>
<SUP>1,2</SUP>
</P>
</TD>
<TD>
<P>Absolute improvement 8% (10% worsening to 27% improvement), relative improvement 17% (18% worsening to 67% improvement), NNTB not applicable, as difference not statistically significant.</P>
</TD>
</TR>
<TR>
<TD ALIGN="LEFT" ROWSPAN="1" VALIGN="TOP">
<P>
<B>Quality of life</B>
</P>
</TD>
<TD ROWSPAN="1" VALIGN="TOP">
<P>See comment</P>
</TD>
<TD ROWSPAN="1" VALIGN="TOP">
<P>See comment</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="1" VALIGN="TOP">
<P>Not estimable</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="1" VALIGN="TOP">
<P>-<BR/>
</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="1" VALIGN="TOP">
<P>See comment</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="1" VALIGN="TOP">
<P>This outcome was not reported.</P>
</TD>
</TR>
<TR>
<TD ALIGN="LEFT" ROWSPAN="1" VALIGN="TOP">
<P>
<B>Function/disability</B>
</P>
<P>0 to 100 visual analogue scale (higher score = less disability) and 10-point Likert scale (lower score = less disability)</P>
</TD>
<TD ROWSPAN="1" VALIGN="TOP">
<P>See comment</P>
</TD>
<TD ROWSPAN="1" VALIGN="TOP">
<P>See comment</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="1" VALIGN="TOP">
<P>Not estimable</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="1" VALIGN="TOP">
<P>292<BR/>(2 studies)<BR/>
</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="1" VALIGN="TOP">
<P>&#8853;&#8853;&#8853;&#8861;<BR/>
<B>low</B>
<SUP>1,2,3</SUP>
</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="1" VALIGN="TOP">
<P>Results could not be pooled because one trial reported medians, but neither study found a significant difference between groups.</P>
</TD>
</TR>
<TR>
<TD>
<P>
<B>Withdrawal due to adverse events</B>
</P>
</TD>
<TD>
<P>See comment</P>
</TD>
<TD>
<P>See comment</P>
</TD>
<TD>
<P>Not estimable</P>
</TD>
<TD>
<P>-<BR/>
</P>
</TD>
<TD>
<P>See comment</P>
</TD>
<TD>
<P>Withdrawals due to adverse effects were not reported in one study, and another study reported one withdrawal in the NSAID group due to diarrhoea. Studies reported a variety of adverse effects including gastrointestinal effects in participants receiving NSAIDs, and one participant had an allergic reaction (oedema).</P>
</TD>
</TR>
<TR>
<TD>
<P>
<B>Adverse events</B>
</P>
</TD>
<TD>
<P>See comment</P>
</TD>
<TD>
<P>See comment</P>
</TD>
<TD>
<P>Not estimable</P>
</TD>
<TD>
<P>292 (2 studies)</P>
</TD>
<TD>
<P>See comment</P>
</TD>
<TD>
<P>Could not be pooled because one trial reported counts, not rates.</P>
</TD>
</TR>
<TR>
<TD COLSPAN="7">
<P>*The basis for the <B>assumed risk</B> (e.g. the median control group risk across studies) is provided in footnotes. The <B>corresponding risk</B> (and its 95% confidence interval) is based on the assumed risk in the comparison group and the <B>relative effect</B> of the intervention (and its 95% CI).<BR/>
<B>CI:</B> Confidence interval.</P>
</TD>
</TR>
<TR>
<TD COLSPAN="7">
<P>GRADE Working Group grades of evidence:<BR/>
<B>High quality:</B> Further research is very unlikely to change our confidence in the estimate of effect.<BR/>
<B>Moderate quality:</B> Further research is likely to have an important impact on our confidence in the estimate of effect and may change the estimate.<BR/>
<B>Low quality:</B> Further research is very likely to have an important impact on our confidence in the estimate of effect and is likely to change the estimate.<BR/>
<B>Very low quality:</B> We are very uncertain about the estimate.<BR/>
</P>
</TD>
</TR>
</TABLE>
<FOOTNOTES>
<P>
<SUP>1</SUP> Studies did not adequately address or describe how incomplete data were managed.<BR/>
<SUP>2</SUP> One study had some baseline imbalance.<BR/>
<SUP>3</SUP> Unclear whether 2-week intervention period in one study was sufficient to be clinically meaningful.<BR/>
<SUP>4</SUP> A high level of inconsistency was observed between studies.<BR/>
<SUP>5</SUP> Risk of treatment success in the placebo group of the single study reporting this outcome.<BR/>
</P>
</FOOTNOTES>
</SOF_TABLE>
<SOF_TABLE ID="SOF-03" MODIFIED="2013-04-22 21:43:25 -0400" MODIFIED_BY="Porjai Pattanittum" NO="3" READONLY="YES">
<TITLE MODIFIED="2013-04-22 21:43:19 -0400" MODIFIED_BY="Grade Profiler">Oral NSAIDs compared to glucocorticoid injection for treating lateral elbow pain in adults</TITLE>
<TABLE COLS="7" ROWS="13">
<TR>
<TD COLSPAN="7">
<P>
<B>Oral NSAIDs compared with glucocorticoid injection for treating lateral elbow pain in adults</B>
</P>
</TD>
</TR>
<TR>
<TD COLSPAN="7">
<P>
<B>Patient or population:</B> Adults with lateral elbow pain<BR/>
<B>Settings:</B> Not described<BR/>
<B>Intervention: </B>Oral NSAIDs<BR/>
<B>Comparison: </B>Glucocorticoid injection</P>
</TD>
</TR>
<TR>
<TH ALIGN="LEFT" ROWSPAN="3" VALIGN="TOP">
<P>Outcomes</P>
</TH>
<TH ALIGN="LEFT" COLSPAN="2" VALIGN="TOP">
<P>Illustrative comparative risks* (95% CI)</P>
</TH>
<TH ALIGN="LEFT" ROWSPAN="3" VALIGN="TOP">
<P>Relative effect<BR/>(95% CI)</P>
</TH>
<TH ALIGN="LEFT" ROWSPAN="3" VALIGN="TOP">
<P>No of participants<BR/>(studies)</P>
</TH>
<TH ALIGN="LEFT" ROWSPAN="3" VALIGN="TOP">
<P>Quality of the evidence<BR/>(GRADE)</P>
</TH>
<TH ALIGN="LEFT" ROWSPAN="3" VALIGN="TOP">
<P>Comments</P>
</TH>
</TR>
<TR>
<TH ALIGN="LEFT" VALIGN="TOP">
<P>Assumed risk</P>
</TH>
<TH ALIGN="LEFT" VALIGN="TOP">
<P>Corresponding risk</P>
</TH>
</TR>
<TR>
<TH ALIGN="LEFT" VALIGN="TOP">
<P>Glucocorticoid injection</P>
</TH>
<TH ALIGN="LEFT" VALIGN="TOP">
<P>
<B>Oral NSAIDs</B>
</P>
</TH>
</TR>
<TR>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>
<B>Pain</B>
</P>
<P>9- and 10-point Likert scales (lower score = less pain)<BR/>
</P>
</TD>
<TD>
<P>See comment</P>
</TD>
<TD>
<P>See comment</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>Not estimable</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>126<BR/>(2 studies)</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>&#8853;&#8861;&#8861;&#8861;<BR/>v<B>ery</B> <B>low</B>
<SUP>1,2</SUP>
</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>Studies were inconsistent. One study reported a significant improvement in pain with glucocorticoid injection. Another study found no significant effect.</P>
</TD>
</TR>
<TR>
<TD>
<P>
<B>Treatment success</B>
</P>
<P>Fair, good or excellent effectiveness</P>
</TD>
<TD>
<P>
<B>734 per 1000</B>
<SUP>3</SUP>
</P>
</TD>
<TD>
<P>
<B>543 per 1000</B>
</P>
<P>(316 to 925)</P>
</TD>
<TD>
<P>
<B>RR 0.74</B> (0.43 to 1.26)</P>
</TD>
<TD>
<P>126</P>
<P>(2 studies)</P>
</TD>
<TD>
<P>&#8853;&#8861;&#8861;&#8861;<BR/>v<B>ery</B> <B>low</B>
<SUP>1,4</SUP>
</P>
</TD>
<TD>
<P>Absolute risk difference 20% worse with NSAIDs (60% worse to 20% better), relative difference 26% worse with NSAIDs (57% worse to 26% better).</P>
</TD>
</TR>
<TR>
<TD ALIGN="LEFT" ROWSPAN="1" VALIGN="TOP">
<P>
<B>Quality of life</B>
</P>
</TD>
<TD ROWSPAN="1" VALIGN="TOP">
<P>See comment</P>
</TD>
<TD ROWSPAN="1" VALIGN="TOP">
<P>See comment</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="1" VALIGN="TOP">
<P>Not estimable</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="1" VALIGN="TOP">
<P>-<BR/>
</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="1" VALIGN="TOP">
<P>See comment</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="1" VALIGN="TOP">
<P>No studies reported this outcome.</P>
</TD>
</TR>
<TR>
<TD ALIGN="LEFT" ROWSPAN="1" VALIGN="TOP">
<P>
<B>Function/disability </B>
</P>
<P>10-point Likert scale (lower score = less disability)</P>
</TD>
<TD ROWSPAN="1" VALIGN="TOP">
<P>See comment</P>
</TD>
<TD ROWSPAN="1" VALIGN="TOP">
<P>See comment</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="1" VALIGN="TOP">
<P>Not estimable</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="1" VALIGN="TOP">
<P>105 (1 study)<BR/>
</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="1" VALIGN="TOP">
<P>&#8853;&#8853;&#8861;&#8861;<BR/>l<B>ow</B>
<SUP>1</SUP>
</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="1" VALIGN="TOP">
<P>An overall effect estimate was not presented, but a significant improvement in function with glucocorticoid injection was observed.</P>
</TD>
</TR>
<TR>
<TD>
<P>
<B>Withdrawal due to adverse events</B>
</P>
</TD>
<TD>
<P>See comment</P>
</TD>
<TD>
<P>See comment</P>
</TD>
<TD>
<P>Not estimable</P>
</TD>
<TD>
<P>-<BR/>
</P>
</TD>
<TD>
<P>See comment</P>
</TD>
<TD>
<P>Adverse effects were not reported in two studies, and another study reported cessation of NSAIDs due to gastrointestinal adverse effects in four participants and an allergic reaction (oedema) in one participant. Other adverse effects reported included local skin atrophy in three participants (only one of whom received glucocorticoid injection) and pain after injection.</P>
</TD>
</TR>
<TR>
<TD>
<P>
<B>Adverse events</B>
</P>
</TD>
<TD>
<P>See comment</P>
</TD>
<TD>
<P>See comment</P>
</TD>
<TD>
<P>Not estimable</P>
</TD>
<TD>
<P>-</P>
</TD>
<TD>
<P>See comment</P>
</TD>
<TD>
<P>Adverse effects were not reported in two studies, and another study reported cessation of NSAIDs due to gastrointestinal adverse effects in four participants and an allergic reaction (oedema) in one participant. Other adverse effects reported included local skin atrophy in three participants (only one of whom received glucocorticoid injection) and pain after injection.</P>
</TD>
</TR>
<TR>
<TD COLSPAN="7">
<P>*The basis for the <B>assumed risk</B> (e.g. the median control group risk across studies) is provided in footnotes. The <B>corresponding risk</B> (and its 95% confidence interval) is based on the assumed risk in the comparison group and the <B>relative effect</B> of the intervention (and its 95% CI).<BR/>
<B>CI:</B> Confidence interval; <B>RR:</B> Risk ratio.</P>
</TD>
</TR>
<TR>
<TD COLSPAN="7">
<P>GRADE Working Group grades of evidence:<BR/>
<B>High quality:</B> Further research is very unlikely to change our confidence in the estimate of effect.<BR/>
<B>Moderate quality:</B> Further research is likely to have an important impact on our confidence in the estimate of effect and may change the estimate.<BR/>
<B>Low quality:</B> Further research is very likely to have an important impact on our confidence in the estimate of effect and is likely to change the estimate.<BR/>
<B>Very low quality:</B> We are very uncertain about the estimate.<BR/>
</P>
</TD>
</TR>
</TABLE>
<FOOTNOTES>
<P>
<SUP>1</SUP> Very limited description of study methods and some important design flaws (see risk of bias table).<BR/>
<SUP>2</SUP> A high level of inconsistency was observed between studies.<BR/>
<SUP>3 </SUP>Median of reported risks of treatment success in glucocorticoid injection group for two studies included in the meta-analysis.<BR/>
<SUP>4</SUP> A high level of imprecision was observed with this result, consistent with a clinically important benefit with either glucocorticoid injection or oral NSAIDs.<BR/>
</P>
</FOOTNOTES>
</SOF_TABLE>
</SOF_TABLES>
<ADDITIONAL_TABLES MODIFIED="2013-04-22 13:48:27 -0400" MODIFIED_BY="[Empty name]">
<ADDITIONAL_TABLE ID="TBL-01" MODIFIED="2013-04-22 13:48:22 -0400" MODIFIED_BY="[Empty name]" NO="1">
<TITLE MODIFIED="2012-05-25 00:01:08 -0400" MODIFIED_BY="[Empty name]">Oral NSAID vs glucocorticoid injection vs placebo (Hay 1999)</TITLE>
<TABLE COLS="4" ROWS="11">
<TR>
<TH>
<P>Assessment and timing</P>
</TH>
<TH ALIGN="CENTER">
<P>Glucocorticoid injection<BR/>median (interquartile range)</P>
</TH>
<TH ALIGN="CENTER">
<P>Naproxen<BR/>median (interquartile range)<BR/>
</P>
</TH>
<TH ALIGN="CENTER">
<P>Placebo<BR/>median (interquartile range)</P>
</TH>
</TR>
<TR>
<TD>
<P>
<B>Pain</B> (10-point Likert scale)</P>
</TD>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
</TR>
<TR>
<TD>
<P>Baseline</P>
</TD>
<TD ALIGN="CENTER">
<P>6 (4-7)</P>
</TD>
<TD ALIGN="CENTER">
<P>4 (2.75-6.25)</P>
</TD>
<TD ALIGN="CENTER">
<P>5 (4-7)</P>
</TD>
</TR>
<TR>
<TD>
<P>4 weeks</P>
</TD>
<TD ALIGN="CENTER">
<P>1 (0-3)</P>
</TD>
<TD ALIGN="CENTER">
<P>4 (2-6)</P>
</TD>
<TD ALIGN="CENTER">
<P>3.5 (2-6)</P>
</TD>
</TR>
<TR>
<TD>
<P>6 months</P>
</TD>
<TD ALIGN="CENTER">
<P>2 (1-5)</P>
</TD>
<TD ALIGN="CENTER">
<P>1 (0-3)</P>
</TD>
<TD ALIGN="CENTER">
<P>1 (0-2.25)</P>
</TD>
</TR>
<TR>
<TD>
<P>12 months</P>
</TD>
<TD ALIGN="CENTER">
<P>1 (0-2)</P>
</TD>
<TD ALIGN="CENTER">
<P>0 (0-2)</P>
</TD>
<TD ALIGN="CENTER">
<P>0 (0-2)</P>
</TD>
</TR>
<TR>
<TD>
<P>
<B>Function </B>(10-point Likert scale)</P>
</TD>
<TD ALIGN="CENTER">
<P/>
</TD>
<TD ALIGN="CENTER">
<P/>
</TD>
<TD ALIGN="CENTER">
<P/>
</TD>
</TR>
<TR>
<TD>
<P>Baseline</P>
</TD>
<TD ALIGN="CENTER">
<P>4 (2-5)</P>
</TD>
<TD ALIGN="CENTER">
<P>4 (2-5)</P>
</TD>
<TD ALIGN="CENTER">
<P>4 (2-5)</P>
</TD>
</TR>
<TR>
<TD>
<P>4 weeks</P>
</TD>
<TD ALIGN="CENTER">
<P>0 (0-2)</P>
</TD>
<TD ALIGN="CENTER">
<P>3 (1-5)</P>
</TD>
<TD ALIGN="CENTER">
<P>2 (1-5)</P>
</TD>
</TR>
<TR>
<TD>
<P>6 months</P>
</TD>
<TD ALIGN="CENTER">
<P>1 (0-3)</P>
</TD>
<TD ALIGN="CENTER">
<P>0 (0-2.75)</P>
</TD>
<TD ALIGN="CENTER">
<P>0.5 (0-2.75)</P>
</TD>
</TR>
<TR>
<TD>
<P>12 months</P>
</TD>
<TD ALIGN="CENTER">
<P>0 (0-2)</P>
</TD>
<TD ALIGN="CENTER">
<P>0 (0-1)</P>
</TD>
<TD ALIGN="CENTER">
<P>0 (0-0)</P>
</TD>
</TR>
</TABLE>
<FOOTNOTES/>
</ADDITIONAL_TABLE>
<ADDITIONAL_TABLE ID="TBL-02" MODIFIED="2013-04-22 13:48:25 -0400" MODIFIED_BY="[Empty name]" NO="2">
<TITLE MODIFIED="2012-05-25 00:01:02 -0400" MODIFIED_BY="[Empty name]">Oral NSAID and bandaging vs bandaging alone vs glucocorticoid injection and bandaging (Ertuk 1997)</TITLE>
<TABLE COLS="4" ROWS="5">
<TR>
<TD ALIGN="CENTER">
<P>
<B>Improvement in outcome at 3 weeks</B>
</P>
</TD>
<TH ALIGN="CENTER">
<P>NSAID+bandage (n = 9)</P>
</TH>
<TH ALIGN="CENTER">
<P>Bandage only (n = 8)</P>
</TH>
<TH ALIGN="CENTER">
<P>Injection+bandage (n = 9)</P>
</TH>
</TR>
<TR>
<TD>
<P/>
</TD>
<TD COLSPAN="3">
<P>Mean change scores, SD not reported</P>
</TD>
</TR>
<TR>
<TD>
<P>Pain at rest (100-mm VAS)</P>
</TD>
<TD ALIGN="CENTER">
<P>-10.78</P>
</TD>
<TD ALIGN="CENTER">
<P>-5.13</P>
</TD>
<TD ALIGN="CENTER">
<P>-10.30</P>
</TD>
</TR>
<TR>
<TD>
<P>Pain during resisted wrist extension (100-mm VAS)</P>
</TD>
<TD ALIGN="CENTER">
<P>-12.56</P>
</TD>
<TD ALIGN="CENTER">
<P>-13.62</P>
</TD>
<TD ALIGN="CENTER">
<P>-40.90</P>
</TD>
</TR>
<TR>
<TD>
<P>Grip strength (kg)</P>
</TD>
<TD ALIGN="CENTER">
<P>1.69</P>
</TD>
<TD ALIGN="CENTER">
<P>0.42</P>
</TD>
<TD ALIGN="CENTER">
<P>5.40</P>
</TD>
</TR>
</TABLE>
<FOOTNOTES/>
</ADDITIONAL_TABLE>
<ADDITIONAL_TABLE ID="TBL-03" MODIFIED="2013-04-22 13:48:27 -0400" MODIFIED_BY="[Empty name]" NO="3">
<TITLE MODIFIED="2012-06-27 01:03:41 -0400" MODIFIED_BY="[Empty name]">One oral NSAID vs another oral NSAID (Adelaar 1987)</TITLE>
<TABLE COLS="3" ROWS="8">
<TR>
<TH>
<P>Outcome</P>
</TH>
<TH>
<P>Naproxen (n = 9)</P>
</TH>
<TH>
<P>Diflunisal (n = 9)</P>
</TH>
</TR>
<TR>
<TD>
<P/>
</TD>
<TD COLSPAN="2">
<P>Mean scores, SD not reported</P>
</TD>
</TR>
<TR>
<TD>
<P>
<B>Pain (participant-reported, scale 0-3)</B>
</P>
</TD>
<TD ALIGN="CENTER">
<P/>
</TD>
<TD ALIGN="CENTER">
<P/>
</TD>
</TR>
<TR>
<TD>
<P>Baseline</P>
</TD>
<TD ALIGN="CENTER">
<P>2.1</P>
</TD>
<TD ALIGN="CENTER">
<P>1.9</P>
</TD>
</TR>
<TR>
<TD>
<P>Post-treatment (time point not specified)</P>
</TD>
<TD ALIGN="CENTER">
<P>1.1</P>
</TD>
<TD ALIGN="CENTER">
<P>0.9</P>
</TD>
</TR>
<TR>
<TD>
<P>
<B>Function (participant-reported, scale 0-3)</B>
</P>
</TD>
<TD ALIGN="CENTER">
<P/>
</TD>
<TD ALIGN="CENTER">
<P/>
</TD>
</TR>
<TR>
<TD>
<P>Baseline</P>
</TD>
<TD ALIGN="CENTER">
<P>1.7</P>
</TD>
<TD ALIGN="CENTER">
<P>1.7</P>
</TD>
</TR>
<TR>
<TD>
<P>Post-treatment (time point not specified)</P>
</TD>
<TD ALIGN="CENTER">
<P>0.7</P>
</TD>
<TD ALIGN="CENTER">
<P>0.4</P>
</TD>
</TR>
</TABLE>
<FOOTNOTES/>
</ADDITIONAL_TABLE>
</ADDITIONAL_TABLES>
<ANALYSES_AND_DATA CALCULATED_DATA="YES" MODIFIED="2013-03-11 03:09:49 -0400" MODIFIED_BY="[Empty name]">
<COMPARISON ID="CMP-001" MODIFIED="2013-03-11 01:08:17 -0400" MODIFIED_BY="[Empty name]" NO="1">
<NAME>Topical NSAIDs versus placebo</NAME>
<CONT_OUTCOME CHI2="2.6923059214345977" CI_END="-0.863949979745798" CI_START="-2.421534544224901" CI_STUDY="95" CI_TOTAL="95" DF="2" EFFECT_MEASURE="MD" EFFECT_SIZE="-1.6427422619853496" ESTIMABLE="YES" I2="25.714236852612274" I2_Q="0.0" ID="CMP-001.01" MODIFIED="2012-08-19 22:13:55 -0400" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="0.26023968185275304" P_Q="1.0" P_Z="3.56128252051803E-5" Q="0.0" RANDOM="YES" SCALE="3.57" SORT_BY="STUDY" STUDIES="3" SUBGROUPS="NO" SUBGROUP_TEST="YES" TAU2="0.13155034065117407" TOTALS="YES" TOTAL_1="78" TOTAL_2="75" UNITS="" WEIGHT="100.0" Z="4.134241880407828">
<NAME>Pain at endpoint of study (10 days to 4 weeks) on 10cm VAS (10=maximum pain)</NAME>
<GROUP_LABEL_1>NSAID</GROUP_LABEL_1>
<GROUP_LABEL_2>Placebo</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours topical NSAID</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours topical placebo</GRAPH_LABEL_2>
<CONT_DATA CI_END="0.019084984974216068" CI_START="-3.0190849849742163" EFFECT_SIZE="-1.5" ESTIMABLE="YES" MEAN_1="2.1" MEAN_2="3.6" MODIFIED="2012-05-23 23:57:36 -0400" MODIFIED_BY="[Empty name]" ORDER="76" SD_1="2.1" SD_2="2.0" SE="0.7750576015460308" STUDY_ID="STD-Burnham-1998" TOTAL_1="14" TOTAL_2="14" WEIGHT="21.561503485208096"/>
<CONT_DATA CI_END="-1.306106082353573" CI_START="-2.893893917646427" EFFECT_SIZE="-2.1" ESTIMABLE="YES" MEAN_1="1.73" MEAN_2="3.83" MODIFIED="2012-05-23 23:57:37 -0400" MODIFIED_BY="[Empty name]" ORDER="77" SD_1="1.84" SD_2="1.89" SE="0.40505536015383997" STUDY_ID="STD-Jenoure-1997" TOTAL_1="44" TOTAL_2="41" WEIGHT="53.40882345346351"/>
<CONT_DATA CI_END="0.5948640064033519" CI_START="-2.174864006403351" EFFECT_SIZE="-0.7899999999999996" ESTIMABLE="YES" MEAN_1="2.99" MEAN_2="3.78" MODIFIED="2012-03-20 03:34:18 -0400" MODIFIED_BY="[Empty name]" ORDER="78" SD_1="2.37" SD_2="2.09" SE="0.70657625207758" STUDY_ID="STD-Spacca-2005" TOTAL_1="20" TOTAL_2="20" WEIGHT="25.0296730613284"/>
</CONT_OUTCOME>
<DICH_OUTCOME CHI2="0.0" CI_END="0.0" CI_START="0.0" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="RR" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="32" EVENTS_2="20" I2="0.0" I2_Q="0.0" ID="CMP-001.02" LOG_CI_END="-Infinity" LOG_CI_START="-Infinity" LOG_EFFECT_SIZE="-Infinity" METHOD="MH" MODIFIED="2012-08-20 01:27:37 -0400" MODIFIED_BY="[Empty name]" NO="2" P_CHI2="0.0" P_Q="0.0" P_Z="0.0" Q="0.0" RANDOM="YES" SCALE="19.25" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="NaN" TOTALS="NO" TOTAL_1="44" TOTAL_2="41" WEIGHT="0.0" Z="0.0">
<NAME>Treatment success (proportion reporting fair, good or excellent overall effectiveness of treatment) at 28 days (14 days of therapy)</NAME>
<GROUP_LABEL_1>NSAID</GROUP_LABEL_1>
<GROUP_LABEL_2>Placebo</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours topical placebo</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours topical NSAID</GRAPH_LABEL_2>
<DICH_DATA CI_END="2.1414624606240533" CI_START="1.0379868702940573" EFFECT_SIZE="1.490909090909091" ESTIMABLE="YES" EVENTS_1="32" EVENTS_2="20" LOG_CI_END="0.33071046571053714" LOG_CI_START="0.016191860068408566" LOG_EFFECT_SIZE="0.17345116288947285" MODIFIED="2012-05-22 07:04:48 -0400" MODIFIED_BY="[Empty name]" ORDER="20" O_E="0.0" SE="0.18474978584639348" STUDY_ID="STD-Jenoure-1997" TOTAL_1="44" TOTAL_2="41" VAR="0.03413248337028825" WEIGHT="0.0"/>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.305843537057186" CI_END="12.140886492877492" CI_START="0.1979253454978619" CI_STUDY="95" CI_TOTAL="95" DF="1" EFFECT_MEASURE="RR" EFFECT_SIZE="1.5501577835024094" ESTIMABLE="YES" EVENTS_1="2" EVENTS_2="1" I2="0.0" I2_Q="0.0" ID="CMP-001.03" LOG_CI_END="1.0842503988404608" LOG_CI_START="-0.7034985882845041" LOG_EFFECT_SIZE="0.19037590527797843" METHOD="MH" MODIFIED="2012-08-20 01:15:00 -0400" MODIFIED_BY="[Empty name]" NO="3" P_CHI2="0.5802421279795524" P_Q="1.0" P_Z="0.6763640081044671" Q="0.0" RANDOM="YES" SCALE="1000.0" SORT_BY="STUDY" STUDIES="3" SUBGROUPS="NO" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="78" TOTAL_2="75" WEIGHT="100.0" Z="0.41742987472655135">
<NAME>Adverse events</NAME>
<GROUP_LABEL_1>NSAID</GROUP_LABEL_1>
<GROUP_LABEL_2>Placebo</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours NSAID</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours Placebo</GRAPH_LABEL_2>
<DICH_DATA CI_END="67.90969947701805" CI_START="0.13252893282270775" EFFECT_SIZE="3.0" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="0" LOG_CI_END="1.8319318085736291" LOG_CI_START="-0.8776892991343044" LOG_EFFECT_SIZE="0.47712125471966244" MODIFIED="2012-03-20 03:40:37 -0400" MODIFIED_BY="[Empty name]" ORDER="79" O_E="0.0" SE="1.5916448515084427" STUDY_ID="STD-Burnham-1998" TOTAL_1="14" TOTAL_2="14" VAR="2.5333333333333328" WEIGHT="43.53072975444204"/>
<DICH_DATA CI_END="14.4160952743426" CI_START="0.060230257045560294" EFFECT_SIZE="0.9318181818181818" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="1" LOG_CI_END="1.1588476438475661" LOG_CI_START="-1.22018528338047" LOG_EFFECT_SIZE="-0.03066881976645196" MODIFIED="2012-05-24 00:42:04 -0400" MODIFIED_BY="[Empty name]" ORDER="80" O_E="0.0" SE="1.3974557178566656" STUDY_ID="STD-Jenoure-1997" TOTAL_1="44" TOTAL_2="41" VAR="1.9528824833702882" WEIGHT="56.46927024555796"/>
<DICH_DATA CI_END="0.0" CI_START="0.0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" MODIFIED="2012-03-20 03:41:09 -0400" MODIFIED_BY="[Empty name]" ORDER="81" O_E="0.0" SE="0.0" STUDY_ID="STD-Spacca-2005" TOTAL_1="20" TOTAL_2="20" VAR="0.0" WEIGHT="0.0"/>
</DICH_OUTCOME>
</COMPARISON>
<COMPARISON ID="CMP-002" MODIFIED="2013-03-11 02:40:04 -0400" MODIFIED_BY="[Empty name]" NO="2">
<NAME>Topical NSAID versus leech therapy</NAME>
<CONT_OUTCOME CHI2="0.0" CI_END="0.0" CI_START="0.0" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="MD" EFFECT_SIZE="0.0" ESTIMABLE="NO" I2="0.0" I2_Q="0.0" ID="CMP-002.01" MODIFIED="2013-03-11 01:25:10 -0400" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="0.0" P_Q="0.0" P_Z="0.0" Q="0.0" RANDOM="YES" SCALE="28.246579621616778" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="YES" SUBGROUP_TEST="NO" TAU2="NaN" TOTALS="NO" TOTAL_1="40" TOTAL_2="40" UNITS="" WEIGHT="0.0" Z="0.0">
<NAME>Overall pain (0 to 300mm VAS)</NAME>
<GROUP_LABEL_1>Diclofenac</GROUP_LABEL_1>
<GROUP_LABEL_2>Leech therapy</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours topical NSAID</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours leech therapy</GRAPH_LABEL_2>
<CONT_SUBGROUP CHI2="0.0" CI_END="0.0" CI_START="0.0" DF="0" EFFECT_SIZE="0.0" ESTIMABLE="NO" I2="0.0" ID="CMP-002.01.01" MODIFIED="2013-03-11 01:25:10 -0400" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="0.0" P_Z="0.0" STUDIES="1" TAU2="0.0" TOTAL_1="20" TOTAL_2="20" WEIGHT="0.0" Z="0.0">
<NAME>7 days</NAME>
<CONT_DATA CI_END="76.1525911715973" CI_START="2.647408828402689" EFFECT_SIZE="39.39999999999999" ESTIMABLE="YES" MEAN_1="134.7" MEAN_2="95.3" MODIFIED="2013-03-11 01:25:10 -0400" MODIFIED_BY="[Empty name]" ORDER="28" SD_1="70.7" SD_2="45.1" SE="18.751666592599175" STUDY_ID="STD-B_x00e4_cker-2011" TOTAL_1="20" TOTAL_2="20" WEIGHT="0.0"/>
</CONT_SUBGROUP>
<CONT_SUBGROUP CHI2="0.0" CI_END="0.0" CI_START="0.0" DF="0" EFFECT_SIZE="0.0" ESTIMABLE="NO" I2="0.0" ID="CMP-002.01.02" MODIFIED="2013-03-11 01:14:18 -0400" MODIFIED_BY="[Empty name]" NO="2" P_CHI2="0.0" P_Z="0.0" STUDIES="1" TAU2="0.0" TOTAL_1="20" TOTAL_2="20" WEIGHT="0.0" Z="0.0">
<NAME>45 days</NAME>
<CONT_DATA CI_END="17.837867363304817" CI_START="-1.8378673633048237" EFFECT_SIZE="7.9999999999999964" ESTIMABLE="YES" MEAN_1="33.3" MEAN_2="25.3" MODIFIED="2013-03-11 01:14:18 -0400" MODIFIED_BY="[Empty name]" ORDER="29" SD_1="16.7" SD_2="15.0" SE="5.0194123161979824" STUDY_ID="STD-B_x00e4_cker-2011" TOTAL_1="20" TOTAL_2="20" WEIGHT="0.0"/>
</CONT_SUBGROUP>
</CONT_OUTCOME>
<CONT_OUTCOME CHI2="0.0" CI_END="0.0" CI_START="0.0" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="MD" EFFECT_SIZE="0.0" ESTIMABLE="NO" I2="0.0" I2_Q="0.0" ID="CMP-002.02" MODIFIED="2013-03-11 02:25:39 -0400" MODIFIED_BY="[Empty name]" NO="2" P_CHI2="0.0" P_Q="0.0" P_Z="0.0" Q="0.0" RANDOM="YES" SCALE="24.363871010690136" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="YES" SUBGROUP_TEST="NO" TAU2="NaN" TOTALS="NO" TOTAL_1="40" TOTAL_2="40" UNITS="" WEIGHT="0.0" Z="0.0">
<NAME>DASH</NAME>
<GROUP_LABEL_1>Diclofenac</GROUP_LABEL_1>
<GROUP_LABEL_2>Leech therapy</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours NSAID</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours leech</GRAPH_LABEL_2>
<CONT_SUBGROUP CHI2="0.0" CI_END="0.0" CI_START="0.0" DF="0" EFFECT_SIZE="0.0" ESTIMABLE="NO" I2="0.0" ID="CMP-002.02.01" MODIFIED="2013-03-11 02:24:56 -0400" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="0.0" P_Z="0.0" STUDIES="1" TAU2="0.0" TOTAL_1="20" TOTAL_2="20" WEIGHT="0.0" Z="0.0">
<NAME>7 days</NAME>
<CONT_DATA CI_END="13.14733378574371" CI_START="-7.147333785743703" EFFECT_SIZE="3.0000000000000036" ESTIMABLE="YES" MEAN_1="34.2" MEAN_2="31.2" MODIFIED="2013-02-24 05:54:03 -0500" MODIFIED_BY="[Empty name]" ORDER="23" SD_1="17.2" SD_2="15.5" SE="5.177306249392632" STUDY_ID="STD-B_x00e4_cker-2011" TOTAL_1="20" TOTAL_2="20" WEIGHT="0.0"/>
</CONT_SUBGROUP>
<CONT_SUBGROUP CHI2="0.0" CI_END="0.0" CI_START="0.0" DF="0" EFFECT_SIZE="0.0" ESTIMABLE="NO" I2="0.0" ID="CMP-002.02.02" MODIFIED="2013-03-11 02:25:05 -0400" MODIFIED_BY="[Empty name]" NO="2" P_CHI2="0.0" P_Z="0.0" STUDIES="1" TAU2="0.0" TOTAL_1="20" TOTAL_2="20" WEIGHT="0.0" Z="0.0">
<NAME>45 days</NAME>
<CONT_DATA CI_END="19.83208402204707" CI_START="1.1679159779529318" EFFECT_SIZE="10.5" ESTIMABLE="YES" MEAN_1="31.9" MEAN_2="21.4" MODIFIED="2013-02-24 05:54:41 -0500" MODIFIED_BY="[Empty name]" ORDER="24" SD_1="15.5" SD_2="14.6" SE="4.761354849199963" STUDY_ID="STD-B_x00e4_cker-2011" TOTAL_1="20" TOTAL_2="20" WEIGHT="0.0"/>
</CONT_SUBGROUP>
</CONT_OUTCOME>
<CONT_OUTCOME CHI2="0.0" CI_END="0.0" CI_START="0.0" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="MD" EFFECT_SIZE="0.0" ESTIMABLE="NO" I2="0.0" I2_Q="0.0" ID="CMP-002.03" MODIFIED="2013-03-11 02:25:18 -0400" MODIFIED_BY="[Empty name]" NO="3" P_CHI2="0.0" P_Q="0.0" P_Z="0.0" Q="0.0" RANDOM="YES" SCALE="15.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="YES" SUBGROUP_TEST="NO" TAU2="NaN" TOTALS="NO" TOTAL_1="40" TOTAL_2="40" UNITS="" WEIGHT="0.0" Z="0.0">
<NAME>Quality of life- physical</NAME>
<GROUP_LABEL_1>Diclofenac</GROUP_LABEL_1>
<GROUP_LABEL_2>Leech therapy</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours leech therapy</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours topical NSAID</GRAPH_LABEL_2>
<CONT_SUBGROUP CHI2="0.0" CI_END="0.0" CI_START="0.0" DF="0" EFFECT_SIZE="0.0" ESTIMABLE="NO" I2="0.0" ID="CMP-002.03.01" MODIFIED="2013-03-11 02:25:12 -0400" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="0.0" P_Z="0.0" STUDIES="1" TAU2="0.0" TOTAL_1="20" TOTAL_2="20" WEIGHT="0.0" Z="0.0">
<NAME>7 days</NAME>
<CONT_DATA CI_END="4.830038979197" CI_START="-4.430038979196994" EFFECT_SIZE="0.20000000000000284" ESTIMABLE="YES" MEAN_1="42.1" MEAN_2="41.9" MODIFIED="2013-02-24 05:57:11 -0500" MODIFIED_BY="[Empty name]" ORDER="26" SD_1="6.9" SD_2="8.0" SE="2.362308193271996" STUDY_ID="STD-B_x00e4_cker-2011" TOTAL_1="20" TOTAL_2="20" WEIGHT="0.0"/>
</CONT_SUBGROUP>
<CONT_SUBGROUP CHI2="0.0" CI_END="0.0" CI_START="0.0" DF="0" EFFECT_SIZE="0.0" ESTIMABLE="NO" I2="0.0" ID="CMP-002.03.02" MODIFIED="2013-03-11 02:25:18 -0400" MODIFIED_BY="[Empty name]" NO="2" P_CHI2="0.0" P_Z="0.0" STUDIES="1" TAU2="0.0" TOTAL_1="20" TOTAL_2="20" WEIGHT="0.0" Z="0.0">
<NAME>45 days</NAME>
<CONT_DATA CI_END="5.175243382942709" CI_START="-4.175243382942709" EFFECT_SIZE="0.5" ESTIMABLE="YES" MEAN_1="46.1" MEAN_2="45.6" MODIFIED="2013-02-24 05:57:44 -0500" MODIFIED_BY="[Empty name]" ORDER="25" SD_1="5.4" SD_2="9.2" SE="2.3853720883753127" STUDY_ID="STD-B_x00e4_cker-2011" TOTAL_1="20" TOTAL_2="20" WEIGHT="0.0"/>
</CONT_SUBGROUP>
</CONT_OUTCOME>
<CONT_OUTCOME CHI2="0.0" CI_END="0.0" CI_START="0.0" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="MD" EFFECT_SIZE="0.0" ESTIMABLE="NO" I2="0.0" I2_Q="0.0" ID="CMP-002.04" MODIFIED="2013-03-11 02:35:37 -0400" MODIFIED_BY="[Empty name]" NO="4" P_CHI2="0.0" P_Q="0.0" P_Z="0.0" Q="0.0" RANDOM="NO" SCALE="100.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="YES" SUBGROUP_TEST="NO" TAU2="0.0" TOTALS="NO" TOTAL_1="40" TOTAL_2="40" UNITS="" WEIGHT="0.0" Z="0.0">
<NAME>Maximum peak grip strength</NAME>
<GROUP_LABEL_1>Diclofenac</GROUP_LABEL_1>
<GROUP_LABEL_2>Leech therapy</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours leech therapy</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours topical NSAID</GRAPH_LABEL_2>
<CONT_SUBGROUP CHI2="0.0" CI_END="0.0" CI_START="0.0" DF="0" EFFECT_SIZE="0.0" ESTIMABLE="NO" I2="0.0" ID="CMP-002.04.01" MODIFIED="2013-03-11 02:34:14 -0400" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="0.0" P_Z="0.0" STUDIES="1" TAU2="0.0" TOTAL_1="20" TOTAL_2="20" WEIGHT="0.0" Z="0.0">
<NAME>7 days</NAME>
<CONT_DATA CI_END="34.00892559761544" CI_START="-38.208925597615455" EFFECT_SIZE="-2.1000000000000085" ESTIMABLE="YES" MEAN_1="65.8" MEAN_2="67.9" MODIFIED="2013-03-11 02:34:14 -0400" MODIFIED_BY="[Empty name]" ORDER="32" SD_1="59.3" SD_2="57.2" SE="18.4232597549945" STUDY_ID="STD-B_x00e4_cker-2011" TOTAL_1="20" TOTAL_2="20" WEIGHT="0.0"/>
</CONT_SUBGROUP>
<CONT_SUBGROUP CHI2="0.0" CI_END="0.0" CI_START="0.0" DF="0" EFFECT_SIZE="0.0" ESTIMABLE="NO" I2="0.0" ID="CMP-002.04.02" MODIFIED="2013-03-11 02:34:33 -0400" MODIFIED_BY="[Empty name]" NO="2" P_CHI2="0.0" P_Z="0.0" STUDIES="1" TAU2="0.0" TOTAL_1="20" TOTAL_2="20" WEIGHT="0.0" Z="0.0">
<NAME>45 days</NAME>
<CONT_DATA CI_END="29.708467635615982" CI_START="-52.10846763561599" EFFECT_SIZE="-11.200000000000003" ESTIMABLE="YES" MEAN_1="70.1" MEAN_2="81.3" MODIFIED="2013-03-11 02:34:33 -0400" MODIFIED_BY="[Empty name]" ORDER="33" SD_1="63.3" SD_2="68.6" SE="20.872050689857954" STUDY_ID="STD-B_x00e4_cker-2011" TOTAL_1="20" TOTAL_2="20" WEIGHT="0.0"/>
</CONT_SUBGROUP>
</CONT_OUTCOME>
<DICH_OUTCOME CHI2="0.0" CI_END="0.0" CI_START="0.0" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="RR" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="1" EVENTS_2="10" I2="0.0" I2_Q="0.0" ID="CMP-002.05" LOG_CI_END="-Infinity" LOG_CI_START="-Infinity" LOG_EFFECT_SIZE="-Infinity" METHOD="MH" MODIFIED="2013-03-11 02:40:04 -0400" MODIFIED_BY="[Empty name]" NO="5" P_CHI2="0.0" P_Q="0.0" P_Z="0.0" Q="0.0" RANDOM="NO" SCALE="2.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="NO" TOTAL_1="20" TOTAL_2="20" WEIGHT="0.0" Z="0.0">
<NAME>Adverse events- local skin reaction</NAME>
<GROUP_LABEL_1>Diclofenac</GROUP_LABEL_1>
<GROUP_LABEL_2>Leech therapy</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours topical NSAID</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours leech therapy</GRAPH_LABEL_2>
<DICH_DATA CI_END="0.7099071384231338" CI_START="0.014086349409321746" EFFECT_SIZE="0.1" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="10" LOG_CI_END="-0.14879845678514395" LOG_CI_START="-1.8512015432148559" LOG_EFFECT_SIZE="-1.0" MODIFIED="2013-02-24 05:59:37 -0500" MODIFIED_BY="[Empty name]" ORDER="27" O_E="0.0" SE="1.0" STUDY_ID="STD-B_x00e4_cker-2011" TOTAL_1="20" TOTAL_2="20" VAR="1.0" WEIGHT="0.0"/>
</DICH_OUTCOME>
</COMPARISON>
<COMPARISON ID="CMP-003" MODIFIED="2013-03-11 01:10:24 -0400" MODIFIED_BY="[Empty name]" NO="3">
<NAME>Oral NSAIDs versus placebo</NAME>
<CONT_OUTCOME CHI2="0.0" CI_END="0.0" CI_START="0.0" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="MD" EFFECT_SIZE="0.0" ESTIMABLE="NO" I2="0.0" I2_Q="0.0" ID="CMP-003.01" MODIFIED="2012-08-26 21:04:51 -0400" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="0.0" P_Q="0.0" P_Z="0.0" Q="0.0" RANDOM="YES" SCALE="35.35" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="NO" TAU2="NaN" TOTALS="NO" TOTAL_1="64" TOTAL_2="64" UNITS="" WEIGHT="0.0" Z="0.0">
<NAME>Improvement in pain (100mm vertical VAS) at endpoint of study (28 days)</NAME>
<GROUP_LABEL_1>Oral Diclofenac</GROUP_LABEL_1>
<GROUP_LABEL_2>Placebo</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours oral NSAID</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours Placebo</GRAPH_LABEL_2>
<CONT_DATA CI_END="-4.595169033717079" CI_START="-23.20483096628292" EFFECT_SIZE="-13.899999999999999" ESTIMABLE="YES" MEAN_1="-29.9" MEAN_2="-16.0" ORDER="18" SD_1="26.3" SD_2="27.4" SE="4.747449973406776" STUDY_ID="STD-Labelle-1997" TOTAL_1="64" TOTAL_2="64" WEIGHT="0.0"/>
</CONT_OUTCOME>
<CONT_OUTCOME CHI2="0.0" CI_END="0.0" CI_START="0.0" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="MD" EFFECT_SIZE="0.0" ESTIMABLE="NO" I2="0.0" I2_Q="0.0" ID="CMP-003.02" MODIFIED="2012-05-24 01:08:06 -0400" MODIFIED_BY="[Empty name]" NO="2" P_CHI2="0.0" P_Q="0.0" P_Z="0.0" Q="0.0" RANDOM="NO" SCALE="35.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="NO" TAU2="0.0" TOTALS="NO" TOTAL_1="64" TOTAL_2="64" UNITS="" WEIGHT="0.0" Z="0.0">
<NAME>Improvement in function (100mm vertical VAS at endpoint of study (28 days)</NAME>
<GROUP_LABEL_1>Oral Diclofenac</GROUP_LABEL_1>
<GROUP_LABEL_2>Placebo</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours Placebo</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours oral NSAID</GRAPH_LABEL_2>
<CONT_DATA CI_END="6.526030015350132" CI_START="-13.126030015350134" EFFECT_SIZE="-3.3000000000000007" ESTIMABLE="YES" MEAN_1="18.5" MEAN_2="21.8" ORDER="19" SD_1="29.1" SD_2="27.6" SE="5.013372741977201" STUDY_ID="STD-Labelle-1997" TOTAL_1="64" TOTAL_2="64" WEIGHT="0.0"/>
</CONT_OUTCOME>
<CONT_OUTCOME CHI2="0.0" CI_END="0.0" CI_START="0.0" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="MD" EFFECT_SIZE="0.0" ESTIMABLE="NO" I2="0.0" I2_Q="0.0" ID="CMP-003.03" MODIFIED="2012-05-24 01:08:29 -0400" MODIFIED_BY="[Empty name]" NO="3" P_CHI2="0.0" P_Q="0.0" P_Z="0.0" Q="0.0" RANDOM="NO" SCALE="35.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="NO" TAU2="0.0" TOTALS="NO" TOTAL_1="64" TOTAL_2="64" UNITS="" WEIGHT="0.0" Z="0.0">
<NAME>Improvement in pain-free maximum grip strength (kg) at endpoint of study (28 days)</NAME>
<GROUP_LABEL_1>Oral Diclofenac</GROUP_LABEL_1>
<GROUP_LABEL_2>Placebo</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours Placebo</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours oral NSAID</GRAPH_LABEL_2>
<CONT_DATA CI_END="6.047827484986179" CI_START="-0.8478274849861784" EFFECT_SIZE="2.6000000000000005" ESTIMABLE="YES" MEAN_1="7.2" MEAN_2="4.6" MODIFIED="2012-03-22 01:19:44 -0400" MODIFIED_BY="[Empty name]" ORDER="17" SD_1="9.8" SD_2="10.1" SE="1.7591279799946336" STUDY_ID="STD-Labelle-1997" TOTAL_1="64" TOTAL_2="64" WEIGHT="0.0"/>
</CONT_OUTCOME>
<DICH_OUTCOME CHI2="0.0" CI_END="0.0" CI_START="0.0" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="RR" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="30" EVENTS_2="28" I2="0.0" I2_Q="0.0" ID="CMP-003.04" LOG_CI_END="-Infinity" LOG_CI_START="-Infinity" LOG_EFFECT_SIZE="-Infinity" METHOD="MH" MODIFIED="2012-08-20 22:40:42 -0400" MODIFIED_BY="[Empty name]" NO="4" P_CHI2="0.0" P_Q="0.0" P_Z="0.0" Q="0.0" RANDOM="YES" SCALE="33.53618139687021" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="NaN" TOTALS="NO" TOTAL_1="53" TOTAL_2="58" WEIGHT="0.0" Z="0.0">
<NAME>Treatment success (complete recovery or improved) at 4 weeks</NAME>
<GROUP_LABEL_1>Oral Naproxen</GROUP_LABEL_1>
<GROUP_LABEL_2>Placebo</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours Placebo</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours oral NSAID</GRAPH_LABEL_2>
<DICH_DATA CI_END="1.6733978260008433" CI_START="0.8215452599324146" EFFECT_SIZE="1.1725067385444743" ESTIMABLE="YES" EVENTS_1="30" EVENTS_2="28" LOG_CI_END="0.22359920043524942" LOG_CI_START="-0.08536850575606657" LOG_EFFECT_SIZE="0.06911534733959142" MODIFIED="2012-03-22 01:51:15 -0400" MODIFIED_BY="[Empty name]" ORDER="29" O_E="0.0" SE="0.1814891600315907" STUDY_ID="STD-Hay-1999" TOTAL_1="53" TOTAL_2="58" VAR="0.03293831520897234" WEIGHT="0.0"/>
</DICH_OUTCOME>
</COMPARISON>
<COMPARISON ID="CMP-004" MODIFIED="2013-03-11 01:10:24 -0400" MODIFIED_BY="[Empty name]" NO="4">
<NAME>Oral NSAIDs versus glucocorticoid injection</NAME>
<DICH_OUTCOME CHI2="2.1855988480293282" CI_END="1.263120868407157" CI_START="0.4315013827001798" CI_STUDY="95" CI_TOTAL="95" DF="1" EFFECT_MEASURE="RR" EFFECT_SIZE="0.7382671611518017" ESTIMABLE="YES" EVENTS_1="36" EVENTS_2="54" I2="54.24594952995779" I2_Q="0.0" ID="CMP-004.01" LOG_CI_END="0.10144491031041715" LOG_CI_START="-0.3650178082961735" LOG_EFFECT_SIZE="-0.13178644899287809" METHOD="MH" MODIFIED="2012-08-20 22:58:51 -0400" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="0.13930695048301656" P_Q="1.0" P_Z="0.2680908672931207" Q="0.0" RANDOM="YES" SCALE="6.533393376299625" SORT_BY="STUDY" STUDIES="2" SUBGROUPS="NO" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.09395409395952167" TOTALS="YES" TOTAL_1="63" TOTAL_2="63" WEIGHT="100.0" Z="1.1074698293061682">
<NAME>Treatment success (complete recovery or improved) at 2 or 4 weeks</NAME>
<GROUP_LABEL_1>Favours Injection</GROUP_LABEL_1>
<GROUP_LABEL_2>Glucocorticoid Injection</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours Injection</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours NSAID</GRAPH_LABEL_2>
<DICH_DATA CI_END="0.7861499304496625" CI_START="0.4783101560422936" EFFECT_SIZE="0.6132075471698113" ESTIMABLE="YES" EVENTS_1="30" EVENTS_2="48" LOG_CI_END="-0.10449461966356487" LOG_CI_START="-0.3202903975802645" LOG_EFFECT_SIZE="-0.21239250862191467" MODIFIED="2012-05-24 22:42:44 -0400" MODIFIED_BY="[Empty name]" ORDER="39" O_E="0.0" SE="0.12675950815459783" STUDY_ID="STD-Hay-1999" TOTAL_1="53" TOTAL_2="52" VAR="0.016067972907595554" WEIGHT="68.23847032665448"/>
<DICH_DATA CI_END="2.3047763957798635" CI_START="0.5249966991225518" EFFECT_SIZE="1.1" ESTIMABLE="YES" EVENTS_1="6" EVENTS_2="6" LOG_CI_END="0.36262879749595595" LOG_CI_START="-0.2798434271795057" LOG_EFFECT_SIZE="0.04139268515822507" MODIFIED="2012-05-21 21:06:09 -0400" MODIFIED_BY="[Empty name]" ORDER="40" O_E="0.0" SE="0.3773913650631694" STUDY_ID="STD-Saartok-1986" TOTAL_1="10" TOTAL_2="11" VAR="0.1424242424242424" WEIGHT="31.761529673345528"/>
</DICH_OUTCOME>
<CONT_OUTCOME CHI2="0.0" CI_END="0.0" CI_START="0.0" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="MD" EFFECT_SIZE="0.0" ESTIMABLE="NO" I2="0.0" I2_Q="0.0" ID="CMP-004.02" MODIFIED="2012-05-25 02:16:04 -0400" MODIFIED_BY="[Empty name]" NO="2" P_CHI2="0.0" P_Q="0.0" P_Z="0.0" Q="0.0" RANDOM="NO" SCALE="52.34790514395712" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="NO" TAU2="0.0" TOTALS="NO" TOTAL_1="9" TOTAL_2="9" UNITS="" WEIGHT="0.0" Z="0.0">
<NAME>Change in grip strength (kPa)</NAME>
<GROUP_LABEL_1>Oral Naproxen</GROUP_LABEL_1>
<GROUP_LABEL_2>Betamethasone</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours Injection</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours Naproxen</GRAPH_LABEL_2>
<CONT_DATA CI_END="21.610317907421297" CI_START="-39.6103179074213" EFFECT_SIZE="-9.0" ESTIMABLE="YES" MEAN_1="75.0" MEAN_2="84.0" ORDER="42" SD_1="36.8" SD_2="29.0" SE="15.617796117108059" STUDY_ID="STD-Saartok-1986" TOTAL_1="9" TOTAL_2="9" WEIGHT="0.0"/>
</CONT_OUTCOME>
</COMPARISON>
<COMPARISON ID="CMP-005" MODIFIED="2013-03-11 03:09:49 -0400" MODIFIED_BY="[Empty name]" NO="5">
<NAME>Oral NSAIDs versus vasodilator</NAME>
<CONT_OUTCOME CHI2="0.0" CI_END="0.0" CI_START="0.0" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="MD" EFFECT_SIZE="0.0" ESTIMABLE="NO" I2="0.0" I2_Q="0.0" ID="CMP-005.01" MODIFIED="2013-03-11 03:06:24 -0400" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="0.0" P_Q="0.0" P_Z="0.0" Q="0.0" RANDOM="YES" SCALE="7.652667178725868" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="YES" SUBGROUP_TEST="NO" TAU2="NaN" TOTALS="NO" TOTAL_1="44" TOTAL_2="66" UNITS="" WEIGHT="0.0" Z="0.0">
<NAME>Pain (0 to 10 VAS)</NAME>
<GROUP_LABEL_1>Oral NSAID</GROUP_LABEL_1>
<GROUP_LABEL_2>Vasodilator</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours oral NSAID</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours vasodilator</GRAPH_LABEL_2>
<CONT_SUBGROUP CHI2="0.0" CI_END="0.0" CI_START="0.0" DF="0" EFFECT_SIZE="0.0" ESTIMABLE="NO" I2="0.0" ID="CMP-005.01.01" MODIFIED="2013-03-11 03:06:16 -0400" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="0.0" P_Z="0.0" STUDIES="1" TAU2="0.0" TOTAL_1="22" TOTAL_2="33" WEIGHT="0.0" Z="0.0">
<NAME>10 days</NAME>
<CONT_DATA CI_END="4.423068349333894" CI_START="2.7969316506661057" EFFECT_SIZE="3.61" ESTIMABLE="YES" MEAN_1="6.0" MEAN_2="2.39" MODIFIED="2013-02-24 20:09:34 -0500" MODIFIED_BY="[Empty name]" ORDER="31" SD_1="1.38" SD_2="1.68" SE="0.41483841322966836" STUDY_ID="STD-Polat-2011" TOTAL_1="22" TOTAL_2="33" WEIGHT="0.0"/>
</CONT_SUBGROUP>
<CONT_SUBGROUP CHI2="0.0" CI_END="0.0" CI_START="0.0" DF="0" EFFECT_SIZE="0.0" ESTIMABLE="NO" I2="0.0" ID="CMP-005.01.02" MODIFIED="2013-03-11 03:06:24 -0400" MODIFIED_BY="[Empty name]" NO="2" P_CHI2="0.0" P_Z="0.0" STUDIES="1" TAU2="0.0" TOTAL_1="22" TOTAL_2="33" WEIGHT="0.0" Z="0.0">
<NAME>6 months</NAME>
<CONT_DATA CI_END="4.147234746319376" CI_START="2.7927652536806256" EFFECT_SIZE="3.4700000000000006" ESTIMABLE="YES" MEAN_1="4.86" MEAN_2="1.39" MODIFIED="2013-02-24 20:10:13 -0500" MODIFIED_BY="[Empty name]" ORDER="30" SD_1="1.08" SD_2="1.48" SE="0.34553428106909945" STUDY_ID="STD-Polat-2011" TOTAL_1="22" TOTAL_2="33" WEIGHT="0.0"/>
</CONT_SUBGROUP>
</CONT_OUTCOME>
</COMPARISON>
<COMPARISON ID="CMP-006" MODIFIED="2013-03-11 03:09:49 -0400" MODIFIED_BY="[Empty name]" NO="6">
<NAME>Oral Diflusinal versus oral Naproxen</NAME>
<DICH_OUTCOME CHI2="0.8050462863149064" CI_END="1.6223727671521193" CI_START="0.8756054637235667" CI_STUDY="95" CI_TOTAL="95" DF="1" EFFECT_MEASURE="RR" EFFECT_SIZE="1.191871829986227" ESTIMABLE="YES" EVENTS_1="23" EVENTS_2="19" I2="0.0" I2_Q="0.0" ID="CMP-006.01" LOG_CI_END="0.21015064772793124" LOG_CI_START="-0.05769153712512877" LOG_EFFECT_SIZE="0.07622955530140124" METHOD="MH" MODIFIED="2012-05-25 03:04:57 -0400" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="0.3695889368883507" P_Q="1.0" P_Z="0.2645780223454708" Q="0.0" RANDOM="YES" SCALE="5.92" SORT_BY="STUDY" STUDIES="2" SUBGROUPS="NO" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="28" TOTAL_2="28" WEIGHT="100.0" Z="1.115635933377833">
<NAME>Treatment success defined as no remaining symptoms or improved at 2 weeks</NAME>
<GROUP_LABEL_1>Diflusinal</GROUP_LABEL_1>
<GROUP_LABEL_2>Naproxen</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours Diflusinal</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours Naproxen</GRAPH_LABEL_2>
<DICH_DATA CI_END="1.6386365154557931" CI_START="0.6102634663440574" EFFECT_SIZE="1.0" ESTIMABLE="YES" EVENTS_1="7" EVENTS_2="7" LOG_CI_END="0.21448262847056265" LOG_CI_START="-0.21448262847056268" LOG_EFFECT_SIZE="0.0" MODIFIED="2012-05-21 19:27:39 -0400" MODIFIED_BY="[Empty name]" ORDER="45" O_E="0.0" SE="0.25197631533948484" STUDY_ID="STD-Adelaar-1987" TOTAL_1="9" TOTAL_2="9" VAR="0.06349206349206349" WEIGHT="38.986452584044144"/>
<DICH_DATA CI_END="1.9787370585917972" CI_START="0.8984406341704462" EFFECT_SIZE="1.3333333333333333" ESTIMABLE="YES" EVENTS_1="16" EVENTS_2="12" LOG_CI_END="0.2963880874911073" LOG_CI_START="-0.04651061427450744" LOG_EFFECT_SIZE="0.12493873660829992" MODIFIED="2012-05-25 02:52:35 -0400" MODIFIED_BY="[Empty name]" ORDER="46" O_E="0.0" SE="0.20142039479307075" STUDY_ID="STD-Stull-1986" TOTAL_1="19" TOTAL_2="19" VAR="0.04057017543859648" WEIGHT="61.01354741595585"/>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.8881062311978488" CI_END="2.046016847515241" CI_START="0.9587445737363759" CI_STUDY="95" CI_TOTAL="95" DF="1" EFFECT_MEASURE="RR" EFFECT_SIZE="1.400574007444249" ESTIMABLE="YES" EVENTS_1="21" EVENTS_2="14" I2="0.0" I2_Q="0.0" ID="CMP-006.02" LOG_CI_END="0.3109092055016441" LOG_CI_START="-0.01829708103828797" LOG_EFFECT_SIZE="0.14630606223167805" METHOD="MH" MODIFIED="2012-05-31 20:11:52 -0400" MODIFIED_BY="[Empty name]" NO="2" P_CHI2="0.34599112707318" P_Q="1.0" P_Z="0.08149150369599856" Q="0.0" RANDOM="YES" SCALE="155.08" SORT_BY="STUDY" STUDIES="2" SUBGROUPS="NO" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="28" TOTAL_2="28" WEIGHT="100.0" Z="1.74209682146627">
<NAME>Treatment success defined as excellent, very good or good overall pain relief at 2 weeks</NAME>
<GROUP_LABEL_1>Diflusinal</GROUP_LABEL_1>
<GROUP_LABEL_2>Naproxen</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours Naproxen</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours Diflunisal</GRAPH_LABEL_2>
<DICH_DATA CI_END="9.689537280987865" CI_START="0.6450256414476381" EFFECT_SIZE="2.5" ESTIMABLE="YES" EVENTS_1="5" EVENTS_2="2" LOG_CI_END="0.9863030380299346" LOG_CI_START="-0.19042302068585934" LOG_EFFECT_SIZE="0.3979400086720376" MODIFIED="2012-05-21 19:28:38 -0400" MODIFIED_BY="[Empty name]" ORDER="47" O_E="0.0" SE="0.6912147117775906" STUDY_ID="STD-Adelaar-1987" TOTAL_1="9" TOTAL_2="9" VAR="0.4777777777777777" WEIGHT="7.826822733041883"/>
<DICH_DATA CI_END="1.9787370585917972" CI_START="0.8984406341704462" EFFECT_SIZE="1.3333333333333333" ESTIMABLE="YES" EVENTS_1="16" EVENTS_2="12" LOG_CI_END="0.2963880874911073" LOG_CI_START="-0.04651061427450744" LOG_EFFECT_SIZE="0.12493873660829992" MODIFIED="2012-05-25 02:40:42 -0400" MODIFIED_BY="[Empty name]" ORDER="48" O_E="0.0" SE="0.20142039479307075" STUDY_ID="STD-Stull-1986" TOTAL_1="19" TOTAL_2="19" VAR="0.04057017543859648" WEIGHT="92.17317726695812"/>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.022938889422492857" CI_END="20.65967038169653" CI_START="0.6453433470572372" CI_STUDY="95" CI_TOTAL="95" DF="1" EFFECT_MEASURE="RR" EFFECT_SIZE="3.6513806749260347" ESTIMABLE="YES" EVENTS_1="5" EVENTS_2="1" I2="0.0" I2_Q="0.0" ID="CMP-006.03" LOG_CI_END="1.3151233882120483" LOG_CI_START="-0.1902091627938364" LOG_EFFECT_SIZE="0.562457112709106" METHOD="MH" MODIFIED="2012-05-31 20:12:25 -0400" MODIFIED_BY="[Empty name]" NO="3" P_CHI2="0.8796161105110095" P_Q="1.0" P_Z="0.1430153365013026" Q="0.0" RANDOM="YES" SCALE="100.0" SORT_BY="STUDY" STUDIES="2" SUBGROUPS="NO" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="28" TOTAL_2="28" WEIGHT="100.0" Z="1.4646540168437827">
<NAME>Number of participants experiencing any adverse effects</NAME>
<GROUP_LABEL_1>Diflusinal</GROUP_LABEL_1>
<GROUP_LABEL_2>Naproxen</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours naproxen</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours diflunisal</GRAPH_LABEL_2>
<DICH_DATA CI_END="65.16081469815073" CI_START="0.13811982004355478" EFFECT_SIZE="3.0" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="0" LOG_CI_END="1.8139865056042341" LOG_CI_START="-0.8597439961649094" LOG_EFFECT_SIZE="0.47712125471966244" MODIFIED="2012-05-25 03:10:21 -0400" MODIFIED_BY="[Empty name]" ORDER="19" O_E="0.0" SE="1.5705625319186327" STUDY_ID="STD-Adelaar-1987" TOTAL_1="9" TOTAL_2="9" VAR="2.4666666666666663" WEIGHT="31.697838231722134"/>
<DICH_DATA CI_END="32.56722412436301" CI_START="0.4912914879973039" EFFECT_SIZE="4.0" ESTIMABLE="YES" EVENTS_1="4" EVENTS_2="1" LOG_CI_END="1.5127807429416706" LOG_CI_START="-0.3086607602857459" LOG_EFFECT_SIZE="0.6020599913279624" MODIFIED="2012-05-31 20:08:27 -0400" MODIFIED_BY="[Empty name]" ORDER="21" O_E="0.0" SE="1.069923755276638" STUDY_ID="STD-Stull-1986" TOTAL_1="19" TOTAL_2="19" VAR="1.1447368421052633" WEIGHT="68.30216176827787"/>
</DICH_OUTCOME>
</COMPARISON>
</ANALYSES_AND_DATA>
<FIGURES MODIFIED="2013-04-22 21:39:45 -0400" MODIFIED_BY="Porjai Pattanittum">
<FIGURE FILENAME="Flowchart2013.jpg" FILE_TYPE="JPG" ID="FIG-01" MODIFIED="2013-04-21 21:44:11 -0400" MODIFIED_BY="[Empty name]" NO="1" SHORT_VERSION_FIGURE="YES" TYPE="OTHER">
<CAPTION>
<P>Results of screening for studies that met inclusion criteria.
</P>
</CAPTION>
<FILE>/9j/4AAQSkZJRgABAgAAAQABAAD/2wBDAAgGBgcGBQgHBwcJCQgKDBQNDAsLDBkSEw8UHRofHh0a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</FILE>
</FIGURE>
<FIGURE FILENAME="Risk of bias graph.png" FILE_TYPE="PNG" ID="FIG-02" MODIFIED="2013-04-22 21:39:45 -0400" MODIFIED_BY="Porjai Pattanittum" NO="2" SHORT_VERSION_FIGURE="YES" TYPE="QUALITY_GRAPH_PLOT">
<CAPTION>
<P>Risk of bias across all trials: review authors' judgements for each risk of bias item presented as percentages across all included trials.
</P>
</CAPTION>
<FILE>iVBORw0KGgoAAAANSUhEUgAAAiMAAADnCAMAAAD7EqYIAAADAFBMVEUAAADAAAAAwAAAAMDg4ADA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</FILE>
</FIGURE>
<FIGURE FILENAME="Risk of bias summary.png" FILE_TYPE="PNG" ID="FIG-03" MODIFIED="2013-04-22 21:39:45 -0400" MODIFIED_BY="Porjai Pattanittum" NO="3" SHORT_VERSION_FIGURE="YES" TYPE="QUALITY_TABLE_PLOT">
<CAPTION>
<P>Risk of bias summary: review authors' judgements about each risk of bias item for each included trial.</P>
</CAPTION>
<FILE>iVBORw0KGgoAAAANSUhEUgAAAR8AAALcCAIAAABRoSOdAAAk4klEQVR42u2dsW4kudWFG3DioAMF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</FILE>
</FIGURE>
</FIGURES>
<FEEDBACK MODIFIED="2012-08-22 00:18:44 -0400" MODIFIED_BY="[Empty name]"/>
<APPENDICES MODIFIED="2012-08-22 00:23:01 -0400" MODIFIED_BY="[Empty name]">
<APPENDIX ID="APP-01" MODIFIED="2012-08-22 00:20:18 -0400" MODIFIED_BY="[Empty name]" NO="1">
<TITLE MODIFIED="2012-08-22 00:19:39 -0400" MODIFIED_BY="[Empty name]">MEDLINE search strategy</TITLE>
<APPENDIX_BODY MODIFIED="2012-08-22 00:20:18 -0400" MODIFIED_BY="[Empty name]">
<P>1. exp Tendinopathy/</P>
<P>2. exp Tendon Injuries/</P>
<P>3. (Tendinitis or Tendinosis or Tendonitis).tw.</P>
<P>4. or/1-3</P>
<P>5. Elbow Joint/</P>
<P>6. elbow$.tw.</P>
<P>7. 5 or 6</P>
<P>8. exp Pain/</P>
<P>9. pain$.tw.</P>
<P>10. 8 or 9</P>
<P>11. 7 and (4 or 10)</P>
<P>12. Tennis Elbow/</P>
<P>13. tennis elbow.tw.</P>
<P>14. common extensor origin.tw.</P>
<P>15. (epicondylalgia or epicondylitis).tw.</P>
<P>16. or/11-15</P>
<P>17. randomized controlled trial.pt.</P>
<P>18. controlled clinical trial.pt.</P>
<P>19. randomized.ab.</P>
<P>20. placebo.ab.</P>
<P>21. drug therapy.fs.</P>
<P>22. randomly.ab.</P>
<P>23. trial.ab.</P>
<P>24. groups.ab.</P>
<P>25. or/17-24</P>
<P>26. (animals not (humans and animals)).sh.</P>
<P>27. 25 not 26</P>
<P>28. 16 and 27</P>
</APPENDIX_BODY>
</APPENDIX>
<APPENDIX ID="APP-02" MODIFIED="2012-08-22 00:21:41 -0400" MODIFIED_BY="[Empty name]" NO="2">
<TITLE MODIFIED="2012-08-22 00:21:41 -0400" MODIFIED_BY="[Empty name]">EMBASE search strategy</TITLE>
<APPENDIX_BODY MODIFIED="2012-08-22 00:21:27 -0400" MODIFIED_BY="[Empty name]">
<P>1. exp Tendinitis/</P>
<P>2. exp Tendon Injury/</P>
<P>3. (Tendinitis or Tendinosis or Tendonitis).tw.</P>
<P>4. or/1-3</P>
<P>5. Elbow/</P>
<P>6. elbow$.tw.</P>
<P>7. 5 or 6</P>
<P>8. exp pain/</P>
<P>9. pain$.tw.</P>
<P>10. 8 or 9</P>
<P>11. 7 and (4 or 10)</P>
<P>12. tennis elbow/</P>
<P>13. tennis elbow.tw.</P>
<P>14. common extensor origin.tw.</P>
<P>15. (epicondylalgia or epicondylitis).tw.</P>
<P>16. or/11-15</P>
<P>17. (random$ or placebo$).ti,ab.</P>
<P>18. ((single$ or double$ or triple$ or treble$) and (blind$ or mask$)).ti,ab.</P>
<P>19. controlled clinical trial$.ti,ab.</P>
<P>20. RETRACTED ARTICLE/</P>
<P>21. or/17-20</P>
<P>22. (animal$ not human$).sh,hw.</P>
<P>23. 21 not 22</P>
<P>24. 16 and 23</P>
</APPENDIX_BODY>
</APPENDIX>
<APPENDIX ID="APP-03" MODIFIED="2012-08-22 00:22:01 -0400" MODIFIED_BY="[Empty name]" NO="3">
<TITLE MODIFIED="2012-08-22 00:21:13 -0400" MODIFIED_BY="[Empty name]">CENTRAL search strategy</TITLE>
<APPENDIX_BODY MODIFIED="2012-08-22 00:22:01 -0400" MODIFIED_BY="[Empty name]">
<P>#1             MeSH descriptor Tendinopathy explode all trees</P>
<P>#2             MeSH descriptor Tendon Injuries explode all trees</P>
<P>#3             (Tendinitis or Tendinosis or Tendonitis):ti,ab</P>
<P>#4             (#1 OR #2 OR #3)</P>
<P>#5             MeSH descriptor Elbow Joint, this term only</P>
<P>#6             elbow*:ti,ab</P>
<P>#7             (#5 OR #6)</P>
<P>#8             MeSH descriptor Pain explode all trees</P>
<P>#9             pain*:ti,ab</P>
<P>#10          (#8 OR #9)</P>
<P>#11          (#7 AND ( #4 OR #10 ))</P>
<P>#12          MeSH descriptor Tennis Elbow, this term only</P>
<P>#13          "tennis elbow":ti,ab</P>
<P>#14          epicondylitis:ti,ab</P>
<P>#15          "common extensor origin":ti,ab</P>
<P>#16          epicondylalgia:ti,ab</P>
<P>#17          (#11 OR #12 OR #13 OR #14 OR #15 OR #16)</P>
</APPENDIX_BODY>
</APPENDIX>
<APPENDIX ID="APP-04" MODIFIED="2012-08-22 00:22:28 -0400" MODIFIED_BY="[Empty name]" NO="4">
<TITLE MODIFIED="2012-08-22 00:22:11 -0400" MODIFIED_BY="[Empty name]">CINAHL search strategy</TITLE>
<APPENDIX_BODY MODIFIED="2012-08-22 00:22:28 -0400" MODIFIED_BY="[Empty name]">
<P>S1 (MH "Tendinopathy+")<BR/>S2 (MH "Tendon Injuries+")</P>
<P>S3 TI Tendinitis OR AB Tendinitis</P>
<P>S4 TI Tendinosis OR AB Tendinosis</P>
<P>S5 TI Tendonitis OR AB Tendonitis</P>
<P>S6 S1 or S2 or S3 or S4 or S5</P>
<P>S7 (MH "Elbow Joint")<BR/>S8 TI elbow* OR AB elbow*</P>
<P>S9 S7 or S8<BR/>S10 (MH "Pain+")<BR/>S11 TI Pain* OR AB Pain*</P>
<P>S12 S10 or S11<BR/>S13 S9 and (S6 OR S12)</P>
<P>S14 (MH "Tennis Elbow")</P>
<P>S15 TI tennis elbow OR AB tennis elbow</P>
<P>S16 TI epicondylitis OR AB epicondylitis </P>
<P>S17 TI common extensor origin OR AB common extensor origin</P>
<P>S18 TI epicondylalgia OR AB epicondylalgia</P>
<P>S19 S13 or S14 or S15 or S16 or S17 or S18</P>
<P>S20 (MH "Clinical Trials+")</P>
<P>S21 PT clinical trial<BR/>S22 TI clinical* trial* or AB clinical* trial* Search modes - Boolean/Phrase</P>
<P>S23 TI singl* blind* or TI singl* mask* or TI doub* blind* or TI doubl* mask* or TI trebl* blind* or TI trebl* mask* or TI tripl* blind* or TI tripl* mask* Search modes - Boolean/Phrase S24 AB singl* blind* or AB singl* mask* or AB doub* blind* or AB doubl* mask* or AB trebl* blind* or AB trebl* mask* or AB tripl* blind* or AB tripl* mask*  </P>
<P>S25 TI Randomi?ed control* trial* or AB Randomi?ed control* trial*</P>
<P>S26 (MH "Random Assignment")</P>
<P>S27 TI Placebo* or AB Placebo*</P>
<P>S28 (MH "Placebos")<BR/>S29 (MH "Quantitative Studies")</P>
<P>S30 TI Allocat* random* or AB Allocat* random*<BR/>S31 S20 or S21 or S22 or S23 or S24 or S25 or S26 or S27 or S28 or S29 or S30</P>
<P>S32 S19 and S31</P>
</APPENDIX_BODY>
</APPENDIX>
<APPENDIX ID="APP-05" MODIFIED="2012-08-22 00:23:01 -0400" MODIFIED_BY="[Empty name]" NO="5">
<TITLE MODIFIED="2012-08-22 00:22:50 -0400" MODIFIED_BY="[Empty name]">ISI Web of Science search strategy</TITLE>
<APPENDIX_BODY MODIFIED="2012-08-22 00:23:01 -0400" MODIFIED_BY="[Empty name]">
<P>#1 TS=(tennis elbow or tendinitis or tendonitis tendinosis or (elbow* and pain*) or epicondylitis or common extensor origin or epicondylalgia)</P>
<P>#2 TS=(trial* or random* or placebo* or control* or double or treble or triple or blind* or mask* or allocat* or prospective* or volunteer*or comparative or evaluation or follow-up or followup)</P>
<P>#3 #1 AND #2</P>
</APPENDIX_BODY>
</APPENDIX>
</APPENDICES>
<EXTENSIONS MODIFIED="2012-08-22 00:18:44 -0400" MODIFIED_BY="[Empty name]"/>
</COCHRANE_REVIEW>